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SUMMARY
The present study aimed to optimise mutation detection strategies for three 
autosomal dominant neurological diseases, myotonic dystrophy (DM), amyotrophic 
lateral sclerosis (ALS) and tuberous sclerosis complex (TSC).
(A) Myotonic dystrophy: After exploring different methods that have been used 
for the detection of CTG repeat expansions in DM patients, a strategy was chosen, 
optimised and applied to screen 49 DM families (86 DM affected and 96 apparently 
normal individuals). Using published primer sets, both radiolabelled and non-radiolabelled 
PCR amplification of the area containing the CTG repeat were optimised using the 
published conditions as a starting point. After PCR optimisation, DM alleles carrying up 
to 90 CTG repeats were properly amplified however, amplification of > 90 CTG repeats 
was not possible due to PCR limitations. To detect such expansions, Southern blot 
analysis using the BglI enzyme and the p5B1.4 DNA probe was optimised. The running 
time and the voltage used for gel electrophoresis were modified to get clear separation of 
the second band that represents the expanded CTG repeats. Meanwhile, normal 
individuals showed only a single band so that they were not confused with the affected 
persons. Using this strategy, all CTG repeat expansions between 50 and several 
thousands were detected. Analysis of the results obtained revealed the following: 1) A 
correlation between the intergenerational repeat expansion and the patient phenotype 
giving legitimacy to the phenomenon of anticipation. 2) Two cases of reduction of the 
repeat size upon paternal transmission. Since the age of both asymptomatic daughters 
were younger than the age at onset of the disease in their fathers, it was not possible to 
anticipate their clinical outcome. 3) Lastly, a severely affected child with mental 
retardation and onset in infancy was found to be paternally transmitted.
(B) Amyotrophic lateral sclerosis: Two mutations in the superoxide dismutase 
{SOD-1) gene, Ala4Val and Ilell3Thr, were previously shown to be prevalent among
familial amyotrophic lateral sclerosis (FALS) patients. These two mutations changed 
restriction enzyme recognition sites, so that restriction digestion of the appropriate PCR 
products was optimised and used to screen for their presence in the studied amyotrophic 
lateral sclerosis patients. SSCP analysis was also optimised and applied as a screening 
method for detection of unknown mutations in the SOD-1 gene using DNA samples from 
2 familial and 67 sporadic amyotrophic lateral sclerosis (ALS) patients. Any experiment 
with a positive SSCP screening result was repeated and a few false positive results due to 
PCR errors and/or errors in the gel preparations, loading or electrophoresis were 
detected.
A reproducible SSCP band shift was detected in exon 4 from one of the two 
familial cases. Sequencing of that exon revealed a G277->C point mutation which caused 
a Gly93Arg missense change. This mutation was confirmed to be present in all affected 
members of that family. Gly93 is a neutral and polar amino acid and is highly conserved 
among 18 different species and it was substituted by the basic arginine. Mapping of Gly93 
to the crystallographic structure of the SOD-1 gene revealed that it is one of the critical 
glycine residues that allow main chain conformation and packing interactions so that a 
mutation affecting this residue should have a deleterious effect on the conformation and 
stability of the enzyme dimer. In this FALS family, the affected members showed an early 
age of onset of the disease (26-40 years). Analysis of the results obtained revealed that: 
1) In the two FALS families screened one SOD-1 mutation was detected in the two 
screened FALS patients. 2) No SOD-1 mutations could be detected in any of the sporadic 
cases. These results suggested that other gene(s) may be involved in the familial form of 
the disease and make it unlikely that SOD-1 mutations are major determinants of sporadic 
ALS.
(C) Tuberous sclerosis: In order to screen the tuberous sclerosis complex (TSC) 
patients for point mutations within the TSC2 gene, chemical cleavage of the mismatch 
(CCM) analysis was optimised and applied to four RT-PCR amplified (from 22 patients)
and two DNA PCR amplified (from 32 patients for one segment and from 10 patients for 
the other segment) TSC2 segments. These segments were chosen as they include 
proposed important functional parts of the gene. Using this approach, nine cleavage 
products were detected from the screened patients. Sequence analysis of the 
corresponding cDNA and/or DNA segments revealed three missense mutations in three 
sporadic TSC patients and three polymorphic changes. No mutations could be detected in 
the screened promoter area of the gene.
The first mutation A4822-»G produced a missense Metl602Val change in the 
GAP-3 related domain which is proposed to be an important domain of the gene. Both 
methionine and valine are neutral and hydrophobic amino acids and this change would 
normally be considered a conservative one. However, there are known examples of 
conservative missense mutations that can result in a disease phenotype if they occupy 
sites in the protein that are key determinants of stability or function.
The second mutation T5161-^A produced a missense Serl715Thr change. In 
spite of the fact that both serine and threonine are neutral and polar amino acids this 
mutation was associated with a severe phenotype. The third mutation C5176—>T caused a 
missense Argl720Trp change which changed the basic arginine to the neutral and 
hydrophobic tryptophan which may affect the protein structure and function. Moreover, 
both Serl715 and Argl720 are in exon 40 of the gene which was found to be conserved 
among different species.
The three missense mutations modified restriction enzyme sites. This was used to 
confirm for their presence in the corresponding patients. None of these missense 
mutations could be detected upon the screening of 100 normal chromosomes, in view of 
this and the expected effect on protein they were predicted to be responsible for the TSC 
phenotype in these patients. Until more is known about the function and structure of 
tuberin it will be difficult to speculate about the exact function of these mutations and 
their effects both on tuberin and on patient phenotype.
Three polymorphisms were also detected in the screened cohort of TSC patients. 
Two of them C4098—>T and G5346—»C were silent. They did not change known 
restriction sites, so that screening of the normal chromosomes for their presence was not 
performed. G5346-»C was detected in four different patients and it may worth designing 
a technique to screen normal chromosomes for its presence. This may provide useful 
information for a linkage study analysis of the TSC2 gene. The third polymorphism was 
due to an AA deletion at positions 5433 and 5434 in one of the polyadenylation signals of 
the gene. It was detected in one of the familial cases but failure to detect it in other 
affected family members and its detection in one normal control led to the conclusion that 
it was a polymorphic change.
In conclusion, the most appropriate screening strategy for the detection of 
molecular pathology is influenced by the expected nature of the mutation, size and 
structure of the gene in question and the availability of mRNA. Therefore, for each of the 
three studied disorders, a different mutation strategy was chosen and optimised. SSCP 
analysis suited the small, well characterised SOD-1 gene. On the other hand, RT- 
PCR/CCM analysis allowed screening of a large part of the coding sequences of the 
TSC2 gene even before the complete genomic structure was known. For myotonic 
dystrophy the nature of the underlying molecular pathology of the expanded CTG repeats 
which could be detected as bands of different sizes made the PCR/Southern blot 
approach the appropriate mutation detection procedure.
IV

(1) INTRODUCTION
1.1 Genes and single gene disorders
Genes are the units of heredity. Genetic information is stored in the nucleus of 
cells in deoxyribonucleic acid (DNA) which is packaged into 23 pairs of 
chromosomes. Each gene is a nucleic acid sequence which determines the amino acid 
content of an enzyme or other proteins. Genes are situated at specific sites, or loci, on 
chromosomes. Like the chromosomes, genes exist in homologous pairs one from each 
parent.
Inheritance of single gene disorders follows a simple Mendelian form of 
transmission in families and it can be divided into autosomal dominant, autosomal 
recessive, sex linked dominant, sex linked recessive and mitochondrial inheritance 
(Thompson et al., 1991).
1.2 Molecular pathology of single gene disorders
An alteration of the structure of a gene is called a mutatioa As a result of 
mutation individual genes may exist in alternate forms, or alleles, only two of which 
can be present in one individual. The mutation may be present on only one 
chromosome of a pair (heterozygous) or on both chromosomes of the pair 
(homozygous). In either case, the cause is a single critical error in the genetic 
information.
1.2.1 Types and levels of abnormal gene expression
Gene action is mediated by a regulated flow of information reflecting the 
transcription of structural genes into messenger RNA (mRNA) precursors, a 
complicated series of steps involving processing of the large precursor molecules into 
definitive mRNAs and finally cytoplasmic translation of mRNA into a protein
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product. Mutations may manifest themselves at any of these levels. That is, there may 
be a reduced rate of transcription of a gene, a variety of abnormalities involving the 
processing of mRNA precursors, defects of initiation, translation or termination of the 
synthesis of the protein product on the cytoplasmic mRNA template, or an 
abnormality in the structure of the gene product.
Mutations that produce disease are manifest in two ways. First, a single base 
substitution or other rearrangement in a gene can lead to an abnormal protein 
product. The second group of mutations are those that cause a reduction or absence 
of a particular protein product. This kind of disorder may result from mutations that 
involve transcription or processing of mRNA or that act at the translation level by 
interfering with initiation, elongation or termination. Unfortunately no classification is 
entirely satisfactory. For example, it turns out that some disorders that appear to 
result from defective synthesis of a particular protein are actually caused by the 
production of a structurally abnormal protein which is so unstable that its level in the 
cell is markedly reduced.
(D Mutations causing synthesis of an abnormal gene product
Most of these mutations are due to single base substitutions ( point mutations) 
in the parent genes. There are a few examples of structural variants that are caused by 
major rearrangements that lead to the formation of fusion genes which code for novel 
protein products. The first example of this kind of protein was haemoglobin Lepore.
Point mutations, on the bases of codon change, can be classified into silent, 
non-sense, missense, and sense mutations. A silent mutation is a mutation that 
causes no change in the amino acid present in the corresponding protein. A missense 
mutation causes the substitution of one amino acid for another in a protein. The result 
of single amino acid substitutions in proteins or their subunits vary depending on the 
type of the amino acid that is substituted and the site of the substitution in the 
particular protein. Also, most proteins are folded into a complex tertiary structure and 
the substitution of a charged for an uncharged amino acid can disrupt this structure
and lead to molecular instability. On the above basis, missense mutations may or may 
not affect the function of the gene product. Sickle cell anaemia, an autosomal 
recessive disorder leading to a form of haemolytic anaemia and intravascular 
thrombosis is a result of a missense mutation in codon 6 of the beta globin gene 
changing GAG (Glu) to GUG (Val). Another missense change in the same codon 
GAG (Glu) to AAG (Lys) results in a condition known as haemoglobin C which is 
associated with mild clinical symptoms. A harmless haemoglobin variant 
(haemoglobin Makassar) results from missense change in the same codon changing 
GAG (Glu) to GCG (Ala) ( Weatherall, 1991).
(II) Mutations causing reduced output of a gene product
Many genetic disorders are caused by a reduced output of an enzyme or other 
type of protein and in some cases no product can be detected. These disorders result 
from mutations of the structural genes and the resulting defects are manifest at the 
levels of transcription, mRNA processing, translation or post- translational stability.
(A) Mutations that cause defective transcription: These mutations comprise:-
(i) Gene deletions and variation in gene number : Examples of this group 
are provided by the a  thalassaemias. Normally, there are two closely linked a  globin 
genes on chromosome 16. In many forms of a + thalassaemia there is a deletion 
involving this chromosome which leave a single functional a  gene. In most types of 
a °  thalassaemia both a  globin genes are lost.
(ii) Fusion genes : These result from chromosomal misalignment and 
abnormal crossing over. Examples of this are the genetic abnormalities that underlie 
red-green colour blindness. These appear to have resulted from unequal crossing-over 
between the red and green pigment genes that lie in a tandem array on the X- 
chromosome on which there is a single red pigment gene and variable numbers of 
green pigment genes.
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(iii) Inversions : This term signifies that a region of DNA is back-to-front 
with respect to its normal orientation in the genome. A good example of this type of 
mutation has been shown in patients with 5p thalassaemia and in haemophilia A 
patients where half the serious cases have an intron 22 inversion.
(iv) Insertions : This mechanism underlies the molecular pathology of several 
varieties of Lesch-Nyhan syndrome, one form of Marfan's syndrome, lipoprotein 
lipase (LPL) deficiency and in several other conditions.
(v) Promoter box mutations : Examples of this kind of mutation have been 
found in several forms of P-thalassaemia and in haemophilia B Leyden type where 
mutations were found upstream from these genes either within or adjacent to 
promoter boxes. These mutations are associated with variable reductions in output 
from the adjacent gene loci.
(B) Mutations that cause defective mRNA processing: The primary mRNA 
transcript has to be processed by the removal of introns, joining together of exons and 
by polyadenylation. Normal splicing of mRNA is dependent on the presence of GT 
and AG dinucleotides at the 5' and 3' intron-exon junctions. Splice site mutations that 
affect the 5' donor (GT) or the 3' acceptor (AG) sequences will interfere with the 
normal splicing, resulting in an mRNA that retains an intron or is missing an exon. 
Examples of this are known in P° thalassaemia, phenylketonuria, acute intermittent 
porphyria, neurofibromatosis type 1, retinoblastoma and more other conditions. In 
addition to the GT/AG junctional sequences there are highly conserved sequences at 
the boundaries between introns and exons that must also be involved in splicing of 
mRNA. Several forms of (3+ thalassaemia have been described which result from the 
production of cryptic splicing sites within these consensus sequences (Weatherall, 
1991).
Polyadenylation signal site mutations also interfere with the normal processing 
of mRNA. Cleavage of the 3' end of the mRNA and addition of the poly A tail is 
controlled at least in part, by an AATAAA consensus sequence approximately 20
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base pairs before the polyadenylation site. For example a single base change 
AATAAA —> AATAAT, found in a  globin genes of patients with a  thalassaemia 
drastically reduces the production of a  globin chains from the 0 C2  globin gene. Some 
genes have a number of alternative polyadenylation sites, selection among which may 
influence the stability of the resulting mRNA and thus the steady-state level of the 
mRNA (Thompson et al., 1991).
(C) Mutations causing abnormal translation: These include
(i) Initiation codon mutations : Several mutations have been observed in 
patients with a  thalassaemia which involve either the initiation codon itself (ATG) or 
the sequences immediately adjacent to it leading to no a  chain production from the 
affected a  globin gene. Other examples have been seen in pseudohypoparathyroidsm 
and Tay-Sachs disease.
(ii) Non-sense mutations : Non-sense point mutations create stop codons 
and premature termination of translation with shortened gene products. These have 
been detected in a variety of genetic disorders such as Duchenne muscular dystrophy 
and neurofibromatosis type 1.
(iii) Frameshift mutations : Since proteins are encoded by a triplet code the 
loss or insertion of any number of nucleotides which are not three or its multiples will 
alter the reading frame of the message downstream of the change. The result is an 
anomalous amino acid sequence that is added to a normally initiated chain. 
Sometimes the altered base sequence generates a new termination codon leading 
either to premature termination of translation or elongation of the abnormal mRNA. 
Examples of this kind of mutation have been seen in p thalassaemia, Duchenne 
muscular dystrophy (DMD), haemophilia A and Christmas disease.
(iv) Termination codon mutations : Termination codon mutations were first 
described in the a  globin genes. These mutations produce a longer than normal 
protein by changing a termination codon into one that codes for amino acid. In 
haemoglobin Constant Spring the a- chain is elongated at its C- terminus due to
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single base mutation in the a- chain termination codon UAA to CAA (Gin) 
(Weatherall, 1991).
(v) Mutations that are distant from the structural genes : Most of the 
mutations that interfere with the production of peptide chains involve either the 
structural genes themselves or important regulatory sequences in their immediate 
flanking regions. However, there are other sequence elements that can markedly alter 
the efficiency of the transcription. The best characterised of these activating 
sequences are called enhancers. These are sequence elements that can act at quite a 
distance (often several kilobases) from a gene to stimulate transcription. Specific 
enhancer elements function only in certain cell types and thus appear to be involved in 
establishing the tissue specificity of many genes (Thompson et al., 1991). A so-called 
dominant control region (DCR) has been identified upstream from both the (3 like and 
a  globin gene clusters. Several deletions that involve this sequence have been found 
to inactivate the structurally normal a  globin genes in the same chromosome 
(Weatherall, 1991).
1.2.2 Mechanisms of mutagenesis
(!) Cytosine methvlation and hot spots for point mutations
Point mutations have so far been the most common type of mutation in coding 
DNA sequences. The category of mutations that includes deletions and insertions 
accounts for 5 to 10 % of all known mutations (Cummings, 1994). Nucleotide 
changes that involve the substitution of one purine for the other (A<-»G) or one 
pyrimidine for the other (T<-»C) are called transitions. The replacement of a purine 
for pyrimidine or vice versa is called transversion. If nucleotide substitutions were 
random, there should be twice as many transversions as transitions. In fact there is a 
higher frequency of transitions than transversions among a collection of mutant 
alleles. The excess of transitions can be explained with the finding that the major form
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of DNA modification in the human genome involves methylation of cytosine residues 
to form 5-methylcytosine, specifically when they are located immediately 5' to 
guanine i.e. as a dinucleotide 5-CG-3'. Spontaneous deamination of 5' methylcytosine 
to thymidine in CG doublet gives rise to C-»T or G-»A transitions (depending on 
which strand of DNA the 5-methylcytosine is mutated). More than 30 % of all single 
nucleotide substitution detected in many inherited disorders are of this type 
(Thompson et al., 1991). Thus the CG doublet represents a true hotspot for mutation 
in the human genome (Cooper and Krawczak, 1990).
(ID Insertions, deletions and gene duplication
Alterations of gene structure by insertions or deletions have been described in 
numerous inherited disorders. The observed frequency of such mutations differs 
markedly among different genetic diseases. Some disorders are characterised by a 
higher frequency of detectable deletions, whereas in others deletion is a very rare 
cause of mutation.
A frequent cause of mutation involves a large deletion or duplication mediated 
by recombination between highly similar DNA sequences. Many genes exist as 
members of multigene families (e.g. the a  and p globin gene clusters, immunoglobulin 
superfamily and colour vision gene family). When the members of such a gene family 
are located in a head-to-tail tandem fashion in the same chromosomal region, they 
sometimes misalign and pair out of register either in meiosis (when two homologues 
pair) or in mitosis after replication (when two sister chromatids often exchange 
DNA). Recombination with unequal crossing over occurring between mispaired 
chromosomes or sister chromatids can lead to gene deletion or duplication.
Recombination between homologous non-coding DNA sequences of the Alu 
family has been documented as the cause of duplication of several exons in the low 
density lipoprotein receptor gene in familial hypercholesterolaemia (Lehrman et al., 
1987). A similar example is the mutational event in a case of XX maleness resulting
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from aberrant exchange between an Alu repeat on the short arm of the X 
chromosome and one on the Y chromosome (Rouyer et al., 1987).
Examples of deletions of <20 bp and insertions of <10 bp of DNA sequences 
into human gene coding region were analysed by Cooper and Krawczak (1991). They 
stated that these events are not random and appear to be highly dependent on the 
local DNA sequence context. The majority of insertions can be explained by an 
endogenous replication mechanism of mutagenesis. This may be understood in terms 
of slipped mispairing due to direct repeats, runs of single bases, palindromes (inverted 
repeats) or the presence of symmetrical elements. Direct repeats are also a feature of 
a number of recombination, replication or repair based models of deletional 
mutagenesis. A significant excess of symmetrical sequence elements was found at 
sites of single base deletions. These elements were seen to possess an axis of internal 
symmetry ( e.g. CTGAAGTC, GGACAGG) and varied between 5 base pairs and 11 
base pairs in length. In addition a consensus sequence proposed to be a hot spot for 
deletions was drawn up : (TGA/GA/GG/TA/C).
(Ill) Expansion of trinucleotide repeats
The discovery of trinucleotide repeat expansion and instability in several 
inherited psychomotor disorders has provided a molecular explanation of the 
phenomena of anticipation where the disease shows increased clinical severity over 
successive generations in pedigrees (Richards and Sutherland, 1994). So far, 
expansion of trinucleotide repeat motifs, also referred to as dynamic mutations, have 
been found to be causally involved in several human genetic disorders including 
Fragile X syndromes (FRAXA & FRAXE) (Fu et al., 1991 and Knight et al., 1993); 
Myotonic dystrophy (DM) (Fu et al., 1992); Huntington disease (HD) (The 
Huntington's disease collaborative research group, 1993); Spinocerebellar ataxia type 
I (SCA1) (Orr et al., 1993); Spinal and bulbar muscular atrophy (SBMA, Kennedy 
disease) (La Spada et al., 1991); Dentatorubral and pallidoluysian atrophy (DRPLA) 
(Nagafuchi et al., 1994), Haw River syndrome (HRS) (Burke et al., 1994) and
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Machado-Joseph disease (MJD) (Kawaguchi et al., 1994). In each case, tracts of 
trinucleotide repeats undergo expansion to produce the disease phenotype with 
expansions of either CCG/CGG (FRAXA & FRAXE) or CAG/CTG (All the 
remaining diseases) core sequences. These repeat tracts occur in the coding (HD, 
SBMA, DRPLA/HRS, MJD) as well as non-coding (DM and FRAX) regions of the 
gene. The mechanisms by which these trinucleotide repeat expansions produce their 
phenotypic effects are not clear. In FRAXA & FRAXE syndromes the full mutations 
are associated with fragile mental retardation 1 (FMRJ) gene methylation leading to 
transcriptional suppression and an absence of the encoded protein (McConkie-Rosell 
et al., 1993). In DM there are conflicting reports of decreased (Fu et al., 1993 and 
Hofmann-Radvanyi et al., 1993) and increased (Sabourin et al., 1993) steady state of 
mRNA levels. In other disorders, where the repeat (CAG)n codes for polyglutamine, 
the expansion may confer some gain of function to the protein involved (Housman, 
1995).
When compared to other types of single gene defects the properties of 
dynamic mutation diseases afford distinct advantages and disadvantages for diagnosis. 
The dynamic mutation disorders are remarkably homogeneous. Apart from fragile X 
syndrome, no other mutations in the genes involved in dynamic mutation disorders 
have been recorded. This is a great advantage for the diagnostic laboratories where 
the primary diagnosis of these disorders can now be made with confidence. The major 
disadvantages relate to uncertainty over the relationship between genotype and 
phenotype. Somatic variation can mean that copy number, determined from peripheral 
blood lymphocytes, is not an accurate determination of the size of the repeat in the 
affected tissue(s). In addition (perhaps as a consequence) there can be overlap in the 
copy number for the different phenotypic categories. For example, in the Huntington's 
disease about 2 % of mutant chromosomes have copy numbers at the top of the 
normal range (Sutherland and Richards, 1993).
Recently a GAA repeat expansion is detected within an intron of a novel gene 
(X25) for Friedreich's ataxia (Campuzano et al., 1996). Unlike previously described
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neurological disorders involving triplet repeat expansions, in which a dominant mode 
of inheritance is the norm, Friedreich's ataxia is an autosomal recessively inherited 
disorder. As such, there is no evidence of anticipation within families and carriers of 
the Friedreich's ataxia mutation show no obvious adverse consequence.
DISORDERS STUDIED
1.3 Myotonic Dystrophy (DM, Steinert’s muscular dystrophy)
This disease is so called because patients who present to hospital on account 
of muscle weakness have a distinctive type of muscular dystrophy which is 
accompanied by myotonia of the tongue and hands (Bundey, 1992).
1.3.1 Clinical features
Myotonic dystrophy is the commonest adult form of muscular dystrophy, with 
an estimated incidence of 1 per 7,500, although this is likely to be an underestimate 
because of the difficulty of detecting minimal affected individuals (Harley et al., 
1992). The clinical features of this disease are myotonia, weakness, muscle wasting, 
frontal baldness, cataracts, hypogonadism and ECG changes. Typically, symptoms 
become evident in middle life. Initial symptoms are insidious and by time the patient is 
severely disabled, retrospective questioning will reveal that the disease has been 
present for 20 to 40 years. Moreover, some patients, particularly those with onset late 
in life, may be without muscular symptoms or signs and have only lenticular opacities 
(Bundey, 1992).
Unlike other muscular dystrophies, DM initially involves the distal muscles of 
the extremities and only later affects the proximal musculature. The muscle weakness 
affects firstly the face, sternomastoids, muscles of the forearms and tibialis anterior 
muscle leading to foot drop. Atrophy of masseters, sternocleidomastoids and the 
temporalis muscles produces a characteristic haggard appearance. Myotonia or 
delayed muscular relaxation following contraction is most frequently apparent in the
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tongue, forearm and hand. Myotonia is rarely as severe as in myotonia congenita and 
tends to be less apparent as weakness progresses (McKusick et al., 1994).
Mild endocrine and bony changes have been observed in DM patients. Males, 
particularly those with early onset, develop primary testicular atrophy and may 
present with impotence or infertility rather than with muscle symptoms. Females tend 
to suffer from menstrual irregularities, and they are predisposed to obstetric 
complications, such as prematurity, ante- and post-partum haemorrhage (Bundey, 
1992). DM patients may develop personality changes such as irresponsibility or 
aggression, and if onset is early in life they are often mentally retarded (Bundey,
1992).
Complications affecting different organs have, also, been reported. Schwindt 
et al. (1969) claimed that 25 to 50% of patients have abdominal symptoms due to 
cholelithiasis. Brunner et al. (1992a) pointed out that there are many reports of 
familial occurrence of specific complications of DM e.g. cardiac conduction 
disturbances, focal myocarditis, miteral valve prolapse, polyneuropathy, normal 
pressure hydrocephalus and urinary tract dilatation.
Congenital myotonic dystrophy (CDM) is an unusual and severe type of 
myotonic dystrophy which occurs in about 1 0 % of cases. Symptoms are present in 
the neonatal period and the ultimate prognosis is poor. It is characterised by 
respiratory distress and poor feeding after birth. A typical facial appearance due to 
bilateral facial paralysis and ptosis is present in the newborn. Hypotonia and talipes 
equinovarus are additional features. Respiratory difficulties are frequent and are often 
fatal (McKusick, 1994). The diagnosis is at times difficult if the family history is not 
known as the more characteristic manifestations of the disease (myotonia and 
cataracts) might not develop until much later. Those that survive the neonatal period 
initially follow a static course, eventually learning to walk but with significant mental 
retardation in 60 to 70% of cases. By the age of 10 year they develop myotonia and 
in adulthood develop the additional complications described for the adult onset 
disease. The mean IQ for those cases with neonatal respiratory distress was not
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different from those without distress, suggesting that the mental retardation is 
unlikely to be related to anoxia (Baraitser, 1990). The inheritance of the congenital 
form differs markedly from orthodox Mendelian ratios in that, with only rare 
exception, it is the mother who transmits the disease.
1.3.2 Genetics
Myotonic dystrophy is an autosomal dominant disorder with high penetrance 
and rare new mutations (Harper, 1989a; Meiner et al., 1995). Various studies agree in 
demonstrating that 50% of patients had developed the disorder by around 20 years of 
age, and that a significant number do not develop it until after 50 years of age. Many 
obligatory gene carriers are asymptomatic and Harper (1973) found that 18% of 
asymptomatic first-degree relatives showed unequivocal abnormalities on clinical and 
slit-lamp investigation illustrating the inaccuracy of relying on age at symptomatic 
onset as a basis for penetrance analysis. Variation in clinical picture between a pair of 
monozygous twins has been reported (Harper, 1989b). Unfortunately, there are few 
reports of twins with myotonic dystrophy and further twin data would be particularly 
valuable.
Ives et al. (1989) described possible homozygosity for the DM gene. The 
possible homozygotes were more severely affected than the heterozygotes. On the 
other hand, Cobo et al. (1993b) studied a consanguineous French-Canadian family in 
which two sisters possessed two alleles with repeat sizes normally seen in minimally 
affected patients but were asymptomatic and showed no evidence of myotonic 
dystrophy on extensive clinical examination.
The myotonic dystrophy locus was assigned to chromosome 19 (Eiberg et al., 
1983). Harley et al. (1991) concluded that the DM gene lies in region 19ql3.2-ql3.3. 
Linkage studies by Cobo et al. (1992) established the D19S63 marker as useful for 
prenatal and presymptomatic diagnosis and, as the closest marker to DM, in isolating 
the gene.
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1.3.2.1 Identification of an expanded triplet repeat:
Harley et al. (1992) isolated a human genomic clone that detected novel 
restriction fragments specific to persons with myotonic dystrophy. A 2-allele EcoKl 
polymorphism was seen in normal persons, but in most affected individuals one of the 
normal alleles was replaced by a larger fragment, which varied in length both between 
unrelated affected individuals and within families. The unstable nature of this region 
was thought to explain the characteristic variation in severity and age at onset of the 
disease.
The causative mutation in myotonic dystrophy has been found to be an 
expansion of unstable tandem repeat of the sequence CTG, located in the 3' 
untranslated region of a gene, with strong homology to the protein kinase family, on 
chromosome 19ql3.3 (Harley et al., 1992; Buxton et al., 1992; Aslanidis et al., 1992; 
Brook et al., 1992; Mahadevan et al., 1992 and Fu et al., 1992). In unaffected 
individuals the (CTG)n repeat number is polymorphic and ranges from 5 to 37 repeats 
(Brunner et al., 1992b) and is stably inherited. In DM, at least 50 copies are present in 
the minimally affected patients (Brook et al., 1992) with a dramatic increasing to an 
estimated 2000 copies in severely affected individuals (Fu et al., 1992 and Mahadevan 
et al., 1992). Expanded repeats are much more unstable, and there is a positive 
correlation between the length of the repeat and its instability (Lavedan et al., 1993a). 
Overall, there is an estimated 93 to 94% chance that the expanded allele will show an 
intergenerational enlargement on transmission from an affected parent to an affected 
child (Wieringa, 1994). Relatively stable behaviour of the repeat is most frequently 
found with alleles of less than 80 CTGs (Barcelo et al., 1993) and this could explain 
the persistence of an autosomal dominant disease such as DM, despite the presence of 
anticipation and low reproductive fitness of the severe DM phenotype. There is a 
relative paucity of alleles in the high normal range for the DM locus (Fu et al., 1992) 
and to date no transmission from a normal allele to a premutation allele has been 
observed.
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The factors affecting trinculeotide repeat stability, normal allelic variation and 
the generation of new disease alleles are not fully understood. Both meiotic expansion 
and contraction events may normally occur in the DM allele but expansion is favoured 
once a threshold size is reached (O'Hoy et al., 1993). Hypotheses of both meiotic and 
mitotic instability have been proposed to explain the intergenerational variation in the 
CTG repeat (Jansen et al., 1994 and Wieringa, 1994). At the higher allele range, loss 
of interrupting motifs within tracts of trinucleotide repeats leads to greater instability 
and predisposes alleles to expansion (Chung et al., 1993; Hirst et al., 1994 and 
Leeflang and Arnheim, 1995).
Regressed DM Allele: A reduction in CTG repeat number to within the 
normal range was reported in DM kindreds by many investigators (Shelbourne et al., 
1992; Brunner et al., 1993; O'Hoy et al., 1993 and Jansen et al., 1994). This can be 
either due to non-reciprocal crossovers or to gene conversion events that have been 
originally described in fungi (Orr-Weaver and Szostak, 1985). Cobo et al. (1993a), 
Lavedan et al. (1993a) and Ashizawa et al. (1994b) in their series of parent-child pairs 
showed that contraction rather than amplification of the CTG repeat was seen in the 
children of fathers with a repeat of 1 kb or greater. They also, concluded that for 
parents with large amplifications (1.5 kb or more), the likelihood that there will be 
further amplification as the gene is passed to affected offspring is less for fathers than 
for mothers. The tendency towards contraction of alleles on transmission through the 
male germline may be caused by selection of spermatozoa bearing smaller repeats 
(Giordano et al., 1994 and Jansen et al., 1994). Ashizawa et al. (1994b) also showed 
that the cases with the CTG repeat contraction clustered within sib sets more 
frequently than expected but the mechanism of this phenomenon is unknown.
Sex-related effect on CTG intergenerational expansion: At higher CTG- 
lengths the maternal transmission results in the larger average intergenerational 
increments (Harley et al., 1993). In contrast, careful inspection of the published data 
suggests that expansions of repeats at the lower end of the length spectrum ( < 1 0 0  
CTG) are more exaggerated when inherited from males (Brunner et al., 1993 and
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Wieringa, 1994). An apparently unexplained excess of male transmitters has been 
found in the ancestors' generation by many authors (Harper, 1989a; Harley et al., 
1993; Lavedan et al., 1993a; Brunner et al., 1993). This excess was observed 
whenever the disease was inherited from the father or from the mother. Thus, there 
appears to be a male bias in the generation of new alleles in DM (both contractions 
and expansions). Although ascertainment bias can not be rejected, this male excess 
could be due to the following biases : first, women with neonatal cases will not 
appear as grandmothers of affected patients; second, there are more children bom to 
an affected male than to an affected female (Lavedan et al., 1993a); and, third, it may 
simply reflects the larger number of cell divisions during spermatogenesis (Wieringa,
1994). In females the ovum-to-ovum sequence involves approximately 30 cell 
divisions, whereas the number of the cell divisions for male gamete production ranges 
between 50 and several hundred during the effective fertile life span (Edwards, 1989).
Mosaicism: The amplified CTG repeat region shows both meiotic and mitotic 
instability. The differences in size within one generation of a DM family may be 
explained by meiotic instability of germline mosaicism (Meiner et al., 1995). On the 
other hand, smears of hybridisation in Southern blot analysis, reflecting somatic 
instability, have been reported for the majority of DM patients with a CTG repeat 
length >lkb, in males as well as in females (Mahadevan et al., 1992 and Fu et al.,
1992). Somatic instability has been demonstrated among a number of different 
tissues. Compared to leukocytes larger expansions have been described in several 
tissues including skeletal muscle, liver, testis, brain and may also be found in skin 
(Anvert et al., 1993; Ashizawa et al., 1993, Lavedan et al., 1993a; Zatz et al. 1995 
and Wohrle et al., 1995). Lavedan et al. (1993a) and Brunner et al. (1993) showed 
that somatic instability is not only limited to the larger DM alleles and the PCR 
analysis of the expanded alleles, up to 90 CTG repeats, appeared on the 
polyacrylamide gel as a mosaic pattern of DNA fragments differing by one or a few 
trinucleotide repeats. Wong et al. (1995) showed that somatic heterogeneity is a 
continuous process and seen to be age and size dependent. Martorell et al. (1995)
confirmed that the repeat length in peripheral blood cells of patients increase over a 
time span of five years indicating continuing mitotic instability of the repeat 
throughout life. They also, stated that repeat length progression does not appear to be 
indicative of clinical progression but age probably is. The degree of size heterogeneity 
correlates with the initial repeat size, however, obvious size heterogeneity is not 
observed in congenital cases, regardless of the size of the expansion (Wong et al., 
1995 and Martorell et al., 1995). This heterogeneity of expansions between tissues 
indicates that repeat expansion in vivo might be related to cell proliferation. Tissue- 
specific differences in the efficiency or availability of DNA repair systems may also 
account for the heterogeneity of expansions (Wohrle et al., 1995). Somatic 
heterogeneity in vivo could explain the overlapping in fragment sizes of the different 
clinical groups, especially in adults with classical DM.
Size of the unstable CTG repeat in relation to phenotype: There is a 
consensus among those working on DM that the size of CTG expansions in blood 
lymphocytes correlates to a reasonable degree with the age of onset and severity of 
the disease, although this is more readily observed within rather than between 
pedigrees (Redman et al., 1993). As seen from the typing of repeat sizes in blood 
from comprehensive cohorts of patients, minimally affected patients have repeat sizes 
of <0.45 kb (150 CTGs). Congenital cases have on average the largest repeat sizes, 
expansion of 1.5 to 6  kb or more with the majority in the 4.5 to 6  kb range (1500- 
2000 CTGs), and the classical cases with highly variable manifestation of clinical 
signs and age at onset in the 2nd to 3rd decade, have intermediate expansions. This 
correlation is by no means absolute, however, and overlap between clinical groups 
was present so that the CTG-length typing can not be reliably used as a diagnostic or 
prognostic criterion to predict the clinical status of patients (Hunter et al., 1992; 
Buxton et al., 1992; Mahadevan et al., 1992; Harley et al. 1993; Shelbourne et al., 
1993, and Lavedan et al., 1993a). Zatz et al. (1995) analysed the CTG expansion in 
muscle as compared to lymphocyte DNA in a sample of DM patients of different ages 
and degrees of clinical severity. Results from their study showed that in contrast to
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lymphocytes, no significant correlation was found between the size of the CTG 
expansion in muscle and age at onset of the disease. In addition, large expansions 
were observed in muscle from all adult symptomatic patients independently of the 
presence of muscle weakness, which raised the question of the value of analysing 
CTG expansions in muscle for predicting the severity of the phenotype.
1.3.2.2 Anticipation
The term anticipation has been used to denote the progressively earlier 
appearance of a disease in successive generations, generally with increasing severity 
(Harper, 1989b). Clinically, anticipation has been a strikingly consistent phenomenon 
in a large number of myotonic dystrophy families (Howeler et al., 1989 and Ashizawa 
et al., 1992). A positive correlation is seen between earlier onset/greater severity and 
increasing CTG repeat number (Buxton et al., 1992; Tsilfidis et al., 1992 and 
Lavedan et al., 1993a) and is considered to be the molecular basis for anticipation in 
DM.
Ashizawa et al. (1994b) showed that in about half of the reported cases of 
intergenerational contraction of the CTG repeat observed in lymphocyte DNA, 
clinical anticipation still occurred, despite the contraction and it was proportionally 
more frequent with maternal transmission than with paternal transmission. The most 
striking examples were the two cases in which anticipation resulted in congenital DM 
in offspring with contractions of the CTG repeat. The authors suggest that the 
presence of factors other than the CTG repeat size are responsible for the severity of 
the phenotype.
1.3.2.3 Genetics of congenital myotonic dystrophy
Congenital myotonic dystrophy (CDM) occurs in about 10% of cases and 
appears to be quite distinct from severe adult onset DM. Neither the mostly maternal 
transmission of the mutation nor the early onset of that form are fully explained. 
CDM is usually associated with large CTG triplet expansions in the mother or child or
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both. Tsilfidis et al. (1992); Harley et al. (1993) and Redman et al. (1993) found some 
congenital cases with alleles in the 500 to 999 repeats range and an overlap between 
the CDM and non-CDM patients in the 1300 to 2300 repeats range. The lack of 
CDM in paternal transmissions has been attributed to the limited expansion of the 
CTG repeat through the paternal line (Lavedan et al., 1993b and Mulley et al., 1993). 
However, there is a considerable overlap in the length of the expansion in the blood 
between cases with congenital and adult onset forms (Harley et al., 1993) and males 
do sometimes pass on expansions that, if they were transmitted through the maternal 
line, would probably have led to expression of CDM in the child (Ashizawa et al., 
1994b; Passos-Bueno et al., 1995). These findings indicate that size of the expanded 
CTG repeat sequence is not the only feature determining congenital onset of the 
disease.
Although genomic imprinting is one of the mechanisms that could explain the 
effect of parental sex in CDM, methylation patterns do not differ in offspring of 
maternal and paternal transmissions (Shaw et al., 1993a and Ashizawa et al., 1994a) 
and the DM kinase mRNA of paternal and maternal origins were equally expressed in 
CDM patients (Jansen et al., 1993). The picture is further complicated by the reports 
of CDM with a large CTG repeat of paternal origin (Nakagawa et al., 1994 and Ohya 
et al., 1994) and by the observations that a large expansion of a maternally 
transmitted CTG repeat does not always result in CDM (Abeliovich et al., 1993; 
Lavedan et al., 1993a and Redman et al., 1993). Furthermore, Cobo et al. (1993a) 
reported a case in which CDM is inherited despite a 3 kb contraction on transmission 
from mother to son. The finding that CDM can be paternally transmitted, even if the 
incidence of such cases is very low, casts doubts upon the interaction with 
intrauterine factors as possible mechanism previously postulated to explain the 
maternal transmission of the congenital form (Harper and Dyken, 1972). Poulton et 
al. (1995) have not found evidence that mtDNA is involved in CDM. The possibility 
that CDM may operate with a pathologic mechanism different than that in adult onset 
DM can not be excluded. Bundey (1982) and Lavedan et al. (1993a) put forward the
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hypothesis that the propensity to have neonatally affected offspring is familial. They 
noticed that transmitting sisters, whatever their clinical status or the repeat length, 
always gave birth to children affected with the same clinical type of disease i.e. mild 
form, adult form or congenital form.
1.3.2.4 Founder chromosome and the origin of the expansion mutation in
DM
Haplotype analysis of DM chromosomes has detected a striking total linkage 
disequilibrium in both Caucasian and Japanese patients, between the DM mutation 
and a two-allele insertion/deletion polymorphism located 5 kb upstream from the 
repeat, suggesting a single origin of the mutation (Harley et al., 1992; Mahadevan et 
al., 1992; Yamagata et al., 1992 and Lavedan et al., 1994). This finding was 
unexpected for a dominant disease which, in its severe forms diminishes or abolishes 
reproductive fitness. Such diseases are in general characterised by a high level of new 
mutations, which compensate for the loss of abnormal alleles due to the decreased 
fitness. Further work revealed that normal chromosomes with five and 19-30 repeats 
only carry insertion alleles, while those with 11-13 repeats are almost exclusively 
associated with the deletion alleles (Imbert et al., 1993). These results led to a model 
being proposed to describe the origin of the DM mutation. The initial predisposing 
event(s) leading to the formation of the DM chromosomes were proposed to be a 
limited number of duplication steps of a (CTG) 5  allele that resulted in generation of 
CTG (n > 19), with the lack of a predominant allele in the CTG (n = 19-30) range. 
The heterogeneous class of CTG (n = 19-30) alleles, which was found to have an 
overall frequency of about 10%, may constitute a reservoir for recurrent DM 
mutations. The CTG expansion beyond a certain threshold, approximately 50 repeats, 
would confer a rapid and irreversible instability, leading to increased severity or 
earlier onset of the disease (anticipation), or both. This model has been supported by 
the finding that differences between the frequency of large alleles in the high normal
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range of the allele size distribution (CTG > 19) in global human population are 
congruent with observed variation in prevalence rate of the disease (Watkins et al.,
1995). DM has a very low prevalence rate among ethnic Africans (Ashizawa and 
Epstein, 1991) and Goldman et al. (1994) reported fewer large DM alleles in South 
African Negroids than in Japanese or white subjects. Further support of the model 
proposed by Imbert et al. (1993) came from a report of a Japanese family (Yamagata 
et al., 1994) where the father (which is clinically normal) of the proband (with early 
adolescent onset DM) was found to have alleles containing 29 and 46 repeats and the 
grandmother had alleles of 5 and 44 repeats. From the evidence of the last case it 
seems that a premutation (as few as 44 repeats) can in two generations expand to 
give early adolescent onset DM and this finding is supporting the multistep model for 
the maintenance of the DM mutation in the population. The insertion allele is not a 
prerequisite for CTG expansion beyond 19 repeats or into the pathogenic range and 
suggest that the proposed increased mutability of large normal repeats is simply a 
function of their length. Moreover, it is possible that (CTG) 5  allele gave rise to 
(C TG )u_i3  alleles as the latter alleles found associated with the insertion 
polymorphism in African populations with the additional possibility that the (CTG) 1 9 . 
30 chromosomes may have been derived from the (CTG)] x_i3 chromosomes and the 
deletion event occurred on a (CTG)] j _ ] 3  background.
1.3.2.5 Myotonic dystrophy genet si
Three groups of collaborating DM-researchers simultaneously and 
independently recognised that the unstable CTG repeat element is in the 3' non­
coding segment of a gene that belongs to the serine/threonine protein kinase family 
(Mahadevan et al., 1992; Brook et al., 1992; Fu et al., 1992). This gene is now 
commonly referred to as DM-protein kinase (DMPK) or myotonin protein kinase 
(Mahadevan et al., 1992, Fu et al., 1992).
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Characterisation of the DM region in mouse revealed another active gene 
designated (DMR-N9) that appeared to have a human homologue in close proximity 
to 5' prime end of the DMPK gene. Shaw et al. (1993b) described the human 
homologue of the mouse DMR-N9 gene and called it 59 gene. Transcripts of these 
genes, mainly expressed in brain and testis, possess a single, large open reading frame, 
but the function of its protein product is unknown. Two regions of the predicted 
protein show significant homology to tryptophan/aspartic acid (WD) repeats, highly 
conserved amino acid sequences found in a family of proteins engaged in signal 
transduction or cell regulatory functions. This led Jansen et al. (1995) to concluded 
that the DMR-N9 gene is a candidate for being involved in the manifestation of mental 
and testicular symptoms in severe cases of DM. Strikingly, the combined pattern of 
tissue specific expression of both DMPK and DMR-N9 genes from the DM region 
corresponds exactly to those sites where the clinical manifestations in DM patients are 
most prominent.
At the 3' end of the DMPK gene, there is a CpG island (Shaw et al., 1993b; 
Boucher et al., 1995) where the unstable CTG repeat is located within it. Extensive 
homology between the murine and human sequences 3' to the CTG repeat supported 
the hypothesis that another gene lies in this region and allowed Boucher et al. (1995) 
to identify candidate exons. A highly significant homology with the homeodomain- 
containing protein genes has been identified. Consequently, the gene was named DM 
locus-associated homeodomain protein (DMAHP). Using RT-PCR with primers from 
the putative homeodomain-encoding exonic sequences showed that DMAHP gene is 
widely expressed in a number of human tissues, including skeletal muscle, heart and 
brain. The identification of a gene immediately downstream of the CTG repeat 
supports a model of symptom development in which as the expansion increases in 
length, broader gene dysfunction occurs, correlating with clinical severity. This could 
involve DMPK, 59, DMAHP and possibly other as yet uncharacterised gene(s). It has 
been proposed that level of expression of the DM-kinase isoforms and/or the DMR- 
N9 (59) product(s), as regulated by cis influences on transcription, translation or
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mRNA stability, is affected differentially by the variation in length of the repeat, and 
so the clinical manifestation of DM. It is not inconceivable that other, yet unknown, 
gene(s) in the immediate vicinity of the CTG repeat are also affected at the level of 
expression (Jansen et al., 1992).
DMPK gene: DMPK gene encodes a protein of 624 amino acids with a highly 
conserved kinase domain encoded by exons 2 through 8 . A region showing significant 
homology to the a-helical (coiled-coil) domains of myofibrillar and filamentous 
protein is encoded by exons 9 through 12, with the strongest homology being 
contained in exons 11 and 12. Exon 15, the last exon, contains a relatively short 
region encoding for a hydrophobic, possibly transmembranous domain, and also 
contains the CTG repeat in the 3' untranslated region. Exons 13 and 14, which show 
no strong homology to any proteins or protein domains, are alternatively spliced out 
in several cDNA clones isolated from a human heart cDNA library. As a consequence 
of a shift in the open reading frame, an earlier termination codon (5 bp after the 
beginning of exon 15) is used. This results in loss of the hydrophobic region. 
Immediately following the region encoding the kinase domain there is a cryptic splice 
donor site that, if used, takes out five additional amino acids (VSGGG) from the 
human and mouse proteins. This peptide sequence forms an imperfect (and putative) 
glycoseaminoglycan addition site. Any potential function of this segment will remain 
elusive until more is known about the cellular location of the each of the different 
DMPK isoforms (Mahadevan et al., 1993; Shaw et al., 1993b; Wieringa, 1994). Fu et 
al. (1993) has proposed two alternative N-terminal forms both of which were shorter 
than those proposed by Mahadevan et al. (1993) and Shaw et al. (1993b). It remains 
to be seen which initiators are actually used in vivo. As shown from the above 
different DMPK mRNAs carry open reading frames ending in regions which differ in 
length and use of reading frame. As a consequence, different hydrophobic tail pieces 
are predicted for the putative protein kinase. The finding of alternatively spliced and 
species specific mRNAs with different 3' coding information make it tempting to 
speculate that the variable C-terminus of the protein has a regulatory fimction as a
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kinase inhibitor site (Soderling, 1990) or functions in the differential anchoring of the 
kinase to cellular structures. A similar situation has been shown for muscle myosin 
heavy-chain gene (George et al., 1989).
Until now, not much data were available which address the structure-fimction 
relationship of the individual domains in the DMPK gene product(s) directly. The 
putative kinase may play a specific role in the regulation of excitation-contraction 
coupling or maintenance of cellular physiology via regulation of protein-protein 
interactions in ion channels (Roherkasten et al., 1988; Catterall, 1991) or insulin 
receptor signalling (Moxley et al., 1984). Abnormalities in phosphorylation of 
membrane proteins have been reported to be a characteristic finding in DM (Roses 
and Appel, 1974) and the application of protein kinase C modifier can evoke 
myotonia in mouse muscle (Brinkmeier and Jockusch, 1987). No clear evidence has 
been provided to indicate that the product of DMPK gene is the affected protein in 
DM, though the expression patterns of the gene (Jansen et al., 1992) suggest it is the 
most likely candidate. Antisera have been developed to peptide immunogene and 
fusion protein of the myotonin protein kinase. The antipeptide antibody detected 52- 
55 kd protein species (Fu et al., 1993; Brewster et al., 1993; van der Ven et al.,
1993). Brewster et al. (1993) showed that one of the antisera they developed also 
recognised a dominant 42 kd protein in brain. This smaller protein may result from 
alternative splicing or post-translational processing and be a genuine product of the 
DM-kinase gene. Van der Ven et al. (1993) found that the DMPK 53 kd protein is 
markedly concentrated at the sites of specialised membrane regions like 
neuromuscular junctions (NMJs) and myotendinous junctions (MTJs) in skeletal 
muscle, intercalated discs in the heart and dense plaques in smooth muscle cells. They 
also showed that Purkinje cells and several other neurones of the cerebellum and 
other parts of the brain have been stained by the anti-peptide antibody. The antifusion 
protein antibodies of the DMPK detected prominent protein species in heart, brain 
and skeletal muscle that were larger than the previously detected 52-55 kd species. 
These species (-74 and 82 kd) were more consistent with the size of the DMPK
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expressed in both bacteria and in insect from a full length cDNA. It is likely that the 
lower molecular weight species are detected through cross reactivity with the 
abundant kinases present in muscle and other tissues. This is supported by the fact 
that antibodies raised against the expressed C-terminal half of the DMPK only detect 
the larger species (Johnson and Siciliano, 1995). Using immunofluorescence, Whiting 
et al. (1995) found that the larger species of the DMPK were localised post- 
synaptically at the neuromuscular junctions of skeletal muscle, at intercalated discs of 
cardiac tissue and at the apical membrane of the ependyma and choroid plexus. 
Synaptic localisation of the DMPK in the cerebellum, hippocampus, midbrain and 
medulla was also noted. These results suggest that DMPK plays a specialised role in 
intercellular communications. While this is consistent with the abnormalities noted in 
the heart, the relationship between DMPK localisation at neuromuscular junctions and 
myotonia is uncertain. A selective action of this kinase within the central nervous 
system function has been suggested. However, what the function of DMPK may be in 
the brain is still a matter for speculation.
Studies of DM  kinase gene expression in myotonic dystrophy have provided 
discordant results. Both over-and under-expression, as well as unaltered DMPK 
expression have been reported (Jansen et al., 1993; Fu et al., 1993; Hofmann- 
Radvanyi et al., 1993; Roses et al., 1992; Sabourin et al., 1993; van der Ven et al., 
1993; Koga et al., 1994). Hofmann-Radvanyi et al. (1993) noted also decreased (20- 
30% of normal) expression of the unaffected allele.
Wang et al. (1995), using a new method for RNA quantitation and myopathic 
controls, suggested that the CTG expansion mutation has only a minor effect in the 
transcription and accumulation of the DM  kinase hnRNA from the diseased allele. 
Instead the mutation dramatically alters the ability of the mutant RNA to be processed 
into poly (A)+ mRNA. More importantly, the same expansion-containing hnRNA 
seems to affect the accumulation of the normal allele mRNA in trans. This 
interpretation suggests a dominant-negative RNA mutation model which is consistent 
with the dominant inheritance pattern observed in DM. Moreover, if the mutant RNA
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can affect alteration in the accumulation of the normal DM kinase mRNA, then it is 
possible that it can alter the accumulation of other species of mRNA sharing similar 
regulatory elements. This model could explain the tissue and development specific 
features of myotonic dystrophy. Each tissue has populations of stage specific RNAs, 
which could be affected differently by the expanded DM kinase RNA. However, a 
contrasting study has suggested that while post-transcriptional processing of the 
expansion allele mRNA is impaired, this has little effect on overall DMPK mRNA 
levels in heterozygous patient material (Krahe et al., 1995b).
It is still unclear if the DMPK gene is the only gene involved in DM. Although 
the mutation in the great majority of DM patients is expansion of the CTG repeat in 
the 3' region of the DMPK gene, there are a few cases in which this does not appear 
to be the case (Shaw and Harper, 1992). To my knowledge, there is no reported 
mutation in DMPK gene in such cases. Meiner et al. (1995) reported four such 
families, that fulfilled the criteria of DM diagnosis without CTG repeat expansion in 
the affected persons. Upon full sequencing of the coding region of DMPK gene in 
two of them they could not find any abnormal sequence alterations.
1.4 Motor neurone disease (MNP) [Amyotrophic lateral sclerosis 
(ALS)l
ALS is a progressive neurodegenerative disorder of adults resulting from 
variable combined degeneration of the lower motor neurones (LMN) and upper 
motor neurones (UMN). It is referred to as motor neurone disease (MND) in the UK 
and in some European countries, as amyotrophic lateral sclerosis (ALS) in the USA 
and as Charcot's disease in France. At least three types of the disease are recognised : 
classical sporadic disease, familial and usually dominantly inherited disease and the 
type seen in the high-incidence foci in the western Pacific Ocean (Guam, Kii 
Peninsula of Japan and West New Guinea) (Tandan, 1994).
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1.4.1 Clinical features of MNP [Amyotrophic Lateral Sclerosis (ALS)l
About 90 to 95% of cases of adult onset ALS that occur in Europe and USA 
are isolated. Males are twice as often affected as females. The annual incidence rate 
of classical sporadic MND has varied between 0.5 and 2.4 per 100,000 population, 
and the prevalence rate between 2.5 and 7 per 100,000 population world-wide in 
different studies (Kurtzke, 1991). There are no significant racial differences in the 
incidence, prevalence or death rate of the disease (Tandan, 1994). Onset is generally 
between 50 and 60 years though with a wide range, and mean duration of illness is 
three to four years. The early symptoms usually occur in the limbs or shoulders 
(Bundey, 1992).
Degeneration of the LMN typically produces focal or multifocal and often 
asymmetric muscle weakness and atrophy, cramps, prominent fasciculations, fatigue, 
dysarthria and dysphagia. Clinical involvement from UMN degeneration results in 
spasticity, pathological hyperreflexia, Babiniski sign, brisk jaw jerk and emotional 
lability. By the time of presentation, however, features of combined LMN and UMN 
degeneration are seen in the majority of classical MND patients.
Motor involvement is frequently asymmetrical, and at onset is more common 
in the hands and arms than in the legs and bulbar muscles. With eventual progression 
of the disease, bulbar weakness develops in almost 50% of patients, and respiratory 
muscle weakness occurs almost universally (Tandan, 1994).
About 5 to 10% of cases of ALS are familial (de Belleroche et al., 1995). The 
empirical risk of recurrence in a first degree relative is 1 to 2 %, that is about 1 0 0 0  
times commoner than in the population (Bundey, 1992). Horton et al. (1976) 
concluded that at least three forms of familial ALS (FALS) exist, each inherited as an 
autosomal dominant. In the most usual type, patients have a very similar illness to that 
seen in non-familial ALS, except that onset tends to be earlier ( 2 0  to 40 years), 
duration shorter (2 to 3 years), onset is generally with symptoms in the lower limbs 
rather than in the upper, and sensory symptoms are more frequent (Li et al., 1988).
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The second type, is about one-fifth as common as the first one, with identical clinical 
features but with more extensive pathological features. The third type is similar to the 
second type except for a much longer survival (usually beyond 1 0  and often 2 0  years) 
(Alberca et al., 1981). The initiation of the disease is usually focal and asymmetrical, 
lower motor neurone involvement is usually conspicuous in most cases whereas 
involvement of upper motor neurones is less marked.
There is incomplete penetrance being 0.8 at the age of 85 years. It is therefore 
not uncommon to see obligate carriers in a family who died without manifesting the 
disease (de Belleroche et al., 1995).
Phenotypic heterogeneity was seen in both sporadic and familial ALS. For 
example the age of onset may vary over 30 years within a family as can duration of 
illness (for example, 0.5 to 5 years) and signs at onset.
Although the overall median survival in classical MND is usually about 3 
years from onset of the disease, early diagnosis and more aggressive management 
have led to increased survival (Caroscio et al., 1987). It is generally agreed that, 
independent of the clinical variant of MND present, survival is greater in patients with 
onset of symptoms before the age of 50 years than after (Tandan, 1994). On the other 
hand Pradas et al. (1993) found that sex and age at clinical onset did not affect the 
deterioration rate in their studied group.
1.4.2 Genetics of ALS
1.4.2.1 Genetic linkage study of FALS
It is estimated that 5-10% of ALS cases have a familial aetiology. Siddique et 
al. (1989) presented preliminary data from genetic linkage analysis in 150 families 
with FALS. Two regions of possible linkage were identified on chromosome 11 and 
21. In 1991, a FALS locus was identified on human chromosome 21q22.1-q22.2 
(Siddique et al., 1991). Tests for heterogeneity in these families revealed a significant 
probability of locus heterogeneity. Therefore, it is clear that at least one other FALS
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gene is present in human genome. In 1993, a gene within this region encoding the 
protein cytosolic copper-zinc superoxide dismutase (SOD-1) was found to be in tight 
genetic linkage with FALS. Given this linkage and the potential role of free-radical 
toxicity in neurodegenerative disorders, Rosen et al. (1993) investigated SOD-1 as a 
candidate gene in FALS and identified 11 different missense mutations in different 
FALS families. Other workers failed to find linkage to chromosome 21 loci in their 
FALS families (King et al., 1993). This is to be expected because of the recognised 
heterogeneity. Moreover, the lack of mutations in SOD-1 gene in a number of FALS 
families confirm the genetic heterogeneity.
1.4.2.2 Conner-zinc superoxide dismutase gene (SOD-1) and its product
Cu/Zn SOD-1 is a cytoplasmic enzyme which is responsible for the conversion 
of the toxic free radical superoxide anion Oj~ to molecular oxygen and hydrogen 
peroxide. SOD-1 gene is one of three superoxide dismutase genes, each with a unique 
subcellular localisation; a second one Cu/Zn-containing SOD functions extracellularly 
and an Mn-containing SOD is found in mitochondria.
(11 Genomic structure of SOD-1 gene : The gene locus for human SOD-1 
was assigned to chromosome 21q2.2 (Tan et al., 1973). It has been shown that the 
SOD-1 gene has multiple polyA-addition signals and that there are two predominant 
mRNA species of 0.7 and 0.9 kb found in a variety of human cells. The major 0.7 kb 
species is approximately four times more abundant than the minor 0.9 kb mRNA 
(Sherman et al., 1983; Groner et al., 1986). Isolation of the human SOD-1 gene 
revealed that the two mRNAs are transcribed from a unique SOD-1 active gene on 
chromosome 21q2.2, and that sequence at the 3' untranslated region account for the 
difference between them (Hallewell et al., 1986). This has been further confirmed by 
detecting only one region of human DNA with nucleotide sequences identical to 
SOD-1 cDNA (Groner et al., 1986).
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SOD-1 gene, which is present as a single copy per haploid genome, is known 
to have five exons spanning approximately 11 kb. of genomic DNA of chromosome 
21q2.2 and is interrupted by four introns. In the donor sequence of the first intron a T 
to C transition occurred and hence it deviates from 5' GT...AG 3' consensus, but few 
cases of such violation of the 5' GT...AG 3' consensus have been reported (Levanon 
et al., 1985). At the 5' end of the gene there are the 'TATA' and 'CAT' promoter 
sequences as well as four copies of the -GGCGGG- hexanucleotide. Two of these - 
GC- elements are contained within a 13 nucleotide inverted repeat that can fold into a 
stem-loop structure (Groner et al., 1986). In some cases such sequences appear to 
activate transcription (Hallewell et al., 1986).
(21 SOD-1 related pseudogenes: Four iSOD-Z-related pseudogenes have 
been described by Groner et al. (1986). All these four sequences are devoid of 
introns, which typifies pseudogenes of the processed type (Lewin, 1990). Although 
the overall sequence homology of two of them to the SOD-1 gene was extensive yet 
they contain multiple genetic lesions, such as insertions, deletions and base 
substitutions resulting in-frame termination codons, that preclude the translation of 
the normal SOD-1 polypeptides. These processed pseudogenes do not reside on 
chromosome 2 1 .
(31 SOD-1 enzyme: Superoxide dismutases are thought to be an important 
component of the cellular defence mechanisms against oxidative damage mediated by 
superoxide radicals produced as a by-product of oxygen metabolism (Groner et al., 
1986). SOD-1, which is a cytoplasmic enzyme, is a dimer of 32 kilo dalton (kd) 
composed of two identical non-covalently linked subunits. Each subunit contains one 
zinc and one copper atom, the latter being directly involved in the dismutation 
reaction as an electron acceptor.
(Al SOD-1 enzyme and the free-radicals; A free-radical (FR) is an atom, 
molecule or other chemical species that is capable of independent existence and which
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has one or more unpaired electrons (Pall, 1994). They are usually short-lived as a 
consequence of being highly reactive, an effect resulting from their intrinsic need to 
gain an additional electron or to lose the unpaired one and hence achieve a stable 
electronic configuration. The oxygen-containing FRs include the superoxide (0 2*“) 
and the hydroxyl (OH*) radicals. Hydrogen peroxide (H2 0 2) is a reactive oxygen 
metabolite that is not a FR but which is capable of producing reactive FRs. Many 
biomolecules including DNA, polyunsaturated fatty acids and catecholamines are 
damaged by superoxide radicals (Halliwell and Gutteridge, 1989). Dismutation is the 
term applied to the reaction in which one superoxide radical reduces another to 
peroxide, itself becoming oxidised to oxygen in the process. This appears to be the 
function of the SOD enzymes. The hydroxyl radical (OH*) can also be produced from 
superoxide via hydrogen peroxide by low molecular weight/loosely bound complexes 
containing copper, iron and possibly manganese (fenton reaction). The superoxide 
anion can also react with nitric oxide to form peroxynitrite (Koppenol et al., 1992) 
(Figure 1.1).
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SOD-1
+H Glutathione
peroxidase;
Catalase+NO*
ONOO" — OH’ + N02 OH’ + OH" +Fe3+
(Fenton Reaction)
0 2*- Proteins
ONOO- => (e.g. Neurofilaments) => Oxidative injury 
OH* DNA & Lipids
Figure 1.1 (Top) The superoxide anion (02*-) can react with SOD-1 to be detoxified to form 
hydrogen peroxide(H20 2) that, in turn, is converted to water through the action of catalase 
and glutathione peroxidase. Superoxide may also combine with nitric oxide (NO*) to form 
peroxynitrite (ONOO-) which may then breakdown non-enzymatically to produce hydroxyl 
radicals (OH*). OH* may also be generated from hydrogen peroxide via Fe2+ (Fenton 
Reaction).
These reactive oxygen species may cause oxidative degradation of DNA, lipids and proteins 
(Bottom).
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Crvstallographic structure of the SOD-1 enzyme: Human SOD-1 is a 
dimeric enzyme with ellipsoidal dimensions of about 30x40x70 A. Each identical 
subunit contains 153 residues, one copper and one zinc ion. The two metal ions are 
located in the bottom of a channel formed by the topography of the molecular 
surface. The polypeptide fold of the SOD subunit consists primarily of two large 
loops and eight extended antiparallel p-strands. The overall topology is characterised 
as a Greek-key P barrel (Getzoff et al., 1986). Greek-key p barrel structures tend to 
be structurally quite stable. Overall, there are seven loops in SOD, numbered in 
sequence order. Loops I and V are short P-hairpin connections between adjacent p- 
strands. Loop II (residues 24-27) form the P-hairpin containing the two residue 
insertion relative to bovine SOD. Loops III (residues 37-40) and VI (residues 102- 
114) form the two Greek-key p-barrel connections. The active site channel with its 
bound metal ions is formed between electrostatic loop VII (residues 121-144), 
implicated in substrate attraction, and loop IV (residues 49-84), made up of the 
disulphide and the zinc ligand subloop regions. Superposition of the human SOD-1 
and bovine SOD- 1  structures indicated that the sequence changes do not alter the P- 
barrel diameter, strand angles, or loop conformations except in the region of the two 
amino acid insertion at sequence position 25 (Parge et al., 1992).
At critical position within or near the loops, 14 sequence-conserved, 
structurally- conserved (Parge et al., 1992) side chains appear to play important roles 
in loop conformation and interactions. Most of the dimer contacts are made between 
adjacent strands around the barrel (Getzoff et al., 1986). Cross sections through the 
dimer interface showed the complementarity of fit between the two buried surfaces 
(due to dimer contact), the interdigitation of side chains from one subunit to the 
other, and the twist of the dimer contact. By pulling the two subunits of the dimer 
apart hydrophilic regions contributed by oxygen and nitrogen atoms are scattered 
throughout the interface. Electrostatic potentials calculated from partial charges 
assigned to each of the atoms in the structure can also be mapped into the molecular 
surface. At the dimer interface, the centre of the pattern is electrostatically neutral and
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only the edges show significant electrostatic potential. The surfaces are 
electrostatically complementary to one another and essentially seal the edges of the 
dimer contact at protein-water interface (Getzoff et al., 1986). The copper and zinc 
ions are in high peaks of electron density and one unique feature of this enzyme active 
site is the bridge formed between the zinc and copper ions by the His-63 side chain 
(Getzoff et al., 1986; Parge et al., 1992). This bridge can be seen to be made and 
broken as the reaction proceeds.
Finally, reconstructing the enzymatic dimer and showing the electrostatic 
fields around the two active sites in the dimer emphasises that the enzyme is 
extremely efficient in attracting superoxide radicals (Getzoff et al., 1986).
1.4.2.3 SOD-1 gene and ALS
Of all cases of ALS, 5-10% are familial. Of the familial cases, fewer than 20% 
map to the SOD-1 gene, so there is locus heterogeneity (Rowland, 1995). The SOD-1 
gene was found to be mutated in several FALS families (Rosen et al., 1993). 
Although new mutations must occur, remarkably few have been identified in people 
with the sporadic disease (Jones et al., 1993; Jones et al., 1994). At present at least 
31 ALS missense mutations and one deletion have been characterised in the SOD-1 
gene. Over the last two years, several studies have begun to define the effects of the 
FALS mutations on SOD- 1  function, although many critical questions remain 
unanswered. It is now clear that the mutations reduce total cellular activity of the 
enzyme by 25 to 70%, as analysed in red blood cells, lymphoblastoid cell lines and 
cerebrospinal fluid. (Deng et al., 1993; Bowling et al., 1993; Robberecht et al., 1994; 
Orrell et al., 1995b).
The original demonstration of SOD-1 mutations led Rosen et al. (1993) to 
hypothesise that FALS could raise either by an increase in SOD-1 monomer activity 
(dominant gain of function) or the heterozygous mutation could cause mutant 
monomers to be functionally defective and inhibit wild-type monomers in the
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heterodimer (Dominant negative effect). A third possibility was that the mutation 
could cause a simple loss of function without any effect on the wild type monomer.
The elucidation of the structure of SOD-1 dimer by X-ray crystallography 
permits the localisation of the mutations in FALS (Denge et al., 1993). The majority 
of mutations detected to date lie in regions outside the active site affecting conserved 
regions of the enzyme at turns in the backbone of the protein (beta strands, Greek- 
key connections, turns of loop V) or in regions involved in the dimerisation of the 
two subunits. These mutations will affect the conformation or stability of the enzyme 
dimer (Deng et al., 1993). Overexpression of the normal SOD-1 gene inserted into 
transgenic mice resulted in increased lipid peroxidation (Elory-Stein et al., 1986) and 
distal tongue and hind limb motor deficits (Avraham et al., 1992) in such mice. These 
changes, which were not the classical FALS picture, may have been caused by 
overproduction of H2 O2  by SOD with subsequent paradoxical increase in OH* 
synthesis. In other mice transgenic for SOD-1 with more than 2 -fold overexpression 
of normal mouse SOD activity, paralytic disease has not been seen in animals 
followed to the adult life (Gurney et al., 1994).
Gurney et al. (1994) used transgenic mice to introduce either of two human 
mutant SOD-1 enzymes. The human enzyme was expressed, but at 50% of normal 
activity. The mouse genes also continued to function and, in one line of mice, there 
was overexpression of total SOD-1 nevertheless, the animals developed a clinical 
syndrome of hind limb paralysis, with histological signs of degeneration and loss of 
motor neurones in spinal cord. Similar results have been obtained by other 
investigators (Borchelt et al., 1994; Price et al., 1994). Ripps et al. (1995) 
supplemented Gurney et al. (1994) observations. By using site-directed mutagenesis, 
they introduce a missense mutation, Gly8 6 Arg, which corresponds to a human 
mutation observed in codon 85 (Rosen et al., 1993; Denge et al., 1993), into 
transgenic mice. SOD enzyme activity in these animals did not reveal a diminution of 
activity. However, in two lines of mice, that produce high levels of transgene mRNA
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in the CNS, motor paralysis developed and was associated with degenerative changes 
of motor neurones within the spinal cord, brain stem and neocortex.
More interesting has been the observation that in the case of some mutations 
enzyme activity is only minimally affected despite a normal clinical presentation of the 
disease (Esteban et al., 1994). In one of these mutations, Gly37Arg, it has been 
shown from transient expression of this mutant in primate cells that the mutation 
leads to full activity, in contrast to other SOD mutants studied under similar 
conditions (Borchelt et al., 1994). However, in all cases, including Gly37Arg, 
polypeptide stability of the mutant subunit was found to be reduced. Moreover, a 
mutation has been identified at the active site in codon 125 (Enayat et al., 1995) 
which led to a major charge effects. However, it is associated with a classical form of 
FALS with no evidence that this location of mutation has a greater effect on the 
course of the disease. A mutation in exon 2, His46Arg, was associated with a more 
benign form of the disease and had only slightly reduced (20%) levels of SOD-1 
enzyme activity (Ogasawara et al., 1993). This mutation was the first mutation to be 
detected in the active site, the residue histidine being important in copper binding 
which is essential to the catalytic activity of the enzyme. Recently, Enayat et al., 
(1995) reported a mutation His48Gln. Both His46 and His48 are highly conserved 
residues and are important for copper binding. However, His48 mutation was 
associated with a relatively severe nature of the disease which contrasts with the 
benign course of the His46 mutation.
The Ilell3Thr mutation has been detected in three out of 56 sporadic cases 
in the population based study of Scotland (Jones et al., 1993). A single case of an 
exon 1 mutation, Glu21Lys, has been detected in this cohort as well (Jones et al.,
1994). There are no other published reports of SOD-1 mutations in sporadic cases, 
although several hundred cases have been screened in North America and the 
possibility of incomplete penetrance within the families together with incomplete 
family history can not be ruled out in these cases (de Belleroche et al., 1995).
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How do SOD-1 mutations cause ALS?. Gurney et al. (1994) and others 
(Gurney, 1994; Rowland, 1995; de Belleroche et al., 1995; Brown, Jr., 1995) 
suggested some mechanisms to explain the pathogenetic effect of SOD-1 mutations 
on FALS. All the mechanisms they suggest were consistent with the idea that 
mutations in SOD-1 cause an acquisition of injurious properties by the mutant 
enzyme. The first explanation they suggest is that SOD-1 mutations potentiate 
catalysis of normally unfavourable side reactions to which motor neurones are 
selectively vulnerable. As it is known, in addition to the dismutation reaction 2H+ + 
02*“ —» H2 0 2 , SOD also catalyses several alternate reactions including : (1) the 
formation of the hydroxyl radical from hydrogen peroxide and (2 ) the nitration of 
proteins on tyrosine residues by peroxynitrite. Such side reactions might be facilitated 
by mutations, and to a lesser extent, by high expression of the wild-type enzyme. The 
rate limiting step in reactions (1 ) and (2 ) may be the access of reactants to the copper 
catalytic centre at the bottom of the active site channel. By relaxing constraints on the 
size of the active site channel, the mutation found in affected families might cause a 
"gain-of-function" by facilitating one or more of these alternative reactions. If this is 
true, then high expression of the wild-type enzyme may cause subclinical pathology 
(Gurney, 1994), but more work will need to be done to prove this.
Alternatively, the mutations might adversely affect the binding of copper and 
that cation, in local excess, might have toxic consequences (Rowland, 1995). Thirdly, 
the mutant enzyme may be so unstable that it precipitates to form toxic cytoplasmic 
aggregates. There may be more than one mechanism or a combination of mechanisms, 
some causing peroxidation but others having nothing to do with free radicals.
Glutamate, excitotoxicitv and motor neurone selectivity: The selective 
vulnerability of motor neurones in ALS may depend on specific features of these 
neurones. Motor neurones are seen to possess very high levels of SOD-1 mRNA 
(Tsuda et al., 1994). These neurones which may be critically dependent on SOD-1 for 
protection against superoxide may potentially become susceptible targets for 
additional adverse effects of the protein. On the other hand, an important feature
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distinguishing motor neurones from dorsal root neurones, which do not degenerate in 
ALS, is the presence of excitatory synapses on the former. Glutamatergic excitatory 
synaptic input was suspected to enhance the sensitivity of motor neurones to free 
radical injury. One popular hypothesis is that the activation of nitric oxide synapse by 
N-methyl-D-aspartate (NMD A) glutamate receptors leads to the generation of nitric 
oxide (NO) which reacts readily with superoxide to produce the toxic species 
peroxynitrite, which in turn releases hydroxyl free radicals (Lafon-Cazal et al., 1993). 
Following stimulation of NMDA-sensitive glutamate receptors, 0 2 m~ activated cell 
death was dependent on calcium (Ca2+) and release of arachidonate and was reduced 
by trapping 02*“ (Lafon-Cazal et al., 1993). The motor neurones may be particularly 
sensitive to increase in cytosolic calcium levels because, by comparison with other 
types of neurones, it is relatively poor in some calcium binding proteins (Ince et al.,
1993).
1.5 Tuberous sclerosis (Bourneville disease: Epiloia; TSC)
1.5.1 Clinical manifestations
Tuberous sclerosis complex (TSC) is a disease that affects all tissues. It is 
characterised by the growth of benign tumours (hamartomas) and malformations 
(hamartias) in one or more organs. Its prevalence is between 10 to 14 in 100,000 
persons, more common than previously thought (Hunt and Lindenbaum, 1984; 
Sampson et al., 1988; Sampson et al., 1989a), making it one of the most common 
autosomal dominant disorders. The common clinical picture of TSC is that of a 
mentally retarded epileptic patient with facial angiofibromas (adenoma sebaceum). 
However, milder manifestation may occur and, indeed, the manifestation of TSC may 
be very variable (Bundey, 1992). The organs most frequently involved , in addition to 
the brain and retina, are the skin, kidneys, heart and lungs.
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The full clinical picture evolves gradually and differences are to be expected in 
the presentation in children and adults. Skin lesions due to their accessibility often 
lead to diagnosis of TSC. Hypopigmented macules, which fluoresce under Wood’s 
(UV) light are the earliest signs of TSC. They are probably present at birth in most 
cases. They vary in shape and are only occasionally in the form of mountain ash leaf 
as described by Fitzpatrick et al. (1968). With the passage of time pigmentation does 
occur within the macules (Baraitser, 1990).
Facial angiofibromas (previously misnamed as adenoma sebaceum) are dome­
shaped papules symmetrically distributed on the nasolabial folds, cheeks and chin, but 
with spare of the upper lip and philtrum. Only 50% of patients have this sign (Gomez,
1991). This hamartoma, rarely found before 3 years of age, is usually present by 5 
years and rarely appears after puberty. Two other hamartomas, the periungual 
fibromata and shagreen patches (flat or slightly elevated, flesh-coloured and wrinkled, 
like pigskin), do not develop until the second decade in approximately 20% and 40% 
of patients respectively, and both do not necessarily occur in the same patient. The 
ungual fibroma is pathognomonic, but the shagreen patch is not (Gomez, 1991). 
Pigmented nevi and sublingual fibromata are other cutaneous manifestations seen in 
TSC patients. If, by puberty, no skin lesions have appeared they are unlikely to 
develop in adolescence or adult life (Baraitser, 1990). Fibrous forehead, eyelid, 
cheek, or scalp plaque, can be found at a younger age than can the facial 
angiofibroma, and unlike the facial angiofibroma, it is often seen at birth. The large 
ones on the scalp tend to calcify after many years (Gomez, 1991).
Epilepsy (usually beginning with infantile spasms) occurs in about 80% and 
mental retardation occurs in 60-70% of TSC affected individuals. It is a useful rule of 
thumb that seizures might occur without mental retardation, but the diagnosis is 
unlikely in those with mental retardation without seizures (Baraitser, 1990). Mental 
retardation is of variable severity and may be profound and its pathogenesis is 
obscure. Although, Gomez (1979) suggested that there is a relationship between the 
severity of the seizures and mental retardation this might not be so simple. Central
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nervous system lesions are of two types (Baraitser, 1990), pale, hard gliotic areas in 
the convolutions known as tubers, and multiple tumour-like nodules which have a 
predilection for the subependymal region (giant cell astrocytoma) and project into the 
ventricles giving the radiological picture of candle guttering. The subependymal 
nodules usually calcify and are demonstrable by CAT scan in the brains of some 80% 
of affected individuals (Houser and Nixon, 1988).
Retinal phakomatoses are present in about half of the gene carriers at birth 
(Baraitser, 1990). They are glial cell hamartomas which may be flat or nodular. The 
nodular variety frequently calcify but significant visual impairment is unusual 
(Sampson, 1990).
Kidney lesions are in the form of angiomyolipoma (Anderson and Tannen, 
1969). Indeed, Van Baal et al. (1989) found renal angiomyolipomas in 23 of 38 
patients with proven tuberous sclerosis. Renal cysts are less commonly seen (15% of 
the cases) than renal angiomyolipomas (Gomez, 1991). Multiplicity and bilateral 
localisation were important differences between the TSC cases and the isolated, 
usually solitary, cases. Renal lesions are more common in females and usually 
asymptomatic but cystic disease, when florid, can lead to hypertension or chronic 
renal failure (Sampson, 1990).
Single or multiple (usually) rhabdomyomas occur in 30% of TSC patients 
coming to post-mortem (Baraitser, 1990). The lesions seem to regress by age and 
serious morbidity or mortality due to their presence is unusual after early childhood 
(Sampson, 1990). Most patients seem to be asymptomatic but it may lead to 
mechanical and conductive problems in infancy.
Pulmonary involvement is infrequent and almost exclusively confined to 
women with TSC in the third or fourth decade of life (Gomez, 1991). Angiolipomas 
of the liver and spleen which can be detected by ultrasound or CAT scan have been 
reported (Sampson, 1990).
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1.5.2 Genetics
A sufficient number of multigenerational families have been reported to make 
it clear that TSC is an autosomal dominant condition (Bundey and Evans, 1969; 
Gomez, 1991). Sixty to 90% of cases are isolated and many of these are likely to be 
new mutants. The mutation rate of TSC is estimated to be 2.5 x 10 s mutation per 
gene per generation (Hunt and Lindenbaum, 1984; Sampson et al., 1989a).
1.5.2.1 Phenotypic variability
TSC is notable for its phenotypic variability, which can range from clinical 
normality to dysfunction of multiple organs. Moreover, there is great variability 
within families, and many examples where a single lesion is the only manifestation of 
the disease. In addition, there have been reports of clinically normal parents who have 
had normal CAT scans, but who have two affected children (Wilson and Carter, 
1978; Connor et al., 1986). The probable explanation for those parents who have one 
sign only, or who have no signs but two affected children, is that they have mosaicism 
of their germ cells, with or without mosaicism of somatic cells (Hall and Byers,
1987). Webb and Osborne (1991) reported an instance of apparent non-penetrance in 
two successive generations, between a great-grandfather and his great-grandson. The 
great- grandfather developed a single fleshy ungual fibroma on 1 little toe as the only 
clinical sign; on echocardiography, he showed 2 probable rhabdomyomata in the right 
ventricular wall and right ventricular outflow tract. His daughter had no discernible 
features of the disorder.
1.5.2.2 Linkage studies and locus heterogeneity
Linkage studies have demonstrated locus heterogeneity for TSC. In 1987 a 
TSC locus (now termed TSC1) was assigned to 9q34 (Fryer et al., 1987). This finding 
had been confirmed by different groups of investigators (Sampson et al., 1989b;
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Haines et al., 1991a&b; Janssen et al., 1991; Northrup et al., 1992). The uncertain 
level of locus heterogeneity made it extremely difficult to exclude the possibility of 
subgroups of families linked to particular chromosome regions. Clark et al. (1989) 
described a t(l lq23.3;22ql 1.1) unbalanced translocation in livebom infant with TSC. 
A study indicating linkage between TSC and markers on distal 1 lq seemed to support 
an 1 lq locus (Smith et al., 1990). Subsequently more extensive studies under 
different models of heterogeneity proved inconclusive, leaving the provisional 
assignment in doubt (Kandt et al., 1992; Short et al., 1992). Fahsold et al. (1991) 
reported the association of TSC with a balanced translocation t(3;12)(p26.3;q23.3) 
followed by a report of linkage between TSC and PAH gene locus on 12q. Short et 
al. (1992) found little or no evidence for a TSC locus on 1 lq, 12q, or 14q. Sampson 
et al. (1992) collated data on 1,622 members of 128 tuberous sclerosis families. They 
estimated that the locus on 9q34 accounts for approximately 50% of families and 
concluded that there was no evidence of major loci on 1 lq or 12q. Meanwhile, 
indisputable evidence for linkage between TSC and marker at 16pl3.3 was 
established by investigation of five large families in which TSC was clearly unlinked 
to chromosome 9 (Kandt et al., 1992). Confirmation of a tuberous sclerosis locus on 
chromosome 16 was provided by Pericak-Vance et al. (1992), Short et al. (1992) and 
Smith et al. (1992). With the growing consensus that there is no form of TSC 
encoded by either chromosome 11 or chromosome 12, it seemed desirable to refer to 
the chromosome 16 form of tuberous sclerosis as TSC2. It was estimated that linked 
TSC families are evenly divided between these two loci (Kwiatkowski et al., 1993).
1.5.2.3 TSC genes as tumour suppressor genes
TSC is an autosomal dominant condition characterised by tumour-like malformations 
of different organs and tissues. Another autosomal dominant condition with some 
resemblance to TSC is neurofibromatosis type 1 (NF1) characterised by benign 
tumours of peripheral nerves, pigmented skin lesions and retinal hamartomas. The
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gene for NF1 has been cloned and a somatic deletion of the normal allele has been 
described in neurofibrosarcoma from a familial case of NF1 (Legius et al., 1993).This 
gave rise to the suggestion that NF1 gene acts as a tumour suppressor (Seizinger,
1993) which fits with the Knudson’s two-hit hypothesis (Knudson, 1971). There has 
been speculation that the lesions in TSC might arise in a similar way (Comings, 
1980). Loss of heterozygosity (loss of alleles at constitutionally heterozygous loci 
near the genes; LOH) at TSC1 and 7SC2-associated markers has now been 
demonstrated in hamartomatous lesions of some TSC patients (Green et al., 
1994a&b; Carbonara et al., 1994). The pattern of LOH at 16pl3.3 (TSC2 locus) is 
only 30 kb from the cloned TSC2 gene (The European chromosome 16 Tuberous 
Sclerosis Consortium). On 9q34 (TSC1 locus), LOH is consistent with the map 
position of TSC1 defined by haplotype analysis in TSC families and the segregation 
analysis showed that the 9q34 haplotype lost carried the putative normal TSC1 gene 
product in one family (Kwiatkowski et al., 1993; Carbonara et al., 1994). These data, 
together with the discovery of germline deletions in the TSC2 gene in 5% of TSC 
patients, support the hypothesis that TSC1 and TSC2 genes act as growth suppressor 
genes, analogous to the traditional tumour suppressor genes. Due to the well known 
benign, slow growth of the hamartomatous cells and because TSC is not considered 
as cancer-prone disease, the definition of TSCJ and TSC2 genes as anti-oncogenes 
seems inappropriate, and terms such as stem cell growth suppressors should better 
represent their putative function (Carbonara et al., 1994). Moreover, in the same 
astrocytoma (Carbonara et al., 1994) an additional region of LOH is present at 9p21. 
The possibility of the presence of another gene controlling tumour progression, 
differentiation and/or stem cell proliferation in that region needs further 
investigations.
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1.5.2.4 Positional cloning and characterisation of the TSC2 gene
(1)positional Cloning : Linkage studies have established locus heterogeneity 
with disease-determining loci on chromosomes 9q34 and 16pl3.3, leading to 
apparently indistinguishable phenotypes. The Genome Data Base Nomenclature 
Committee agreed that the loci on chromosomes 9 and 16 should be termed TSC I 
and TSC2, respectively. It was considered that as the TSC genes probably act as cell 
growth suppressors, and if a two-hit mechanism, as proposed by Knudson (1971), 
does apply to TSC, then constitutional deletions might be associated with the TSC 
phenotype in a proportion of cases, the same as that seen in the case of NF1 gene 
(Viskochil et al., 1990). TSC has not been noted in individuals with the chromosome 
16 a-thalassaemia/mental retardation syndrome (ATR-16), who have terminal 
deletions of 16p which extended into the TSC2 area. This suggested that TSC2 was 
localised to the proximal 300 kb of the candidate region. Using pulsed field gel 
electrophoresis (PFGE), The European Chromosome 16 Tuberous Sclerosis 
Consortium (1993) identified five tuberous sclerosis-associated deletions at 16pl3.3. 
These were mapped to a 120-kb region that was cloned in cosmids and from which 4 
genes were isolated. One gene, designated TSC2, was interrupted by all 5 PFGE 
deletions, and closer examination, using TSC2 cDNA subclones as hybridisation 
probes, revealed several intragenic mutations, including one de novo deletion. In this 
case, Northern blot analysis identified a shortened transcript, while reduced 
expression was observed in another TSC family, confirming the TSC2 as the 
chromosome 16 TSC gene.
(2) Characterisation of TSC2 gene : A zoo blot containing genomic DNA 
from various animal species revealed that the TSC2 gene was conserved throughout 
the higher vertebrates. TSC2 is widely expressed and both fibroblasts and 
lymphoblastoid cell lines represent good sources of RNA. The TSC2 transcript is 
composed of ~ 5.5 kb covering a genomic region of -4 3  kb. The cDNA contains an 
open reading frame extending from nucleotide 1 to 5370. The inframe AUG start
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codon was found at nucleotide position 19. At the 3' end are two potentially 
overlapping polyadenylation signals (AATAAA-TAAA) at nucleotide 5425. The 
occurrence of this doublet may cause differential polyadenylation, since there have 
been detected polyadenylation sites that differ by up to 15 bp in four different cDNA 
clones. In one family in which TSC has been shown to co-segregate with 
chromosome 16pl3.3 markers, but in which the deletion in TSC2 locus has not been 
identified, the affected members showed clearly reduced levels of TSC2 transcripts 
(The European Chromosome 16 Tuberous Sclerosis Consortium, 1993).
Maheshwar et al. (1996) characterised the exon/intron boundaries of the TSC2 
gene. It has been found that the gene comprises 41 exons, including the alternatively 
spliced exon 31 which was absent from the originally described human TSC2 
transcript. This exon has been found in one human foetal brain cDNA clone but was 
absent in RNA extracted from human lymphoblastoid cell line. Comparative analysis 
of the TSC2 gene in human and pufferfish (Fugu rubripes) showed 65% sequence 
homology at the nucleotide level.
OYTuberin. the protein product of the TSC2 gene : The total length of the 
predicted protein is 1784 (plus 23 from the alternatively spliced exon 31) amino acids, 
with a calculated molecular mass of -198 kd. Four potential transmembrane domains 
and four potential glycosylation sites were observed downstream of the last putative 
transmembrane domain. No sequence at the amino terminus of the predicted protein 
matched the signal peptide structure as defined by von Heijne (1985). However, the 
occurrence of several transmembrane domains without an apparent signal peptide was 
noted in cystic fibrosis-related protein (Riodran et al., 1989). A periodic array of 
leucine residues (the leucine zipper), a structure associated with protein-protein 
interaction was also observed. Of considerable interest, but undetermined functional 
significance, is a small region of homology to the GTPase activating protein rap 1 GAP 
(GAP3), which suggests that tuberin may itself have GAP activity, consistent with its 
proposed function as a tumour or a stem cell growth suppressor (Green et al., 1994a; 
Carbonara et al., 1994). After optimal alignment the protein product of the TSC2
gene in Fugu and humans revealed 60% identity of amino acid residues, with 79% 
similarity if conservative changes were included (Maheshwar et al., 1996). Four 
regions of high conservation were identified. These include the GAP-related domain 
(human residues 1593-1631) and the sequences flanking this, two small regions 
between residues 750 and 1100, and the N-terminal portion of the molecule. Using 
anti-sera against the N-terminal and the C-terminal portions of the tuberin, Wienecke 
et al. (1995) specifically recognised a 180 kd protein. A wide variety of human cell 
lines express the 180 kd tuberin protein, and subcellular fraction revealed that most 
tuberin is found in a membrane/particulate fraction. Small differences in migration 
rate of tuberin were observed in some cell lines. This might reflect post-translational 
modification or alternative splicing. Immunoprecipitates of native tuberin contain an 
activity that specifically stimulates the intrinsic GTPase activity of Rap la. Tuberin 
does not stimulate GTPase activity of Rap2, Ha-Ras, Rac, or Rho. These results 
suggest that the loss of tuberin leads to constitutive activation of Rap 1 in tumours of 
patients with tuberous sclerosis (Figure 1.2).
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Figure 1.2 (Top) Ras-related family of small GTP-binding proteins bind and hydrolyse 
GTP. They are active when bound to GTP and inactive in the GDP-bound state. Cellular 
regulatory proteins regulate guanine nucleotide binding Ras-related GTPases. GAP proteins 
act by stimulating the intrinsic GTPase of the GTP-binding proteins, keeping them in the 
inactive, GDP-bound state.
(Bottom) Rapla and Raplb GTPases were suggested to have negative effect on cell growth 
either by antagonising Ras through competitive binding of Rapl to Ras effector molecules or 
through transduction of growth-inhibitory signals. In accordance with this scenario, tuberin 
might function as an effector protein (as well as a GAP) for Rapl, and loss of tuberin 
expression would prevent transmission of the growth-inhibitory signals originating from 
Rapl. Alternatively, there is evidence that Rapl, like Ras, may mediate a positive growth 
signal and because tuberin is suggested to have a Rapl-GAP activity it may bind to the Rapl 
preventing it from interacting with its mitogenic effectors. Loss of tuberin expression in cells 
would free up Rapl, thereby allowing it to transmit a positive signal through its effectors.
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1.6 Methods for mutation detection
Detection of mutations and polymorphisms in DNA is an important feature of 
the investigation of gene structure and function. Furthermore, easy identification of 
specific sequences and sequence changes plays a central role in the diagnosis of 
human inherited diseases. Procedures for mutation detection can be separated into 
two distinct groups. The first consists of techniques which efficiently identify known 
disease alleles, e.g. population screening for carriers of the common cystic fibrosis 
mutations. The second group consists of methods to scan sequences for unknown 
mutations.
1.6.1 Methods to detect known sequence alterations
Once mutations or polymorphisms have been described they can be searched 
for using one of the following conditions
(1) Allele-specific oligonucleotide (ASOl
This is a hybridisation based method where sequence variants are 
distinguished by taking advantage of the difference in stability of hybrids formed 
between target sequence (usually amplified by PCR) and oligonucleotide probes that 
are perfectly matched or mismatched to the target sequence (Wallace et al., 1979). 
The original method involved probing separated bands which had been transferred to 
a membrane, but more recently the sample has been directly transferred to the 
membrane (the dot blot). Short oligonucleotide probes of about 19 nucleotides 
corresponding to a particular region of a gene are prepared. Two probes are made; 
one has the normal sequence, while the other is identical except for a single altered 
base corresponding to particular mutation. By carefully regulating hybridisation 
conditions, it is possible to arrange things so that the normal probe hybridises to the 
normal but not to the mutant DNA, while the mutant probe hybridises to the mutant 
but not to the normal DNA. Both radiolabelled and fluorescently labelled probes have
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been used. In the reverse blot (Saiki et al., 1989) different probes were spotted onto 
the membrane and the biotin-labelled target sample applied. The probes forming 
duplexes without mismatches and retaining the target became stained with HRP 
avidin. The main advantage of the current method is that it does not require 
electrophoresis and the method is non-radioactive. The main disadvantage is that two 
primers have to be synthesised for amplification and two more, mutant and wild-type, 
for mutation detection.
(2) Amplification refractory mutation system (ARMS)
The technique was first described by Newton et al. (1989). It is based on the 
concept that PCR primers with the 3' end complementary either to a mutant or a 
normal nucleotide sequence can be used to selectively amplify one or the other allele. 
This is due to the lack of 3' exonucleolytic proof reading activity of Taq DNA 
polymerase. Two target DNA samples, from each patient, were PCR amplified with a 
wild-type or mutant primer and a common primer. The mutant and the wild-type 
primers differ at their 3' ends by a single base which corresponds to the wild-type and 
mutant alleles. As a control, internal primers are added in the same reaction. Upon gel 
electrophoresis of the two target samples the presence of a band defines the presence 
of the corresponding allele. The main advantage of this method is that it requires only 
a single PCR reaction and a result is obtained in a matter of hours. Also, the 
technique can be automated for screening of large number of samples. This technique 
is very useful in screening for a common mutation in a gene such as AF508, the 
common cystic fibrosis mutation. PCR amplification of multiple specific alleles 
(PAMSA) has been shown to be possible by the use of primers that generate PCR 
products of different lengths. Mistry et al. (1992) have been used PAMSA technique 
to screen for 6 Gaucher's alleles in 12 patients.
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(3) Artificial introduction of restriction sites (AIRS)
When a mutation changes a restriction site, it can readily be sought in a 
genome. Unfortunately, most mutations do not change a restriction site. Cohen and 
Levinson (1988) developed a strategy to introduce a restriction site by mismatched 
primers in the region of a mutation for either the wild type or mutant sequence. In this 
method an artificial restriction site is introduced, by a primer that has one base 
mismatch near to the site of mutation. Presence of the mutation will make the proper 
recognition site for a specific restriction endonuclease. Digestion of the PCR products 
using this enzyme followed by gel electrophoresis will enable the identification of the 
absence or presence of the mutation in the sample. This method has been successfully 
used by researchers ( e.g. Ng et al., 1991; Taroni et al., 1993; and Grau and Griffais,
1994) to screen for common mutations in different genes.
1.6.2 Methods to scan sequences for unknown mutations
While several useful technologies for the detection of sequence heterogeneity 
exist, no single method is applicable for all situations. The most appropriate screening 
technology is influenced by the expected nature of the mutation, size and structure of 
the gene in question, degree of sensitivity required and resources available. The 
spectrum of mutations ranges from cytogenetically visible chromosome re­
arrangements to micro-deletions and insertions and finally single base alterations.
1.6.2.1 Detection of large gene alterations
Large gene alterations are mutations in which substantial portions (>500 bp) 
of the gene are deleted, duplicated or otherwise rearranged (Grompe, 1993). 
Techniques used for this kind of mutation detection includes cytogenetic techniques, 
Southern blotting, pulsed field gel electrophoresis (PFGE) and multiplex PCR.
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(1) Cytogenetic techniques
Extremely large (> 4 megabases (Mb)) deletions and insertions can be 
detected by high resolution cytogenetics. The use of fluorescent in situ hybridisation 
(FISH) has improved the power of cytogenetic analysis. FISH uses fluorescently 
labelled DNA probes, which are hybridised to chromosome spreads, to detect both 
numerical and structural chromosome aberrations not only in metaphase, but also in 
interphase nucleus. FISH is particularly suited for the detection of aneuploidy, 
microdeletions or duplications and complex rearrangements (Lichter and Cremer, 
1992).
(21 Southern blot hybridisation
The Southern blotting technique, developed in 1975 by E. Southern, is the 
standard way of analysing the structure of DNA cleaved by restriction enzymes and 
agarose gel electrophoresed. It remains one of the fastest methods to quickly screen 
for mutations. No detailed knowledge of the structure and sequence of a gene is 
required and a preliminary screen can be carried out with a probe of interest 
immediately after its isolation. Large deletions and insertions may be detected by the 
presence of junction fragments or changes in band intensities (in case of autosomal 
dominant conditions and mutation carriers). Point mutations may be also detected, if 
they alter restriction sites. By using appropriate restriction enzymes and probes 
Southern blotting has been used successfully to detect trinucleotide repeat expansion 
in patients with FRAXA and myotonic dystrophy where a massive expansion of the 
repeats occurs in patients with full blown clinical presentation (Fu et al., 1991 and 
Harley et al., 1992).
(31 Pulsed field gel electrophoresis (PFGE)
The gels that have been used for traditional southern blotting can only 
separate DNA fragments of about 20 kb or less. Molecules of this size have linear 
dimensions comparable to the pore size of the gel. On the other hand very large
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molecules, of 100 to 500 kb for example, are much larger or longer than the pores. 
However, even they can move into a gel by finding a path that involves many pores 
simultaneously. In this type of migration the forward force is proportional to the 
electric charge of the molecule, that is its length, and the drag due to friction is 
proportional to the number of pores through which the large molecule is passing, 
again being related to its length. The overall effect is that large molecules of different 
sizes move at the same rate and are not separated (Weatherall, 1991).
The principle of PFGE is periodically to change the orientation of the electric 
field. Every time this happens the large extended molecules must re-orientate and find 
a path through the gel matrix in other direction. This process is size dependent, that is 
very large molecules will take more time to re-orientate than shorter ones. This 
allows the resolution of DNA fragments of 100 to 1000 Kb in size and, in some cases, 
even larger. The large fragments for PFGE are generated by using restriction enzymes 
which have infrequent cutting sites such as Notl and Sfil. The resultant gels can be 
Southern blotted and probed by standard methods. This technique allows the 
identification of major deletions and major chromosomal rearrangements in a single 
test (Weatherall, 1991).
14) Multiplex PCR for the detection of deletions
If a locus of interest is prone to deletions and if its genomic sequences are 
known, the simultaneous PCR amplification of several sequences throughout the gene 
is the most rapid and practical method for their detection. Deletions are indicated by 
the absence of some of the bands in the multiplex pattern in homozygotes. In 
heterozygotes, in spite of being technically difficult, deletions are seen as 50% 
reduction of band intensities in a quantitative analysis of the multiplex PCR reaction 
(Abbs and Bobrow, 1992). The introduction of dye labelled primers and automated 
computer analysis of the multiplex PCR products facilitates this technique. This 
method has been used widely in screening for deletions in Duchenne muscular 
dystrophy, in which 60% of cases represent deletions (Grompe, 1993).
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1.6.2.2 Detection of single base changes and small sequence alterations
Single base substitution and small sequence alterations are the most common 
type of mutation at most loci. A number of methods may be used for detecting these 
subtle changes. All the methods used are polymerase chain reaction (PCR) based 
detection methods using either genomic DNA and/or mRNA as a starting material for 
mutation analysis (Table 1.1). PCR is a technique for the in vitro amplification of 
specific DNA or RNA sequences. The PCR method was devised and named by Mullis 
and Faloona (1987) at the Cetus Corporation, although the principle has been 
described in details by Khorana and colleagues over a decade earlier (Taylor, 1993). 
In brief, PCR is based on the enzymatic amplification of a fragment of DNA that is 
flanked by two short oligonucleotides "primers" that hybridise to the opposite strands 
of the target sequence. A repetitive series of cycles involving template denaturation, 
primer annealing and the extension of the annealed primers by DNA polymerase 
results in the exponential accumulation of a specific fragment whose termini are 
defined by the 5' ends of the primers. Twenty cycles of PCR yields about a million 
fold amplification of the specific DNA fragment.
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Table 1.1 Genomic DNA versus mRNA as a starting material for mutation 
analysis (Grompe, 1993)
Genomic DNA mRNA
Advantages
Easily accessible (blood)
In autosomal loci both alleles 
are equally represented 
Mutations in the promoter and 
intronic splice junctions can be 
detected
First choice in autosomal 
dominant traits
Disadvantages
Genomic sequence and gene 
structure information are needed 
Only small segments of coding 
region (exons) are analysed 
More PCR reactions
Long segment of peptide coding 
region can be analysed 
Gene structure information not needed 
Fewer PCR reactions 
Aberrant mRNA size can be 
seen
First choice in X-linked traits
Gene may not be expressed in 
accessible specimens 
In autosomal loci only one allele 
may be represented 
Mutations in promoter and 
intronic splice junctions are not 
detected
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Some important strategies for mutation detection of unknown single base
changes and/or small sequence alterations are as follows :
(1) Single strand conformational polymorphism (SSCPI analysis
Of the various methods applied for the detection of unknown mutations SSCP 
is by far the easiest and cheapest procedure presently available. In 1989, Orita et al. 
first report the use of SSCP to detect mutations. Wild type and mutant target DNAs 
are amplified by PCR, denatured and then electrophoresed side by side through a non­
denaturing polyacrylamide gel. The two single-stranded DNA molecules from each 
denatured PCR product assume a three-dimensional conformation which is dependent 
on their primary sequence. If a sequence difference (mutation) exists between wild- 
type and mutant DNA, this may result in differential migration of one or both of the 
mutant strands. PCR products with altered migration patterns can then be analysed by 
DNA sequencing to determine the exact nature of the alteration. In most published 
studies the amplification products are rendered radioactive by the addition of 32P 
dCTP to the PCR reaction (Glavac and Dean, 1993). However, non-radioactive 
detection by ethidium bromide staining and silver staining (Grade et al., 1994) have 
been successfully used. No adequate theoretical model is available for predicting the 
three dimensional structure of single stranded DNA under a given set of conditions. 
Accordingly, the effects of mutations on DNA mobility in an SSCP gel cannot be 
reliably predicted.
Different data concerning the efficiency of SSCP have been reported. In 
general, SSCP analysis detects 70 to 95% of mutations in PCR product of 200 bp or 
less (Grompe, 1993). The sensitivity of the method decreases with the size of the 
PCR product and is less than 50% when fragments of > 400 bp are analysed. Some of 
the size limitations of the method may be overcome by restriction digestion of a larger 
amplification product prior to electrophoresis (Iwahana et al., 1992). The use of RNA 
generated by in vitro transcription of PCR products also appears to improve detection 
of mutations in larger fragments (Sarkar et al., 1992a). This modification of SSCP
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requires longer primer (to include phage RNA promoters) and extra experimental 
steps, so it may be less desirable for general mutation detection. There are many 
parameters other than the size of the PCR product that can affect the informativeness 
of SSCP method. Physical factors such as temperature, type of the gel matrix and 
ionic strength is very important such that sequence changes that have little or no 
effect on conformation in one set of conditions can have a dramatically different effect 
under other conditions (Hayashi and Yandell, 1993). A useful consequence of this is 
that it enables empirical optimisation of SSCP sensitivity for a given fragment by 
varying these conditions.
Based on the experience of a number of laboratories, electrophoresis at room 
temperature (20-25°C) with 5-10% glycerol or 4°C without glycerol seems to be a 
good starting point for detection of most mutations (Hayashi, 1991).
Choice of the gel matrix is a second important area for optimisation. 
Complementary single strands are separated more effectively using a polyacrylamide 
matrix containing a low percentage of crosslinker (%C) (the percentage of N,N'- 
methylenebisacrylamide in the total acrylamide monomer). Most investigators have 
found that SSCP gels with 2% C or less are best for detection of single nucleotide 
substitution (Hayashi and Yandell, 1993). New gel products (e.g. MDE™ gel, AT 
Biochem.) are now available and seems to be more appropriate for SSCP analysis.
Overloading of the gel sometimes results in abnormal migration of the bands 
and reduced resolution. For this reason, radioisotopic or fluorescent labelling of the 
PCR products to a high specific activity is highly recommended. Samples can then be 
diluted so that DNA concentrations are sufficiently low in the loading solution, yet 
detectable either by autoradiography in a reasonable exposure time (few hours to 
overnight) or with fluorescent DNA sequencer (Hayashi and Yandell, 1993).
The way the bands are shifted by mutation can be different depending on the 
flanking sequences, and changing primer positions bracketing the region suspected to 
have a mutation is one effective way of enhancing mobility shift.
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Sarkar et al. (1992b) have proposed a dideoxy-termination reaction using 
PCR-amplified fragments followed by SSCP analysis. In this method, DNA fragments 
having various sequences flanking the mutated site can be examined in a single gel. 
This approach, however, involves extra steps of experiments and may be not suitable 
for general mutation detection.
(21 Heteroduplex analysis
This technique is based on the differing electrophoretic mobility between a 
perfectly matched duplex DNA fragment compared with a similar DNA fragment that 
contains a mismatch (a heteroduplex) when analysed side by side. Heteroduplexes 
formed of one mutant strand and one wild type strand migrate at a different rate 
through regular polyacrylamide gels, because the region of mismatch forms a "kink" 
in the DNA. Thus, a heteroduplex frequently appears on the gel as a distinct band, 
separate from the homoduplex DNA (Nagamine et al., 1989). New gel matrices 
(Hydrolink and MDE™ from AT Biochem.) have become available which markedly 
enhance the ability to detect mutation induced mobility shifts in heteroduplex 
molecules (Grompe, 1993). This simple technique was reported to be able to identify 
different types point mutations and minor deletions or insertions in PCR fragments of 
different size. Studies indicate a level of sensitivity similar to SSCP analysis (80-90%) 
in small DNA fragments (<300bp) (Perry and Carrell, 1992; White et al., 1992). This 
technique is simple to perform, does not require complex chemical or temperature 
gradients, bands can generally be detected without radioactive labels and has been 
applied successfully to the study of a number of human genetic disorders (Grompe, 
1993; Friedle et al., 1993 and Schreiber et al., 1995).
(3) Denaturing gradient gel electrophoresis (DGGE1
The denaturing gradient gel electrophoresis is acknowledged to detect almost 
100% of mutations (Dianzani et al., 1993). The mutation-resolving power of DGGE 
relies on a physical separation between similar DNA fragments differing in melting
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properties due to difference in nucleotide composition. The separation is based on the 
fact that DNA molecules differing by a single base change have slightly different 
melting properties, which cause them to migrate differently in a polyacrylamide gel 
containing a linear gradient of DNA denaturants (urea and formamide) (Fischer and 
Lerman, 1983 and Myers et al., 1987). There are two types of denaturant gradient 
gels : (I) Parallel gels, which contain a linearly increasing gradient of DNA 
denaturants from top to bottom in the gel and (II) perpendicular gels, which contain 
a linear gradient of denaturants from left to right across the gel. Both gel types can be 
used independently to screen for point mutation in PCR-amplified DNA products. 
Parallel denaturing gradient gels have the advantage of being useful for analysis of 
multiple samples in a single gel (Sheffield et al., 1990). Two modifications greatly 
increased the sensitivity of the technique : (1) Attachment of a thermostable GC- 
clamp to one PCR primer (Sheffield et al., 1989) and (2) Analysis of heteroduplex 
molecule i.e. hybrids formed between mutant and wild-type strands (Myers et al., 
1985a). Mutations can be found most reliably when sequence heterogeneity lies 
within a domain of relatively low melting temperature. This can be achieved for 
virtually any sequence of interest by the use of computer programs to predict 
theoretical melting profiles and design PCR primers (Grompe, 1993). Base changes in 
the region of the highest melting temperature normally can not be resolved since 
melting of this domain leads to the generation of single strands with loss of the 
sequence-dependant mobility. Introduction of a GC-clamp at one end of the 
sequence, leads to an improved sensitivity of about 90% of all DNA polymorphisms. 
As in SSCP analysis, DGGE detects the presence of sequence difference between 
mutant and wild type DNA fragments but not its location within the fragment, which 
has to be determined by sequencing.
The denaturing gradient can also be generated by temperature. Temperature 
gradient gel electrophoresis (TGGE) allows the separation of molecules depending 
on their different melting behaviour in temperature gradients and has been 
successfully applied to separation of HLA alleles (Meyer et al., 1991) and screening
57
of Tp53 mutations (Scholz et al., 1993). Like DGGE, after parallel TGGE wild-type 
conformation is characterised by one single band, whereas mutations are 
demonstrated usually by the presence of four bands corresponding to the four 
different double strands (one homoduplex wild-type, one homoduplex mutant and 
two heteroduplex mutant/wild-type). Using thermal instead of a chemical denaturant 
gradient, the preparation of gradient gels is avoided and only one gel condition is 
sufficient for TGGE (Scholz et al., 1993).
Both DGGE and TGGE require a special apparatus to control gel temperature 
and long PCR primers which include a 30 to 50 bp high melting temperature GC- 
clamp (Grompe, 1993).
(51 Cleavage of mismatch analysis
The principle of mismatch cleavage is based upon the cleavage of 
heteroduplexes between strands of nucleic acid mismatched at one or more 
nucleotides. Three different techniques adopting this strategy are now known, 
chemical cleavage of mismatch (CCM), RNaseA cleavage and enzyme mismatch 
cleavage (EMC).
(A) Chemical cleavase o f mismatch (CCM) : This technique has been 
described by Cotton et al. (1988). In CCM, a heteroduplex between a radiolabelled 
wild-type DNA molecule and mutant DNA (or RNA) is created by boiling and 
reannealing. Hydroxylamine and osmium tetroxide react to modify mismatched or 
unmatched cytosine or thymine residues, respectively. Sites modified by 
hydroxylamine and osmium tetroxide are more susceptible to cleavage by piperdine 
than unmodified base pairs. Cleavage occurs in one strand of the helix only. Products 
are resolved by denaturing polyacrylamide gel electrophoresis to allow the 
identification and location of the mutation sites. CCM is very sensitive, detecting 
more than 95% of mismatches when only the wild type DNA are labelled and 100%, 
when both wild-type and mutant DNA are labelled (Grompe, 1993). It was shown to
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be an excellent method for the detection and location of mutations, particularly 
because it can easily scan up to 1.7 kb segments of DNA at a time, DNA or RNA 
templates may be used and the precise location and nature of the change is also 
indicated by the size of the cleavage band and the cleaving reagent (Grompe, 1993). 
Improved resolution of larger cleavage products is possible by using of 35S-labelled 
dATP probes rather than 32PdCTP-labelled probes. 35S labelled cleavage products 
are more discrete and therefore more easily identified than those obtained with 32P 
(Saleeba and Cotton, 1991). Saleeba et al. (1992) described a method for unlabelled 
CCM which detect the cleavage products by silver staining. This procedure is thought 
best applied to heteroduplexes < 600 bp long (Cotton, 1993)
The main drawbacks of the technique is that many manipulations need to be 
performed in the fumehood to reduce exposure to toxic chemicals, the use of 
radioactive probes and the need for a two-step reaction and treatment with three 
reagents.
(B) RNase A cleavage : This was first described by Myers et al. (1985b). The 
method is based on the observation that RNase A is frequently able to cleave a 
mismatched base in an RNA probe hybridised to an experimental target containing a 
point mutation. As originally described, the substrates for RNase A digestion were 
RNA/DNA duplexes made by hybridising a radiolabelled wild-type RNA probe to a 
double-stranded DNA target. The enzyme will recognise and cleave single-stranded 
RNA at the points of mismatch. The reaction is analysed by denaturing 
polyacrylamide gel electrophoresis and autoradiography. RNase A can only detect 
-50% of mismatches (Grompe, 1993). It has therefore been largely replaced by the 
similar CCM technique. The recent non-radioactive version developed by Ambion 
laboratories may improve the popularity of the technique. Two different transcription 
promoters are used to produce both sense and anti-sense strands of an RNA duplex 
which gives each mutation two chances of being detected but the detection rate is still 
to be determined.
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(C) Enzyme mismatch cleavage (EMC) : Mashal et al. (1995) and Youil et 
al. (1995) have described a method that may prove superior to existing techniques in 
the search for an elusive mutation. Bacteriophage resolvases, whose function in vivo 
is to cleave branched DNA, have the property of recognising mismatched bases in 
double stranded DNA and cutting the DNA at the site of mismatch. Radiolabelled 
DNA is cleaved by the resolvases at the site of mismatch in heteroduplex DNA and 
digestion products are resolved on a denaturing polyacrylamide gel. Thus, both the 
presence and the estimated position of an alteration is revealed. EMC has the 
potential to be as easy and inexpensive as SSCP and as sensitive as DGGE, with the 
added advantages of predicting the precise position of an alteration and of being 
applicable to fragments 1 kilobase or larger. Both research groups (Mashal et al., 
1995 and Youil et al., 1995) analysed all possible mismatch types as well as several 
deletion mutations and obtained very comparable results with a 94% detection 
sensitivity. However, several improvements need to be made before EMC replaces 
existing methods.
(6) Protein truncation test (PTT)
Having made the effort to identify the mutation, the question often still 
remains :"Does this mutation actually cause disease?". This is where the functional 
assays come into their own right and for some genes they are now considered as the 
first mutation screening test to be performed. The PTT identifies mutations that result 
in premature termination of protein synthesis. This method has been reported by 
Roest et al. (1993) and the technique is based on the combination of RT-PCR, in 
vitro transcription and translation with incorporation of 3H-leucine to detect 
translation products after SDS-polyacrylamide gel electrophoresis. This technique is 
mainly applied to the disorders where protein termination mutations account for a 
significant proportion of mutations. For example the dystrophin gene, four genes for 
hereditary non-polyposis colon cancer, the breast cancer gene (BRCA1) and the gene 
for familial colorectal cancer ((APC), in which translation terminating mutations
account for about 70% of the mutation identified ( Miyoshi et al., 1992)). Compared 
to other point-mutation detection techniques, PTT allows the analysis of relatively 
large stretches of coding sequences of 2.4 kb or even more. The site of the mutation 
is identified so that only a small part of the gene needs to be sequenced.
(7) Direct sequencing
Sequencing can be used either as a screening and/or a diagnostic method. 
Sequencing defines precisely the location and nature of the change and therefore is a 
necessary final step of any mutation detection method. Two methods are used. One 
uses end labelled probe and partial chemical cleavage is achieved at all bases with 
particular chemicals. Size of fragments and the chemicals which produced them can 
then be used to define the sequence (Maxam and Gilbert, 1980). The other method 
uses enough nucleotide analogue (dideoxy) to allow some chain termination at each 
base, and again the base used and the length of the fragments defines the sequence 
(Sanger et al., 1977). The latter method is most frequently used.
In order to sequence PCR products successfully by the conventional dideoxy 
termination protocol, it is essential to convert the double-stranded PCR product into 
a single-stranded sequencing template. Several methods have been described to 
achieve this. In the first technique, termed asymmetric PCR (Gyllensten and Erlich,
1988) one primer is 1 : 50 to 1 : 100 diluted and used for a second round PCR. In the 
second method one biotinylated PCR primer is used to create a 5' biotinylated DNA 
strand which is then magnetically captured on an avidin-coated magnetic beads (Gibbs 
et al., 1990). In a third approach termed genomic amplification with transcript 
sequencing, the original PCR primers carry T7 RNA polymerase binding sites and in 
vitro transcription is then used to generate single-stranded RNA template for 
sequencing (Stoflet et al., 1988).
Cycle sequencing is a newly developed sequencing technique where the DNA 
template is simultaneously amplified and sequenced by the addition of dideoxy 
terminators to a PCR reaction. Recently, a new protocol based on cycle sequencing
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and fluorescence detection technology has been developed (Rosenthal and Charnock,
1992). Fluorescently labelled dideoxy terminators are used with different fluorescent 
dye coupled to each of the four dideoxy nucleotide triphosphate (ddNTPs). A 
computer software analysis of fluorescent cycle sequencing data is used. This method 
appears especially useful when high throughput automated sequencing is available 
(Grompe, 1993).
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1.7 Aims of the present project
The aims of the present project were to optimise and apply strategies for 
detection of mutations in three different autosomal dominant neurodegenerative 
conditions, myotonic dystrophy (DM), amyotrophic lateral sclerosis (ALS) and 
tuberous sclerosis complex (TSC). These diseases were chosen because of their 
differences with regard to known molecular pathology (CTG trinucleotide repeat 
expansion in DM patients, point mutations in ALS patients and point mutations and 
gene deletions in TSC patients), available gene information (only cDNA sequence of 
the TSC2 gene was available) and/or the availability of study materials (RNA was 
available from TSC patients only). These constraints made it necessary to optimise 
different mutation detection strategies for each of them.
Specifically this involved:
(1) Optimisation of PCR and Southern blot analysis to screen for CTG repeat 
expansion in DM patients
(2) Optimisation of PCR , restriction digestion and SSCP analysis to screen for both 
known and unknown point mutations in the SOD-1 gene in both familial and sporadic 
ALS patients.
(3) Optimisation of PCR, RT-PCR of the TSC2 gene cDNA, Southern blot and 
chemical cleavage of the mismatch analysis to screen for mutations in the TSC2 gene 
in patients with tuberous sclerosis complex.
(4) Characterisation of the detected point mutations with direct sequencing of cDNA 
and/or genomic DNA.
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CHAPTER T tf0
(2) MATERIALS AND METHODS
2.1 Patients
Forty nine myotonic dystrophy (DM) families (86 DM patients and 96 
apparently normal individuals) were studied for the status of the CTG repeat 
expansion in the 3' untranslated part of the DM  locus on chromosome 19ql3.3. All 
the families were ascertained by the clinical diagnosis of the proband; an expanded 
DM  allele was identified afterward in each of these individuals.
Two patients from ALS families and 67 sporadic ALS cases were studied for 
the presence of mutations in the copper/zinc superoxide dismutase (SOD-1) gene on 
chromosome 21q2.2. All patients were diagnosed clinically by the presence of a 
progressive neurodegenerative disease of combined upper and lower motor neuron 
features and confirmed by doing some electrophysiologic studies of the muscle and 
nerve.
12 familial and 20 sporadic patients with tuberous sclerosis were studied for 
the presence of mutations in the TSC2 gene on chromosome 16pl3.3. The linkage 
status for all the familial cases, except one, are unknown. One familial case was found, 
later on, to be linked to chromosome 9 markers. All patients were diagnosed 
according to the revised Gomez criteria (Gomez, 1991).
2.2 DNA extraction
From all the patients studied, DNA was extracted from peripheral blood 
leukocytes using a modification of the method described by Kunkel et al. (1977).
In 50 ml Falcon centrifuge tubes, 40 ml of cold lysis buffer was added to each 10 ml 
of patient's blood and mixed gently. Tubes were then centrifuged for 15 minutes at 
4°C and 2500 rpm in an DEC DPR-6000 centrifuge. The resulting pellets were then 
resuspended in 3 ml nuclei lysis buffer, 200 pi 10% SDS and 100 pi proteinase K (10 
mg/ml) and incubated at 37°C for overnight. After incubation, 1 ml of 6M sodium
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chloride was added to each tube and shaken vigorously for few seconds and then 
centrifuged for 15 minutes at 15°C and 2500 rpm. Carefully the supernatant was 
transferred, using a plastic pastette, to a fresh 5 ml Falcon tube and gently mixed, by 
inversion, for 1 minute, with 1 ml buffered phenol/chloroform followed by 
centrifugation at room temperature and 2500 rpm for 15 minutes. The upper aqueous 
phase was transferred to a 20 ml universal tube and the DNA was precipitated by 
addition of two volumes of absolute ethanol. The DNA was then spooled out using a 
sealed glass Pasteur pipette, washed in 70% ethanol, air dried and suspended in 500 pi 
autoclaved T.E. buffer and kept overnight at 4°C to insure its complete dissolution.
Determination of DNA concentration
To determine the concentration of the DNA samples, optical density (O.D.) 
reading at 260 nm, using dual beam spectrophotometer, was performed. An O.D. 
reading of 1 corresponds to 50 pg/ml of DNA.
2.3 Total cellular RNA extraction from peripheral blood lymphocytes
RNA was extracted from 22 patients with tuberous sclerosis using two 
different methods.
2.3.1 Acid-guanidinium thiocvanate method
A modification of Chomczynski and Sacchi (1987) acid-guanidinium 
thiocyanate method was used to extract RNA from peripheral blood lymphocytes. The 
technique involved initial separation of lymphocytes from whole blood, followed by 
the acid-guanidinium thiocyanate phenol/chloroform extraction. The RNA must be 
protected from degradation by ribonucleases. Therefore, all the solutions used (except 
organic solutions) were prepared with 0.1% diethyl pyrocarbonate (DEPC) in distilled 
water and then autoclaved. The tubes and tips required for handling and storing of the
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RNA were treated in 0.1% DEPC in water for 14-16 hours before being autoclaved. 
All plastic-ware were kept aside from general use. Gloves were changed frequently 
during the steps of RNA extraction. Isolated RNAs were stored in aqueous solution at 
-70°C and repeated freeze and thaw cycles were avoided.
fa! Separation of lymphocytes from whole blood: 5 ml of heparinised or 
EDTA treated, freshly collected, whole blood was carefully layered over 5 ml of 
Histopaque (Sigma) in a 20 ml universal tube. Tubes were centrifuged at room 
temperature and 1400 rpm for 30 minutes. The opaque (buffy) interface was 
transferred to a fresh tube and washed, twice, in 15 ml of cold phosphate buffered 
saline (PBS, Gibco BRL), then pelleted by centrifugation at 1400 rpm and 4°C for 15 
minutes and the supernatant was discarded.
(b) The acid guanidinium thiocyanate phenol/chloroform extraction: The 
pellet was re-suspended in 500 pi solution D (37 pi 2-mercaptoethanol, Sigma, was 
added to each 5 ml solution D just before use) by repeated slow pipetting and 
transferred to an autoclaved, DEPC treated, 1.5 ml Eppendorf tube on ice. To the 
dissolved pellet the following ice-cold solutions were added: 50 pi 2 M sodium 
acetate (pH 4), 500 pi water saturated phenol and 100 pi chloroform/isoamyl alcohol 
(98 : 2). Tube contents were mixed by inversion after each reagent addition and the 
final mix was shaken vigorously for 15 seconds and kept on ice for 15 minutes. The 
tubes were centrifuged for 20 minutes at 4°C and 14000 rpm. The upper aqueous 
phase was carefully transferred to another fresh 1.5 ml Eppendorf tube and to it 600 
pi of isopropanol was added and mixed by repeated inversion. Tubes were incubated 
at -20°C for a minimum of one hour then centrifuged for 20 minutes at 4°C and 
14000 rpm. The supernatant was discarded and the pellet was dissolved in 300 pi 
solution D. To the dissolved pellet 300 pi isopropanol was added and the tubes were 
kept at - 20°C for at least one hour. Tubes were then centrifuged for 20 minutes at 
4°C and 14000 rpm. The supernatant was discarded and the pellet was washed in 500 
pi 75% cold ethanol (diluted by DEPC treated autoclaved distilled water) and air 
dried. The pellet was dissolved in 50 pi DEPC treated water and stored at - 70°C.
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2.3.2 TRIzol™ Reagent extraction
TRIzol™ reagent (Life Technologies) is a ready-to-use reagent for isolation 
of total RNA from cells and tissues. The reagent, a mono-phasic solution of phenol 
and guanidine isothiocyanate, is used as a modification to the single-step RNA 
isolation method developed by Chomczynski and Sacchi (1987). Lymphocytes were 
separated as before and only once washed with cold PBS. The pellet was dissolved in 
one ml of TRIzol reagent by repetitive pipetting and then transferred to 1.5 ml DEPC 
treated Eppendorf tube and kept for 5 minutes at room temperature permit the 
complete dissociation of nucleoprotein complexes. After the incubation 0.2 ml of 
chloroform was added to the dissolved pellet and the tube was shaken vigorously for 
15 seconds and incubated at room temperature for 2 to 3 minutes. The samples were 
then centrifuged at no more than 12000 g for 15 minutes at 4°C. The upper aqueous 
phase was transferred to a fresh tube and to it 0.5 ml of isopropanol was added and 
mixed well. The sample was incubated at room temperature for 10 minutes and 
centrifuged at no more than 12000 g for 10 minutes at 4°C. The supernatant was 
discarded and the RNA pellet was once washed with 1 ml of 75% ethanol by brief 
vortexing and then centrifuged at no more than 7500 g for 5 minutes at 4°C. The 
pellet was then briefly air dried for 5-10 minutes and dissolved in 50 pi of DEPC 
treated water by passing the solution a few times through a pipette tip, and incubating 
for 10 minutes at 60°C. Dissolved RNA samples were then stored at -70°C.
Determination of RNA concentration
To determine the concentration of the RNA samples, an optical density (O.D.) 
reading at 260 nm, using a dual beam spectrophotometer, was taken. An O.D. 
reading of 1 corresponds to 40 pg/ml of the RNA. The integrity of the RNA was 
assessed by comparing the ratio of O.D. at 260/280 nm. A good quality preparation 
should give a value of 2 .
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Qualitative assessment of the RNA
To assess the quality of the extracted RNA 1 pi of it was checked by agarose 
gel electrophoresis. The RNA checking gel was prepared by boiling 0.45g agarose in 
2 2  ml distilled water (dH20 ) until dissolved. The evaporated amount of water was 
restored and the gel was cooled to 55°C. Under the fiime hood, 5 ml of 37% 
formaldehyde and 3 ml of 10X MOPS were added to the gel which was then rapidly 
poured and left to set. The RNA sample was prepared by mixing 1 pi total RNA with
1.3 ptl dH20, 5 pi formamide, 1.7 pi 37% formaldehyde and 1 pi 10X MOPS. The 
sample was heated in a 60°C water bath for 1 0  minutes and rapidly quenched on ice. 
To this 2 pi of 10X RNA loading buffer was added and the sample immediately 
loaded alongside 1 pg of E. coli ribosomal RNA (Boehringer Mannheim) as a marker 
and electrophoresed in IX MOPS buffer at 70 to 80 volts for 40 to 60 minutes (till 
the bromophenol dye reached the bottom of the gel). The gel was then rinsed in water 
to wash out the formaldehyde and stained for 5 minutes in 5 pg/ml solution of 
ethidium bromide. The gel was destained in water for 2 to 16 hours and viewed under 
the U. V. light to check for the integrity of ribosomal RNA bands.
2.4 Oligonucleotide design
Oligonucleotides were designed to amplify both DNA and cDNA sequences. 
Seven sets of primers were designed to amplify exon 3 of the SOD-1 gene and exon 1, 
and exons 38-41 (as a single amplification product )of the TSC2 gene. Four cDNA 
segments of the TSC2 gene were also amplified. Moreover, six sequencing primers 
were designed. The computer program Oligo™ version 3.4 (Medprobe) was used for 
primer designing with the following guidelines: 1) The length of the primer was in the 
range of 18 to 30 bases. 2) PCR primers should be free of significant complimentarity 
at their 3’ termini as this promotes the formation of primer-dimer artifacts that reduce 
product yield. 3) Avoidance of hairpin loop forming primers (self-complementarity). 
A hairpin loop forming primer is troublesome when its 3' end is "tied up," since this
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can cause internal primer extension. Hairpins near the 5' end, however, do not 
significantly affect the PCR. 4) The ability of the primer to form a stable duplex (by 
calculating the free energy of duplex formation, AG) with the specific site only on the 
target DNA. 5) The Tm (melting temperature) difference between both primers and 
between the template and the less stable primer is kept to a minimum. 6 ) Avoidance of 
runs of C's or G's at the 3' ends of the primers.
2.5 Synthesis, deprotection and purification of oligonucleotides
All primers, either published or newly designed, were synthesized in-house on 
an ABI 391-DNA synthesizer with "Trityl off'. When synthesis was finished, the 
product exists as phosphate-protected, base-protected phosphotriesters. Complete 
deprotection was necessary to produce biologically active oligonucleotides.
Cleavage and phosphate deprotection
Following synthesis, the primer remains covalently attached to the support and 
it has to be cleaved by a one hour treatment with fresh, concentrated ammonium 
hydroxide and collected in a vial fitted with a Teflon-lined cap. Phosphate 
deprotection (removing of cyanoethyl protecting groups) requires treatment with 
ammonium hydroxide and occurs at the same time as cleavage.
Base deprotection
Base deprotection is an ammoniolysis reaction and the benzoyl and isobutyryl 
base protecting groups are removed by placing the vial containing the oligonucleotide 
at 55°C for 8  to 15 hours. After completion of deprotection, the ammonium 
hydroxide-oligonucleotide solution is cooled at room temperature for 30 minutes. 
Primers are stored in ammonia eluant, which stays liquid at -20°C, enabling the 
dispensing of them without repeat freeze-thawing.
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Purification of the primer
To remove the ammonia, Aliquots from the ammonia stock were left in 
opened tubes under the fume hood for 16-24 hours. Alternatively, the butanol 
extraction method was used. 1 0 0  pi of the ammonia stock was mixed with 1 ml n- 
butanol in a 1.5 ml microcentrifuge tube, vortexed vigorously for 20 seconds and then 
centrifuged at full speed microcentrifuge for 10 minutes. The resulting supernatant 
was discarded, the pellet was air dried and dissolved in 50 pi sterile double distilled 
water and its OD was detected by UV spectroscopy at 260 nm. As a useful 
approximation, 1 OD unit of single-stranded oligonucleotide consists of about 33 
micrograms, by mass. A micromole of oligonucleotide has a number of OD units 
equal to 1 0  times the number of bases e.g., a micromole of a 2 0  mer would be 2 0 0  
OD units.
2.6 Reverse transcriptase PCR (RT-PCR)
2.6.1 Reverse transcription
Because RNA cannot serve as a template for PCR, reverse transcription of 
RNA followed by the polymerase chain reaction is an extraordinarily sensitive method 
to detect as few as 1-100 copies of a specific RNA. Reverse transcription was 
accomplished in a final volume of 20pl. A 2X reverse transcription master mix was 
prepared containing multiples of: 4 pi 5X first strand buffer (Gibco BRL), 2 pi 
dNTP's mix (10 mM each), 2 pi of the 0.1M DTT (dithiothreitol), and 1 pi of M- 
MLV reverse transcriptase (200 u/pl; Gibco BRL). 1 pg of total RNA was made up 
to 9 pi by DEPC treated water, denatured at 95°C for 5 minutes then kept on ice. 2 pi 
(20 pmol) of the downstream primer or 2 pi (200 ng) of oligo (dt)i2-is (Pharmacia 
Biotech.) was added to the denatured RNA, the mixture was heated at 65°C for 10 
minutes and quenched on ice for 5 minutes to anneal the primer. To the annealed 
RNA-primer mix (11 pi), 9 pi of the reverse transcription master mix was added,
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pipetted up and down several times to mix and incubated at 42°C for one hour. After 
reverse transcription tubes were heated at 95°C for 5 minutes to inactivate the M- 
MLV enzyme then stored until used for PCR at -20°C.
2.6.2 Second-strand synthesis and PCR amplification
PCR was performed in a final volume of 50 pi. A PCR master mix was made 
consisting of multiples of: 5 pi 10X GeneAmp PCR buffer (Perkin Elmer/Cetus), 4 pi 
dNTP's mix (200 pM of each dNTP, Boehringer Mannheim), 3 pi of each primer (30 
pmol each), 0.3 pi (1.5 units) Ampli-Ta# polymerase (Perkin Elmer/Cetus) and sterile 
double distilled water up to 45 pi. To each 0.5 ml Eppendorf tubes 45 pi of the PCR 
master mix was aliquoted and covered by 50 pi mineral oil. 5pi of the reverse 
transcription reaction mixture was added under the oil to the PCR master mix and 
mixed by pipetting up and down several times and then centrifuged briefly to obtain a 
clean oil/aqueous interface and to remove air bubbles. Tubes were transferred to a 
pre-heated PCR block at 94°C and incubated for 3 minutes for the initial 
denaturation. 35 PCR cycles were then started at Ta°C for 1 minute annealing (Ta 
determined for each primer set), 72°C extension for 1.5 minutes and 94°C 
denaturation for 1 minute and a final extension step of 72°C for 10 minutes.
2.7 Methods for mutation screening
2.7.1 Southern blot analysis
(Al Probe preparation for Southern blotting
(I) Probe v5B1.4 to detect CTG expansion in myotonic dystrophy patients
The DNA probe p5B1.4 is a 1.4 kb BamHl fragment in a pBluescript plasmid. 
This probe was kindly supplied as plasmid DNA by Dr. Kevin Kelly, Department of 
Medical Genetics, Aberdeen Royal Hospitals NHS Trust. This probe detects a human 
genomic Bgtl fragment of 3.4 kb from individuals with the normal range of CTG
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repeats. Individuals with expansions of the CTG repeats (50 repeats or more) showed 
extra bands with varying sizes. The probe was transformed into bacterial cells, grown 
up and stored as a glycerol stock.
Transformations of the plasmid DNA to competent cells
Plasmid DNA (pBluescript) containing the p5B1.4 probe was transformed to 
DH5 oc™ (Gibco BRL) competent E. Coli cells according to the supplier protocol 
with some modifications. The competent cells were removed from -70°C and thawed 
on wet ice. The required number of autoclaved 1.5 ml Eppendorf tubes were placed 
on ice. The cells were gently mixed and 50 pi were aliquoted into each chilled tube 
using chilled, sterile pipette tips. 10 pi of the plasmid DNA (containing 10 ng of 
DNA) were added to all tubes except the negative control by moving the pipette tip 
through the cells while dispensing. Tubes were gently shaken for 5 seconds 
immediately after addition of DNA and then were incubated on ice for 30 minutes. 
The cells were then heat-shocked at 42°C water bath for 2 minutes without shaking 
and then rapidly placed on ice for 2  minutes. 800 pi of SOC medium was added to all 
tubes and the cells were incubated for one hour at 37°C with mild shaking ( 1 0 0  
r.p.m.). 200 pi of the reaction were spread onto LB agar plates (with 100 pg/ml 
ampicillin) and left at room temperature until the excess moisture has been absorbed. 
The plates were then inverted and incubated at 37°C oven for 12-16 hours then stored 
in 4°C (cold room) for up to one month. Discrete colonies were observed in all plates 
except the negative control.
Isolation of recombinant plasmid DNA and formation of glycerol stocks
The agar plates were removed from the cold room and a single colony was 
picked by autoclaved pipette tip and thrown into 5 ml of LB with ampicillin (100 
pg/ml) in a universal tube. The colony was grown for overnight at 37°C shaker (225 
r.p.m.). Glycerol stock was made by adding 0.7 ml of the growth to 0.3 ml glycerol, 
mixed by brief vortexing and immediately stored at -70°C. To recover bacteria from
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the glycerol stock, the frozen surface of the stock was scraped with sterile inoculating 
loop and streaked out into LB/ ampicillin agar plate to obtain isolated colonies. The 
remaining amount of the culture was used to isolate recombinant plasmid DNA using 
the Insta- Prep™ kit.
Isolation of recombinant plasmid DNA using the INSTA-PREB™ kit (5
®Prime—>3 Prime, Inc. )
The unopened INSTA-PREB™ tube was prepared by centrifuging in a 
microcentrifuge at full speed ( 1 2 , 0 0 0  g or greater) for 1 0  seconds to pellet the 
INSTA-PREB™ gel. To a sterile 1.5 ml Eppendorf tube 1.5 ml of the bacterial 
culture was transferred and centrifuged for 30 seconds at 12,000 to 16,000 g. The 
supernatant was discarded and additional 1 ml of the culture was added to the 
bacterial pellet and centrifuged as before. Virtually all the supernatant was aspirated 
carefully taking care not to disturb the pellet. The pellet was resuspended into 50 pi of 
sterile T.E. (10 mM Tris-Cl, 1 mM EDTA, pH 8 ) by brief vortexing. 300 pi of 
shaken PCI solution (phenol:chloroform:isoamyl alcohol, 50:49:1) was added to the 
tube containing the resuspended pellet and mixed by repeated inversion. The entire 
aqueous and organic contents of the tube were carefully transferred to the pre-spun 
INSTA-PREB™ tube using a large bore pipette tip. The INSTA-PREB™ tube 
(containing bacterial lysate) was then centrifuged in a microcentrifiige at full speed 
(12,000 g or greater) for 30 seconds at speed. 300 pi of Cl solution 
(chloroform:isoamyl alcohol, 49:1) was then added to the spun tube and mixed briefly 
by repeated inversion then centrifuged for another 30 seconds at full speed in a 
microcentrifuge. The topmost phase (containing the plasmid DNA) was recovered by 
pipetting to a fresh sterile microcentrifiige tube and stored at -20°C until used.
Releasing insert probe from plasmid
To release the insert probe from plasmid DNA a 50 pi digest was set up. 14 pi 
of plasmid DNA, obtained by using INSTA-PREP™, along with 4 pi BamHl
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restriction endonuclease, 5 pi 10X enzyme buffer and 27 pi ddH20  were mixed by 
pipetting and incubated at 37°C water bath for 2 hours. The digest was loaded 
alongside 1 kb ladder (Gibco BRL) on 1% low melting agarose gel (SeaKem agarose, 
FMC bioproducts) in IX TAE buffer and electrophoresed at 100 volts for ~ 2 hours. 
The gel was visualised on a UV transilluminator and the 1.4 kb insert band was cut by 
a sterile scalpel blade and placed in a pre-weighed Sarstedt 1.5 ml tube. The weight of 
the insert was then determined and to it a volume of sterile T.E. buffer 2 times the 
weight was added. The insert was then boiled for 5 minutes and stored at -20°C until 
required.
(2) Probes El. 6 and E2.5 to detect major structural rearrangements in patients 
with tuberous sclerosis
Two TSC2 cDNA probes were kindly supplied by Dr. M. Nellist, Institute of 
Medical Genetics, University Hospital of Wales, Cardiff. These probes were EcoRi 
fragments (1.6 kb and 2.5 kb) in pBluescript SK- plasmid. The E2.5 probe contains 
the 3' end of the TSC2 gene while the El . 6  probe covers a 1.6 kb of the TSC2 cDNA 
starting about 0.5 kb from the 5' end of the gene. The probe El. 6  detects 4 and 18 kb 
fragments of EcoRI digested normal genomic DNA while the E2.5 probe detects 3 
and 7.5 kb fragments of Hindlll digested normal genomic DNA. Both probes were 
supplied as cDNA clones in agarose and needed only to be grown up. These two 
probes were grown up, glycerol stocks were made and recombinant plasmid DNAs 
were isolated using the same protocol as for probe p5B1.4. The inserts were released 
from the plasmid DNAs by digestion with EcoRA as previously mentioned for probe 
p5B1.4.
Southern blotting
(1) P i2estion o f genomic DNA
7 to 10 pg of genomic DNA was digested using the appropriate restriction 
endonuclease in a total volume of 40 pi containing IX appropriate enzyme buffer and
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40 units of the specific enzyme. The digests were incubated for overnight in a water 
bath set at the recommended temperature. Digests were either loaded on an agarose 
gel or stored at -20°C for later use.
(2) Agarose gel electrophoresis
The digests were resolved in 20 cm 0.8% agarose gels (FMC bioproducts) 
prepared in IX TAE buffer and containing 0.5 fig/ml ethidium bromide (10 mg/ml). 
Samples were prepared by adding 8  pi of 6 X agarose gel loading buffer (0.25% 
bromophenol blue, 40% (w/v) sucrose in IX TBE buffer) to the 40 pi digest. Samples 
were then loaded alongside 1 kb ladder (Gibco BRL) in the gel and electrophoresed at 
2 volts/cm for 18 hours. After electrophoresis the gel was visualised and 
photographed under UV light and the wells were then cut off. A ruler was always 
photographed alongside the gel so that the mobility of the marker fragments can be 
easily determined. The gel was then transferred to a plastic box, upside down and 
rinsed several times in water, it was then treated in a depurination solution for 15-20 
minutes then rinsed in water. The gel was then transferred to the denaturation solution 
for 30 minutes then rinsed in water and neutralized in two changes of neutralization 
solution for 15 minutes each.
(3) Setting up the transfer ayparatus and Southern transfer o f digested DNA
The transfer apparatus comprised a tray with a raised platform for the gel to 
set on. The tray was half filled with 1.5 liters of 10X SSC. The platform was covered 
by double layer of 3MM Whatman paper wick with its ends dipped into the SSC. The 
3MM paper was left to soak the SSC and became completely wet. Any air bubbles 
between the paper and the platform were smoothed out. After the neutralisation step 
the gel was placed on the wick on the platform and again any air bubbles between the 
gel and the 3MM wick paper were smoothed out. The gel was surrounded by a plastic 
wrap which let out to cover the transfer apparatus. A gel-size Hybond N membrane 
was cut, marked using a permanent pen, wet in 2 X SSC and layered on to the gel
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taking care to get rid of any air bubbles that were trapped between the membrane and 
the gel. A gel-size double sheet of 3MM paper was wet in 2X SSC and layered on to 
the membrane followed by a stack of absorbent paper (paper towels). A glass plate 
and a weight of -  500 g were laid on top of the absorbing paper stack. The blotting 
was carried out for 12-16 hours at room temperature. After the transfer was complete 
the gel was stained in ethidium bromide (0.5 pg/ml in water) to check the efficiency of 
transfer. The Hybond N membrane was rinsed in 5X SSC to remove residual agarose 
and placed between two sheets of 3MM paper and backed for 3 hours at 80°C oven 
to crosslink the DNA fragments to the Hybond N membrane. Filter was then wrapped 
in a Saran wrap and stored in the cold room (4°C) until hybridization.
(C) Hybridization of DNA blot
(1) Prehvbridization o f filter
The filter was soaked in 2X SSC and placed, face to face, onto a mesh then 
rolled up and placed in a hybridization bottle containing 5 ml of 2X SSC. The bottle 
was closed securely, laid flat and gently rolled to unfold the mesh and the filter so as 
they stuck to the wall of the bottle. The bottle was then opened and the SSC was 
discarded. To a pre-warmed 10 ml of prehybridization solution (at 65°C oven for few 
minutes till it became clear) a 1 0 0  pi denatured (by boiling for 1 0  minutes) sonicated 
salmon sperm DNA (10 mg/ml) was added. The mixture was then added to the filter 
in the bottle and placed in 65°C hybridization oven for a minimum of 6  hours. This 
step of prehybridization was carried out to prevent non-specific binding of 
radiolabelled probe to the filter.
(2) Probe labelling
While prehybridization of the filter, the probe was radioactively labelled using 
the random primed DNA labelling kit (Boehringer Mannheim) according to the 
manufacturer protocol. 24 pi of the probe (in low melting agarose) was boiled for 6  
minutes then incubated at 37°C for one minute. The probe was then added to a mix of
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2 pi each of dATP, dGTP and dTTP, 4 jul of the reaction mix, 1.5 pi of Klenow 
enzyme and 5 pi (50 pCi) of oc-32P dCTP (Amersham) and mixed by repeated 
pipetting. The tube was then incubated at 37°C for two hours and the reaction was 
then stopped by addition of 2 pi of 0.5M EDTA. The labelled probe was then 
separated from the unincorporated qc-32P dCTP using NICK™ columns (Pharmacia 
Biotech.) which were prepacked columns containing sephadex G-50 DNA grade. The 
column was rinsed once by 3 ml IX SSC by allowing them to drip through by gravity. 
The labelled probe (~ 40 pi) was added to the top of the suspended column and then 
400 pi IX SSC was added to the column and allowed to drip through. A Sarstedt 
tube was then placed under the column and a further 400 pi IX SSC was added to the 
top of the column and collected. This had the labelled probe after its separation from 
the unincorporated oc-32P dCTP.
(3) Hybridization o f filter
After at least 6  hours of prehybridization of the filter the prehybridization 
solution from the hybridization bottle was poured into a universal tube and to it the 
denatured (boiled for 6  minutes, and kept on ice for 2 minutes) probe was added. The 
contents of the universal tube were mixed gently and transferred back into the 
hybridization bottle and the bottle was returned to the hybridization oven at 65°C for 
overnight incubation.
(4) Washing the filter after hybridization
After hybridization the hybridization solution was discarded and the filter was 
rinsed in 2 X SSC/0.1% SDS while inside the bottle. The filter was washed once by 
adding 10 ml of 2X SSC/0.1% SDS to the bottle and returning it to the 65°C 
hybridization oven for 10 minutes. The filter was then taken out from the bottle and 
placed in a plastic tray with 0.5X SSC/0 .1 % SDS and washed by shaking at 65°C for 
a further 5 minutes. The filter was monitored using a series 900 minimonitor and if a 
signal greater than 1 0  cpm (count per minute) was detected it was then washed at
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increasing stringency (65°C, 0.25X SSC/0 .1 % SDS then 0 .1 X SSC/O.1 % SDS) 
taking care not to over wash it (filter was frequently monitored every 3 minutes).
(DI Autoradiography
After washing the filter, it was briefly dried and covered by a plastic wrap. It 
was then placed in an autoradiography cassette with intensifying screens and exposed 
to Kodak Diagnostic AR Imaging film with the DNA side of the filter facing the film. 
The position of the upper border of the filter was marked on the film surface so that a 
ruler could be used to estimate the size of the bands detected. The cassette was stored 
in a -40°C freezer for 2  to 7 days before developing the film.
2.7.2 PCR amplification of the unstable CTG repeat in the PM-Kinase eene and 
CAG repeat in the androgen receptor gene from genomic DNA
(A) Radiolabelled PCR
Radiolabelled PCR was optimised and used to amplify DNA containing CTG 
repeats in the DM-Kinase gene from patients with myotonic dystrophy (DM). PCR 
reactions were performed in a 15 pi PCR reaction mix containing IX GeneAmp PCR 
buffer, 100 pM of each dNTP, 15 pmol of each primer (409 and 410, Table 2.1), 100 
ng genomic DNA and 2 pCi oc-32P dCTP (Amersham). The reaction was overlaid 
with 25 pi mineral oil, vortexed and centrifuged briefly. Tubes were heated to 95°C 
for 5 minutes then held at 90°C where 1 unit of AmpliTaq DNA polymerase was 
added to each tube under the oil. Immediately after Taq polymerase was added 32 
PCR cycles were started at 95°C for 1 minute, 65°C for 30 seconds and 72°C for 1 
minute each and was then followed by a final extension step of 72°C for 5 minutes.
(B) Non-radiolabelled PCR
Non-radiolabelled PCR reactions to amplify both genomic DNA that contains 
the CTG repeats at the 3' end of the DM-Kinase gene in DM patients (primer set
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409/406; Mhadevan et al., 1992) and the CAG repeat (primer set 1/2; Allen et al., 
1992) in the first exon of the androgen receptor gene in patients with amyotrophic 
lateral sclerosis (Table 2.1) were optimised. PCR reactions were performed in 30 pi 
PCR reaction mix containing IX GeneAmp PCR buffer, 200 pM of each dNTP, 25 
pmol of each primer and 1 pg genomic DNA. The reaction was overlaid with 50 pi 
mineral oil, vortexed and centrifuged briefly. Tubes were heated to 95°C for 5 
minutes then held at 90°C where 2 units of Ampli7a<y DNA polymerase was added to 
each tube under the oil. Immediately after the addition of Taq polymerase PCR cycles 
were started as follows: 1) For CTG repeat amplification, 32 cycles of 95°C for 1 
minute, 64°C for 1 minute and 72°C for 1.5 minutes followed by a final extension 
step of 72°C for 5 minutes. 2 ) For CAG repeat amplification, 30 cycles of 95°C for 1 
minute, 62°C for 1 minute and 72°C for 1 minute without the final extension step. 
Non-radiolabelled PCR products were resolved using agarose gel electrophoresis.
Table 2.1 Primers used for PCR amplification
Primer Name Primer Sequence Comments
409 (Forward) 5'-GAAGGGTCCTTGTAGCCGGGAA-3' For CTG repeat
410 (Reverse) 5 AGAAAGAAATGGTCT GT G ATCCC-3' For CTG repeat
406 (Reverse) 5'-GGAGGAT GGAACACGGACGG-3' For CTG repeat
Primer 1 5-GCTGTGAAGGTTGCTGTTCCTCAT-3' For CAG repeat
Primer 2 5'-TCCAGAATCTGTTCCAGAGCGTGC-3' For CAG repeat
(C) Polyacrylamide gel electrophoresis
(1) Gel preparation
To detect the CTG repeat expansion in DM patients, radiolabelled PCR 
products were resolved on 8 % denaturing polyacrylamide gels (20cm x 50cm x
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0.4cm) with 7M urea prepared and electrophoresed in IX TBE buffer. 30 pi TEMED 
and 300 pi freshly prepared 10% ammonium persulphate were added to the prepared 
gel solution (60 ml) to allow its polymerisation. The gel was then rapidly poured in a 
pre-assembled, clean and bottom sealed Sequigen sequencing gel apparatus (Biorad) 
and a 20 well, 0.4 cm comb was inserted in place. The gel was left to polymerise for a 
minimum of one hour before electrophoresis.
(2) Labelling a DNA size marker
The 1 kb ladder (Gibco BRL) was radioactively end labelled at the 5' ends 
using T4 polynucleotide kinase (Pharmacia Biotech) and [y-32P] ATP. A 10 pi mix of 
1 pi ladder (~ 1 pg), 1 pi One-Phor-All Plus buffer (Pharmacia Biotech), 6  pi sterile 
distilled water, 1 pi [y-32P] ATP (10 pCi of 3000 Ci/mmol) and 1 pi of T4 kinase 
enzyme, was made in 0.5 ml microcentrifuge tube and incubated at 37°C for 45 
minutes. 80 pi of formamide loading buffer (95% formamide, 10 mM NaOH, 0.05% 
bromophenol blue and 0.05% xylene cyanol) was then added to the reaction. The tube 
was stored at -20°C and the labelled ladder can be used for up to 15 days.
(3) Samvle preparation, gel loadins and eel electrophoresis
After the gel has set, it was assembled within the gel kit and the well forming 
comb was removed. Buffer chambers were filled with IX TBE buffer and the wells 
were rinsed thoroughly with buffer. 1 pi of the PCR product was mixed with 5 pi 
formamide loading mix and denatured at 96°C for 2 minutes and immediately 
quenched on ice for few minutes. 3 pi of labelled 1 kb ladder were denatured in the 
same way and loaded alongside prepared samples. Samples were electrophoresed at 
2000 volts for about 2 hours (till the xylene cyanol dye moved 2/3 of the gel length).
(4) Autoradio2raphv
After gel electrophoresis, the glass plates were opened and the gel was 
transferred to 3MM *Whatmann paper, covered with Saran wrap and dried under
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vacuum for 30 minutes at 80°C on a gel dryer (Biorad model 583). The gel was 
autoradiographed in an autoradiographic cassette with intensifying screens using X- 
Omat diagnostic AR imaging film (Kodak), with the DNA side facing the film for 5 to 
16 hours at -40°C.
(D) Agarose gel electrophoresis
Agarose gel electrophoresis was carried out to detect both CTG and CAG 
repeat expansions after non-radiolabelled PCR amplification of the repeat. 1.5%, 15 
cm agarose gels were prepared in IX TBE buffer with 0.5 pg/ml ethidium bromide. 
30 fil of PCR product was mixed with 6  \i\ of 6 X agarose gel loading buffer and 
loaded alongside 1 kb and 100 bp (Gibco BRL) ladders. Gels were electrophoresed at 
170 volts for 3 hours and then visualised and photographed under UV light.
2.7.3 Single strand conformational polymorphism (SSCP) analysis
SSCP analysis allows the detection of a single base change. Wild type and 
mutant target DNAs are amplified by PCR, denatured and then electrophoresed side 
by side through a non-denaturing polyacrylamide gel. The two single-stranded DNA 
molecules from each denatured PCR product assume a three-dimensional 
conformation which is dependent on their primary sequence. If a sequence difference 
(mutation) exists between wild-type and mutant DNA, this may result in differential 
migration of one or both of the mutant strands.
(Al PCR amplification of the SOD-1 gene exons from genomic DNA
Radiolabelled PCR amplification of the SOD-1 gene exons 1, 2, 4 and 5 were 
optimised and carried out using primer sets designed by Rosen et al. (1993) and Deng 
et al. (1993). To amplify exon 3 a primer set was designed using the computer 
program Oligo™ (Medprobe) and the PCR conditions for this primer set was 
optimised. Table 2.2 shows the sequence of the used primer sets. 15 |il PCR reaction
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mix was set up containing IX GeneAmp PCR buffer, 50pM of each dNTP, 15 pmol 
of each primer, 100 ng genomic DNA and 2 pCi oc-32P dCTP. The reaction was 
overlaid with 25 pi mineral oil, vortexed and centrifuged briefly. Tubes were heated to 
95°C for 2 minutes then held at 90°C where 1 unit of AmyXiTaq DNA polymerase 
was added to each tube under the oil. Immediately after the addition of Taq 
polymerase, 28 PCR cycles were started at 95°C for 1 minute, 61°C for 1 minute and 
72°C for 45 seconds each and was then followed by a final extension step of 72°C for 
6  minutes.
Table 2.2 PCR primers used in analysis of the SOD-1 gene
Exon Primer Sequence (5’ to 3' end) Product Size Reference
I ’F’ 
1 fR’
TTCCGTTGCAGTCCTCGGAA
CGGCCTCGCAACACAAGCCT
158 bp Deng et al., 
(1993)
2 set a ’F' 
2 set a ’R’
ACTCTCTCCAACTTTGCACTT
CCCACCTGCTGTATTATCTCC
132 bp Rosen et al., 
(1993)
3 ’F
3 ’R’
T AAAT AGGCT GT ACC AGT GC A 
ATGAACTCCAGAAACGTATCG
130 bp Designed for 
this study
4 set a *F’ 
4 set a ’R*
CAT AT AAGGC AT GTT GG AGACT 
TCTT AGAATTCGCGACT AAC AATC
214 bp Rosen et al., 
(1993)
5 ’F
5 ’R’
AGT GATT ACTT G AC AGCCC A 
TTCT AC AGCT AGC AGGAT AAC A
216 bp Deng et al., 
(1993)
'F' stands for forwards and 'R' stands for reverse primers.
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(B) Sample preparation
After thermal cycling, 1 pi PCR product was mixed with 9 pi formamide 
loading buffer, heat denatured at 95°C for 3 minutes then quenched on ice for at least 
5 minutes before loading 3 pi of it into SSCP gel.
(Q  Gel types and conditions of electrophoresis used in SSCP analysis
(1) MDE™ gel (FMC Biovroducts) electrophoresis:
The MDE™ gel is a polyacrylamide-drived matrix designed to improve the 
resolution of conformationally different DNA molecules. 0.5X MDE™ gel (20 cm x 
40 cm x 0.4 cm) containing 5% glycerol was prepared in 0.6X TBE buffer. The gel 
was left to set for at least one hour before sample loading. 3 pi of each prepared 
sample was loaded and electrophoresis was carried out at 5 watts for 16 hours at 
room temperature.
(2) Polyacrylamide eel electrophoresis (PAGE):
Three different conditions using 8 % non-denaturing PAGE in IX TBE buffer 
were tried. The first was by running gels containing 5% glycerol at 5 watts at room 
temperature. The second was by running gels containing 10% glycerol at 8  watts at 
room temperature and the third by running gels without glycerol at 1 2  watts in cold 
room (4°C).
(D) Autoradiography
Autoradiography was carried out by placing the dried gel with X-Omat 
diagnostic AR film (Kodak) in a cassette with intensifying screens. The gel was 
autoradiographed for 5 to 16 hours at -40°C.
83
2.7.4 Screening for known mutations by digestion of PCR products
Patients with amytrophic lateral sclerosis (ALS) were screened for three 
known mutations in the SOD-1 gene using restriction endonuclease digestion of PCR 
products. These mutations were the Ala4Val in exon one, Gly93Ser and Ilell3Thr in 
exon four. Moreover, 100 normal chromosomes were screened for the presence of 
three missense mutations in the TSC2 gene, Ml602V (TSC2 cDNA segment III), 
S1715T and R1720W (TSC2 cDNA segment IV).
(Al Non-radiolabelled PCR
Non-radiolabelled PCR amplifications were optimised and carried out for both 
exons 1 and 4 using the above mentioned primer sets (Table 2.2). A 50 pi reaction 
mix was set up containing IX GeneAmp PCR buffer, 200 pM of each dNTP, 25 pmol 
of each primer and 1 pg genomic DNA. The reaction was overlaid with 50 pi mineral 
oil, vortexed and centrifuged briefly. Tubes were heated to 95°C for 2 minutes then 
held at 90°C where 2 units of Ampli7 hr<7 DNA polymerase was added to each tube 
under the oil. Immediately after the addition of Taq polymerase, 32 PCR cycles were 
started at at 95°C for 1 minute, 61°C for 1 minute and 72°C for 1 minute each and 
was then followed by a final extension step of 72°C for 6  minutes. TSC2 cDNA 
segments III and IV were amplified as described before (2.6).
(B) Testing the non-radiolabelled PCR
After completion of the PCR reaction 5 pi of the PCR product was aliqouted 
from each tube, mixed with 1 pi loading mix (0.25% bromophenol blue, 40% (w/v) 
sucrose in IX TBE buffer) and resolved on a 1% agarose minigel containing 0.5 
pg/ml ethidium bromide and prepared and electrophoresed in IX TBE buffer at 100 
volts for 30 minutes. The gel was visualised on a UV transilluminator to check for the 
efficacy of the PCR amplification. Single, correctly sized bands were detected from
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most of the PCR reactions. If otherwise, the PCR reaction for the specific product 
was repeated.
(O  Ethanol precipitation of the PCR products
Ethanol precipitation of the PCR products was carried out for the remaining 
45 pi PCR reaction. 4.5 pi 3M Na acetate (pH 5.2), 90 pi absolute ethanol and 2 pi 
glycogen (20 mg/ml) were added to each 45 pi PCR reaction and mixed by brief 
vortexing. Tubes were kept at -70°C for 15 minutes then centrifuged in a 
microcentrifuge at full speed (12,000 g or greater) for 15 minutes. Pellets were 
washed in 70% ethanol and centrifuged for 5 minutes as before. Ethanol was then 
discarded and the pellet air dried for 5 to 10 minutes then dissolved in 15 pi ddH20.
(D) Restriction endonuclease digestion of the PCR products
10 pi of the ethanol precipitated PCR amplification products were digested 
using the appropriate restriction endonuclease according to the supplier recommended 
buffer and temperature, for 2 hours. For one of them, Bsrl enzyme, after 2 hours of 
incubation at 65° C, an extra 1 0  units of the enzyme were added to each reaction tube 
and the whole reaction was incubated at 65° C for overnight. The digested products 
were resolved by 8 % or 12% polyacrylamide gel electrophoresis in IX TBE buffer for
2.5 to 6  hours at 280 volts (constant) then either silver or ethidium bromide stained 
and photographed.
(Et Silver staining
During all the steps the gel was gently shaken. It was first fixed in two 
changes of solution 1 (10% ethanol, 0.5% acetic acid) each for 5 minutes. To stain the 
gel, it was incubated for 15 minutes in freshly prepared 0 .1 % silver nitrate (solution 
2). The gel was rinsed briefly with distilled water and developed by incubation in 
solution 3 (1.5% NaOH, 0.1% formaldehyde, mixed just before use) for 20-30
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minutes. It was then treated with 0.75% Na2CC>3 solution for 10 minutes, sealed in a 
plastic bag and photographed.
2.7.5 Chemical cleavage of mismatches (CCM1 analysis
To screen for mutation sites within the amplified PCR products from TSC2 
cDNA and DNA, the CCM method described by Cotton et al. (1988) was used with 
some modifications. In this technique, mutant DNA was allowed to form a duplex 
with a radiolabelled wild type control DNA (probe) obtained by PCR amplification. 
Where mutations were present, mismatches were chemically modified and cleaved 
leading to detection of different-sized radioactive fragments. The protocol involved 
the following steps: -
(Al Preparation of test DNA
(1) RT-PCR and DNA-PCR
Four RT-PCR segments were optimised and amplified from the TSC2 cDNA 
using four home-designed sets of primer (Table 2.3) and the previously mentioned 
method (2 .6 ).
Two DNA-PCR segments were also optimised and amplified from the same 
gene. The first one gave amplification product from exon 1, 325 bp from the upstream 
promoter area and part of intron 1. The second segment produced amplification 
products from exons 38 to 41 with the intervening intronic sequences. The primer sets 
used for the DNA-PCR were home-designed (Table 2.3) and the PCR amplification 
was accomplished in a 50 |ul reaction mix using standard PCR protocol (2 .7.4-A) with 
32 cycles and a final 5 minutes extension step at 72°C.
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Table 2.3 PCR primers used in amplification of DNA and cDNA segments of the 
TSC2 gene. (F= forward, R= reverse)
Segment/exon Primer Sequence (5* to 3' end) Annealing
Temp.
Product 
size (bp)
Seg. I 'F' 
Seg. I R'
5 ’ -CATC ACC AGGCTC ATC AAGC-3 ’
5 ’ - AG AAAC AGGAAGT C AAAGGC-3 ’
60 °C 837
Seg. II 'F 
Seg. II 'R'
5 ’ -CCT GGACGGGGAAAGT GCT G-3 ’ 
5 ’ -TGGCGATGTGGAAGACGGCT-3 ’
59 °C 602
Seg. Ill F  
Seg. Ill 'R'
5’-ATCGCCGTCCTGTATGTTGG-3’
5 ’ -T AGGCT GGGGTTGGAGT AGG-3 ’
60 °C 663
Seg. IV F  
Seg. IV R'
5 ’ -TC ACCCCGCTGGACT ACGAG-3 ’ 
5’-ATCTGTGCCTCTATGTCTGTGC-3’
63 °C 505
Exon 1 F  
Exon 1 R'
5 ’ -GGGT AGAGGAGAGACGGC AA-3 ’ 
5 ’ -C ACCC AGATCCT GACTTT CG-3 ’
60 °C 663
Exon 38-41 F  
Exon 38-41 R
5 ’ -CCCC AGC AATT AGAGGTGTC-3 ’ 
5 ’ -GC ACC AAGC AGAC AAAGT C A-3 ’
63 °C 1 1 2 0
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(2) Identification o f  PCR products
10 pi aliquots from PCR products were electrophoresed on 1% agarose gels in 
IX TAE buffer with 0.5 pg/ml ethidium bromide. They were visualised with a UV 
transilluminator to confirm the size and to detect any abnormal alterations in it (for 
RT-PCR, where exon skipping and small intragenic insertions or deletions could cause 
alteration of the PCR product size). The bands were then excised from the gels, 
covered with 50 pi sterile double distilled water and stored at -20°C for later use. The 
remaining 40 pi PCR products were cleaned for use in CCM analysis.
(3) Cleanine o f  PCR products
Geneclean™ purification kit (Bio 101 Inc.) was used to purify DNA 
amplification products (the remaining 40 pi) directly from the PCR mixture. If there 
was non-specific amplification products, the whole PCR product was electrophoresed 
on 1% low melting point agarose gel (NuSieve) in TAE buffer and the required band 
was cut out and the DNA was recovered using the same kit. The cleaning procedure 
was as follows:-
To the PCR product (or the excised band) 3 volumes of 6 M Nal (supplied with the 
kit)was added. If purifying DNA from excised gel band, tubes were kept at 55°C for 5 
minutes, with mixing after one minute, to ensure gel dissolving. 7 pi glassmilk (silica 
matrix in water) was added to each tube, vortexed briefly every two minutes for ten 
minutes at room temperature then pelleted by centrifugation in a microcentrifuge at 
full speed for 5 seconds. The resulting pellet was washed two times with 300 pi NEW 
wash solution (14 ml of the NEW concentrate, 280 ml dH20 , 310 ml 1 0 0 % ethanol) 
Pellet was then dissolved in 10 pi double distilled water and incubated at 65°C water 
bath for 10 minutes. DNA was recovered by centrifugation in microcentrifuge at full 
speed for 2 minutes and the supernatant (containing the recovered DNA, ~ 10 pi) was 
transferred to a fresh tube and stored at -20°C until used. 1 pi of the recovered DNA 
was tested on 1% agarose gel to judge for the efficacy of the recovery. The 
purification results in removal of both PCR primers and unincorporated nucleotides
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which are likely to affect mismatch signal by serving as additional targets for chemical 
modification.
(B) Preparation of labelled probes
A probe is a PCR product obtained from wild-type DNA for the segment of 
interest. Internal labelling of the PCR was carried out by direct incorporation of 2  pCi 
[a-32P] dCTP in the PCR reaction mix. PCR was carried out in 50 pi reaction mix 
using standard PCR conditions and PCR cycles as the non-radiolabelled one. The 
labelled probe was isolated from low-melting-point agarose using Geneclean™ 
purification and its specific activity was determined (approximately 1 0 7c.p.m./pg).
Alternatively, 5' end labelling of the probe (both strands) was done by mixing 
100 ng of the probe DNA (after Geneclean™ purification), 10 pCi [y-32P] ATP, IX 
One-Phor-All buffer Plus (Pharmacia Biotech), ~10 units of polynucleotide kinase 
FPLCpure (Pharmacia Biotech.) and up to 1 0  pi ddfbO. The mixture was incubated 
at 37°C for 45 minutes then stored at -20°C until later use. Probes were stored for a 
maximum of two weeks before radiolysis rendered them impractical.
(Cl Formation of the hybrids (heteroduplexes)
To minimise the formation of probe homoduplexes, hybridisation between 
probe and target were set up in which the target DNA was present in 10 to 20 fold 
molar excess over probe DNA. Approximately 5 ng of probe DNA per target sample 
per modification reaction was needed. A premix containing IX hybrid buffer and the 
appropriate quantity (-10 ng/ test DNA sample) of labelled probe in T0.iE. buffer was 
made. 9 volumes of this premix was added to one volume of test DNA (-100 to 150 
ng) in 0.5 ml Eppendorf tubes, topped with 50 pi mineral oil and then placed in a 
boiling water bath for 5 minutes. Immediately, after boiling, the tubes were transferred 
to 65°C water bath and incubated for 5 to 16 hours to allow hybrid formation to 
occur. Tubes were then transferred on ice and the aqueous phase from each tube 
(containing the hybrids) was equally divided between two 1.5 ml siliconized
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Eppendorf tubes (one for each chemical modification). To each tube, 3 pi of 20 mg/ml 
mussel glycogen (Boehringer-Mannheim) and 750 pi of the stop precipitation mix was 
added, mixed well and chilled on dry-ice for 10 minutes. Tubes were spun in a 
microcentrifuge at full speed (~ 14000 g) for 1 0  minutes. Supernatants were discarded 
and the pellets were washed in 70% ethanol, air dried and resuspended in 7 pi To.iE 
buffer. Samples were either used immediately or stored for no more than 16 hours at 
-20°C for later use.
(D) Mismatch analysis
(1) Chemical modification m itts hvdroxvlamine and osmium tetroxide
Approximately 6.5M solution of hydroxylamine hydrochloride (BDH) pH 6  
(adjusted with diethylamine, BDH) was made and stored at 4°C for up to one week. 
1.39 g of hydroxylamine was dissolved in 1.6 ml double distilled water and its pH was 
adjusted to 6  by approximately 1.5 ml diethylamine. 20 pi of this solution was added 
to 7 pi hybrid, mixed well and incubated at 37°C for 2 hours.
Fresh solution of osmium tetroxide (Aldrich) and pyridine (BDH) was made 
on ice by mixing 6.75 pi pyridine with 1.5 pi osmium tetroxide (4% solution stored at 
4°C for up to 2 months) and 154 pi T0.iE buffer. 18 pi of this solution was added to 
the other 7 pi hybrid, mixed well and incubated at 37°C for two hours.
Modification reactions were stopped and precipitated by adding 750 pi stop/ 
precipitation solution to each tube, mixing them well, incubating the tubes on dry ice 
for 1 0  minutes and centrifugation in a microcentrifuge at full speed (-14000 g) for 1 0  
minutes. The pellets were washed in 70% ethanol and air dried.
(2) Piperdine cleavage o f the chemically modified mismatches
1M (10%) freshly made solution of piperdine (Fluka) was made in ddH20  and 
50 pi of it was added to each pellet and the tubes were vortexed for 1 minute to 
resuspend the pellet then briefly centrifuged. Tubes were incubated at 90°C for 30 
minutes then kept on ice for few minutes and precipitated by 750 pi stop/precipitation
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solution as above. The pellets were washed in 70% ethanol, air dried and resuspended 
in 10 pi formamide loading buffer (95% deionized formamide, lOmM EDTA, 10 
mg/ml bromophenol blue and 1 0  mg/ml xylene cyanol).
(3) Denaturing volvacrvlamide sel electrophoresis and autoradiography
6 % denaturing polyacrylamide gel (20cm x 50cm x 0.4cm) with 7M urea was 
prepared in IX TBE buffer and cast in a sequencing gel apparatus (Biorad) as before. 
Samples were denatured by heating at 95°C for 5 minutes and quenched on ice for 
few minutes then loaded (5 pi) alongside a labelled ladder (1 kb ladder) and 
electrophoresed at 2000 constant volts for approximately 3 hours (until the 
bromophenol blue dye reached the bottom of the gel). Gel was dried and 
autoradiographed for 1 2  to 16 hours as before.
2.8 Sequencing of the PCR products
After screening for point mutations or minor sequence alterations using either 
SSCP or CCM analysis, samples that gave positive screening results were subjected to 
sequencing of the PCR products from the corresponding exon(s) or cDNA segments 
to detect any sequence alterations. Three different sequencing strategies were used in 
this study. (1) Direct sequencing of the asymmetric PCR products, (2) PCR 
sequencing using PRISM™ Ready Reaction DyeDeoxy™ Terminator Cycle 
Sequencing Kit (Perkin Elmer) and (3) Sequencing of cloned PCR products. Any 
alterations in the normal sequence were confirmed by sequencing of the opposite 
DNA strand.
2.8.1 Direct sequencing of the asymmetric PCR products
In this technique asymmetric PCR amplification of the genomic DNA or 
cDNA template to be sequenced was followed by dideoxynucleotide sequencing of
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the PCR products (Sanger et al., 1977) using US Biochemicals sequanase version 2.0 
kit.
(A) Asymmetric PCR
Asymmetric PCR was performed according to the protocol developed by 
Mgone et al. (1992). The templates used for asymmetric PCR reaction were the PCR 
products of the corresponding regions. DNA or cDNA was amplified normally by 
PCR. PCR products were resolved by agarose gel electrophoresis and bands were cut 
out of the gels, placed in 1.5 ml Eppendorf tubes with 50 pi TE buffer and frozen at - 
20°C for overnight. 5 pi aliquots were then used for asymmetric PCR amplification 
using standard protocol of 40 cycles, unequal primer ratios (1/50 to 1/100) and the 
same conditions as symmetric PCR for that region. Two PCR reactions were 
performed for each segment where the second reaction used a reversed primer ratio 
so that both single strands could be generated. 5 pi aliquots from each reaction was 
tested by agarose gel electrophoresis alongside a DNA size marker and a double 
stranded control PCR. The remaining PCR volumes were cleaned prior to sequencing 
to remove excess dNTPs, salt and primers. Equal volume of 4M ammonium acetate 
and two volumes of isopropanol were added to each reaction, mixed by brief 
vortexing and incubated at room temperature for 1 0  minutes then centrifuged in 
microcentrifuge at full speed (-14000 g) for another 10 minutes. Pellets were washed 
in 70% ethanol, air dried and resuspended into 7 pi of ddH20  and used directly in 
sequencing reaction.
Sequencing protocol using USB seauenase version 2.0 sequencing kit
T7 DNA polymerase (sequenase version 2.0) was diluted by mixing the whole 
amount of the enzyme (25 pi) with 25 pi inorganic pyrophosphatase and 150 pi of 
glycerol enzyme dilution buffer. This diluted the polymerase 8  folds to its working 
concentration of 1 . 6  units/pl.
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7 pi of the cleaned asymmetric PCR product was mixed with 2 pi 5X 
sequenase buffer to give a final concentration of 40 mM Tris-HCl pH 7.5, 50 mM Na 
Cl and 20 mM MgCl2 and 1 pi (1 pmol) of sequencing primer complementary to the 
synthesised single strand. Primer concentration was determined using the arbitrary 
formula: Concentration (pmol/pl)= primer OD at 260 nm/ (0.01 x number of primer 
bases). The tube was vortexed and centrifuged briefly then incubated at 65°C in a 
PCR block for 2 minutes and slowly cooled to less than 35°C over 15 to 30 minutes 
then quenched on ice for few minutes. To each tube 1 pi of 0.1M DTT, 2 pi of a 1/5 
dilution of labelling mix (1.5 pM of each dNTP except dATP), 0.5 pi of [a-35S]dATP 
(1000 Ci/mmol; lOpCi/pl) and 2 pi of a 1/8 dilution of T7 DNA polymerase were 
added, mixed well, briefly centrifuged and incubated at room temperature for 2-5 
minutes. Once the labelling reaction was completed 3.5 pi of the mix was transferred 
to a prewarmed (at 42°C ) 2.5 pi of each termination mix and continued the 
incubation at 42°C for 5 minutes. There were four termination mixes contained 80 
pM of each dNTP and 8  pM of the appropriate dideoxyribonucleoside triphosphate 
(ddNTP). The reaction was then terminated by the addition of 4 pi formamide dye 
stop solution. Tubes were then stored at -20°C until further need.
{Q  Gel electrophoresis
8 % denaturing polyacrylamide gels containing 7M urea were prepared and run 
in IX TTE buffer (glycerol tolerant buffer) as before (2.7.2). Gels were pre-run for 
variable periods of time (30 to 60 minutes) at 2500 volts to heat it to 50°C then the 
volts was reduced to keep this temperature constant. Samples were denatured at 75°C 
for 3 minutes, quenched on ice and 2.5 pi from each termination reaction was loaded. 
Electrophoresis was carried out at 50°C for 2-4 hours depending how far was the 
area of interest. After electrophoresis the gel was taken out and dried in a vacuum gel 
dryer then exposed to Kodak X-Omat AR film using a cassette with intensifying 
screens for 16 to 40 hours at -40°C.
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(D) Sequencing close to the primer
To read sequences close to the primer (few bases) some modifications were 
done in the sequencing protocol. One of these was to add 1 pi of Mn buffer (0.15M 
Na isocitrate, 0.1M MnCh) to the labelling mix before adding sequenase enzyme. Mn 
reduces the average length of DNA synthesised in the termination step, intensifying 
the sequencing ladder close to the primer. Mn buffer is supplied with the USB 
sequencing kit. Other modification was to use a higher dilution of the labelling mix 
(1/10 or 1/20) instead of the ordinary 1/5 dilution. It was important to have a 
sufficient quantity of the PCR template and to double the amount of the sequencing 
primer to read sequences close to the primer. The gel running time of such samples 
was around two hours.
(E) Sequencing far from the primer
To read sequences more than 200 bp from the primer it was essential to make 
some modifications in the sequencing protocol. These changes were recommended by 
the 'Step-by-Step' protocol 9- edition supplied with the sequanase version 0 . 2  kit, by 
using more nucleotides in the labelling reaction, by adding undiluted labelling mix and 
by lengthening the labelling time to 5 minutes. Altering the nucleotide mixture in the 
termination mix was another recommendation. This was achieved by using the 
sequence extending mix. 1.5 pi of the termination mix was mixed with 1 pi of the 
extending mix to replace the usual 2.5 pi termination mix. Gels were usually run at a 
lower temperature (40°C ) for a longer time ( 8  hours).
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2.8.2 Automated sequencing of PCR products using PRISM™ Ready Reaction
DveDeoxv™ Terminator Cycle Sequencing Kit (Perkin Elmer)
(A) DNA preparation and cycle sequencing
Double stranded PCR products were obtained from areas of interest as 
mentioned before. The products were cleaned using the Geneclean™ kit (2.7.5) or by 
ethanol precipitation (2.7.4). A 10.5 pi PCR mix was made containing 2 pi of the 
cleaned PCR product, 3.2 pmol of one of the primers used for the initial PCR and 
ddH20  and kept on ice. 9.5 pi of the terminator premix (Prism™ Ready Reaction 
DyeDeoxy™ Terminator Cycle Sequencing Kit, Perkin Elmer) was added to each
10.5 pi PCR mix on ice, mixed well, overlaid with one drop of mineral oil (-40 pi) 
and placed on 96°C preheated PCR block (Perkin Elmer/Cetus PCR model 480). 
Immediately a 25 PCR cycles of 96°C for 30 seconds, 50°C for 15 seconds and 60°C 
for 4 minutes was started. The PCR cycles were then followed by a rapid thermal 
ramp to 4°C and held.
(B) Purification of the extension products
At the end of thermal cycling 80 pi of ddH20  was added to each 2 0  pi 
reaction volume under the oil and mixed by pipetting. The whole 100 pi volume was 
transferred from under the oil to a fresh 0.5 ml Eppendorf tube. The terminators were 
extracted two times with 100 pi phenol:water:chloroform (68:18:14) at room 
temperature. The extension products were precipitated by adding 15 pi of 2M Na 
acetate, pH 4.5, and 300 pi of absolute ethanol followed by incubation at -70°C for 
15 minutes and centrifugation in microcentrifuge at full speed for another 15 minutes 
at room temperature. Pellets were washed in 70% ethanol and vacuum centrifugation 
dried for 5 minutes.
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(Cl Running of the sequencin2 reaction on the automated sequencer (ABI Prism
373 automated sequencing apparatus)
6 % denaturing polyacrylamide gels with 8 M urea was prepared and run in IX 
TBE buffer according to the parameters suggested by the ABI. Gel plates were 
carefully cleaned to avoid smearing and background noise which could interfere with 
data analysis. The plates were scanned for any signal artifacts caused by dirt. If such 
artifacts were present, the gel-scanning area was cleaned once with a damp tissue then 
re-scanned. The gel was pre-run before loading for 10 minutes and re-scanned for 
signal artifacts as before. 4 jliI of gel loading mix was added to each sample pellet. 
Samples were denatured at 92°C for 2 minutes, rapidly quenched on ice then loaded 
into the gel.
(DI Result analysis
Analysis of the results obtained from each gel run was done by the Mackintosh 
computer attached to the prism 373 DNA sequencer system using 373A software 
version 1.2.1 (ABI). The sequencer which has a fluorescence detection system sends 
the collected data to the computer. The computer processes the data and presents it as 
a chromatogram with four coloured peaks, each representing one of the four bases 
(A,T,C & G). Base designation is also given above each peak. Heterozygosity is 
represented by two superimposed peaks and designated as an N'. Heterozygosity was 
always confirmed by sequencing the other DNA strand.
2.8.3 Sequencing of cloned PCR products
(Al Cleaning of the PCR products
PCR products were obtained as previous. To prepare the PCR products for 
cloning, each product was mixed thoroughly with SDS and EDTA, pH 8.0 to a final 
concentrations of 0.5% and 5 mM respectively in a 0.5 ml microcentrifuge tube. 
Proteinase K was added to each tube to a final concentration of 100 fig/ml and the
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tubes were incubated for 30 minutes at 56°C. DNA was precipitated by 0.1 volume 
3M Na acetate, pH 7.0 and 2 volumes ethanol at -20°C for 15 minutes. DNA was 
recovered by centrifugation at 1 2 0 0 0  g for 15 minutes at 4°C in a microcentrifuge. 
Pellets were washed with 70% ethanol at 4°C and recentrifuged. Pellets were then air 
dried and redissolved in 30 pi sterile T.E. buffer, pH 7.6.
(B) PCR cloning using pGEM -T vector systems (Promegal
® ®The pGEM -T vector is prepared by cutting Promega's pGEM -5Zf(+)
vector with EcoK V and adding a 3' terminal thymidine to both ends. Ligation of these
single 3'-T overhangs at the insertion site takes advantage of the non-template
dependent addition of a single deoxyadenosine to the 3' end of PCR products by
®certain thermostable polymerases. A 1:1 molar ratio of the pGEM -T vector to a
®PCR product was used in the ligation reaction. The pGEM -T vector is about 3 kb in 
length and to calculate the appropriate amount of PCR product the following equation 
was used:
ng of vector x kb size of insert .
 ——:-----   x insert: vector molar ratio = ng of insert
kb size of vector
®Following the protocol supplied by Promega, the pGEM -T vector and
®pGEM -T vector control DNA tubes were briefly centrifuged to collect contents at 
the bottom of the tube. A 10 pi ligation reaction was set up in two 0.5 ml 
microcentrifuge tubes, one tube for the control reaction and the other for the standard 
reaction as follows:
Standard Reaction Control Reaction
T4 DNA ligase 10X Buffer 1 pi 1 pi
pGEM@-T vector (50 ng) 1 pi 1 pi
PCR product (or pGEM°-T vector control) x pi 2  pi
T4 DNA ligase (1 Weiss unit/pl) 1 pi 1 pi
dH20  to a final volume of 1 0  pi 1 0  pi
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The reactions were incubated overnight at 15°C and 2  pi of each reaction was used 
for the transformation reaction as described in 2.7.1 with only one difference. The 
transformation culture was grown on LB/ampicillin/IPTG/X-gal plates equilibrated to 
room temperature prior to plating. 100 pi of 0.1M IPTG and 20 pi of 50 mg/ml X- 
Gal were spread over the surface of LB/ampicillin plate and allowed to absorb for 30 
minutes at 37°C prior to use. Insertional inactivation of the a-peptide coding region 
of the enzyme (3-galactosidase of the ligation vector allowed recombinant clones to be 
directly identified (white colonies) by colour screening on indicator plates. Colonies 
containing (3-galactosidase activity (usually has no insertion of the PCR fragment) will 
produce blue colonies.
(Cl Isolation of recombinant plasmid DNA
Recombinant plasmid DNA was grown up and isolated using INSTA-PREB™ 
kit as described in 2.7.1 with only one modification where the plasmid DNA was 
extracted with an additional 200 pi of PCI solution. After the first PCI extraction, 200 
pi of PCI solution was added to the spun tubes, mixed briefly by repeated inversion 
and spun again. This was followed by the standard addition of 300 pi of Cl solution 
and the standard protocol was continued. Recombinant plasmid DNA was isolated 
from at least 10 single white colonies for each target PCR DNA.
(D1 Double stranded sequencing of the recombinant plasmid DNA
Prior to sequencing, using the USB sequenase version 2.0 sequencing kit, 4 
pg of plasmid DNA was alkaline-denatured. 20 pi of plasmid DNA (~4 pg) was 
mixed with 2 pi of 2M NaOH/2mM EDTA solution and incubated at 37°C for 30 
minutes. Denatured DNA was then precipitated by 0.1 volume 3M Na acetate, PH 
4.5-5.5 and 3 volumes 100% ethanol at -70°C for 15 minutes. DNA was recovered by 
centrifugation in a microcentrifuge at full speed for 15 minutes. Pellets were washed 
with 70% ethanol, air dried and redissolved in 7 pi ddH20. Sequencing and sequence
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analysis were carried out as described before (2.8.1). For each insert-PCR, sequencing 
of 1 0  colonies was carried out and any sequence abnormalities were confirmed by 
sequencing the opposite DNA strand.
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(3) RESULTS
3.1 Screening for the CTG repeat expansion in DM families
3.1.1 Radiolabelled PCR amplification of the DNA sequence containing the 
(CTGln repeat
The status of the DM locus was surveyed in 49 DM families ( 8 6  DM patients 
and 96 apparently normal individuals). All the families were ascertained by clinical 
diagnosis of the proband; an expanded DM allele was identified afterwards in each of 
these individuals. Primer set 409/410 (Mahadevan et al., 1992) was used and the PCR 
conditions were optimised to amplify the region of the myotonic dystrophy protein 
kinase (DMPK) gene that contains the unstable CTG repeat sequence. 32P dCTP was 
used in the PCR reaction mix to internally label the PCR products. The products of 
the PCR reactions were resolved in 8 % denaturing polyacrylamide gels. Gels were 
exposed to Kodak X-AR5 film and autoradiographed at -70° C for 16 hours. PCR 
amplified products from subjects of the same family were electrophoresed in the same 
gel to avoid electrophoresis variability.
The size of the amplified products from the normal chromosome varies 
between 64 bp (for the 5 repeats) and 140 bp (for the 37 repeats). Expanded alleles 
containing up to -83 repeats could be amplified from DM chromosome. The 
expanded alleles always show a multiple band pattern which may reflect somatic 
mosaicism or stuttering during the PCR reaction (Figure 3.1)
100
(a)
2 3 4 5 6 7  8 9 10 II 12
(b)
: -tM
■
i  •
F ig u r e  3.1
(a) Size distribution o f  C T G  repeats in a DM  family using ' P-labelled PCR products  
analysed by denaturing polyacrylamide electrophoresis. Lanes 1 and 12 are 
radiolabelled 1 kb ladder. Lanes 2, 4, 6, 9 and 10 show PCR products  from 
individuals with one allele (either normal hom ozygous for that allele or heterozygous 
with the second allele too large to amplify). Lane 7 shows PCR products  from a DM 
patient with one normal allele (5 repeats) and one expanded (~  59 repeats) allele 
(arrow ).
(b)  Zoom -in  o f  som e C T G  expanded alleles to show the multiple band pattern o f  
amplification
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3.1.2 Non-radiolabelled PCR amplification of CTG repeats
Non-radiolabelled PCR amplification of DNA sequences containing CTG 
repeats was optimised in a subset of DM families using primer set 406/409 
(Mahadevan et al., 1992). PCR products were resolved in 1.5% agarose gels stained 
with ethidium bromide then visualized and photographed under UV light. The size of 
the amplified products from the normal chromosome varied between 149 bp (for the 5 
repeats) and 245 bp (for the 37 repeats). Expanded alleles containing up to 90 repeats 
were detected (Figure 3.2).
3.1.3 Southern analysis to detect CTG expansion in DM chromosome
CTG repeats of more than 90 repeats are not usually visible upon PCR 
amplification although the unaffected alleles are readily amplified. These large 
expansions can be seen on Southern blots of BglI digested genomic DNA hybridized 
with the p5B1.4 genomic probe. Some of the expanded alleles were seen as diffuse 
hybridization signals (Figures 3.3 & 3.4).
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F ig u re  3.2
Example o f  PCR products  resolved in 1.5% agarose gels and stained with ethidium 
brom ide (a) Products  obtained by PCR amplification o f  D N A  from DM patients with 
minimal symptoms. The upper bands represent expanded DM  alleles (lane 1= - 9 0  
repeats, lane 2= -7 1  repeats, lane 3= - 8 7  repeats, lanes 4 & 5 -  - 7 0  repeats). The 
lower bands are the normal alleles in these individuals ( - 1 5 ,  25, 5, 5 and 21 repeats 
respectively).
(b)  P roducts  obtained by PCR  amplification o f  D N A  from a DM family Lane 1 
shows p roduc ts  from an individual with one normal allele ( - 5  repeats, either normal 
h om ozygous  for that allele or heterozygous with the second allele to o  large to 
amplify). The other lanes(2-4) show  normal heterozygous individuals ( -1 3 /2 8 ,  5/28 
and 13/28 repeats  respectively). M =  1 kb ladder
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Figure 3.3
A restriction map of the region containing the CTG polymorphism, showing the 
position of the genomic probe p5B1.4 and the relevant restriction sites (Shelboume et
al. 1992).
104
1 2 3 4  5 6 7  8 9  10 1 1 1 2  13
Fig ure  3.4
Example o f  Southern blot analysis, using Bgfl enzyme and the p5B 1.4  probe, showing 
varying degrees o f  allelic expansion (upper bands) in DM-aflfected individuals. The 
lower band ( - 3 .4  kb) show s the normal size allele in these individuals. Lanes 1,2 and 
3 are from affected siblings with variable degrees o f  allelic expansions ( -3 3 0 ,  1200 
and 1320 repeats respectively). Lanes 8 and 9 are from a father (lane 8) carrying an 
expanded allele o f -1 9 0 0  repeats  and a daughter carrying - 5 8 0  repeats (lane 9) w here 
a reduction in repeat size occurred during paternal transmission Lanes 10, 11 and 12 
are from a father (lane 12) with a smear o f  expansion ( - 3 7 0  repeats), a daughter (lane 
1 1) with an expansion o f  - 4 0 0  repeats and a g randdaughter (lane 10) who did not 
inherit the expanded maternal allele, she only carries normal alleles o f - 3 .4  kb
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3.1.4 Size of the expanded CTG repeat sequence in relation to phenotype
The clinical status of the DM patients was classified according to the method 
of Harley et al. (1992b). Five categories of the patients can be recognized (1) mild 
disease, in individuals presenting in later life with minimal features of the disease (e.g. 
cataracts) and asymptomatic obligate carriers (grandparents); (2 ) classic adult-onset 
type; (3) childhood type; (4) young carriers without symptoms and (5) congenitally 
affected individuals. In all of the studied patients the DM expansion mutation was 
associated with the disease. Table 3.1 shows the range of repeat sizes in each clinical 
category, separated by the sex of the individual. The only obvious difference observed 
between the sexes was in the minimally affected group, with an excess of males having 
the smallest repeat size (<0.25 kb; -85 repeats), which is not statistically significant 
(p>0.05). The correlation between the disease severity and CTG repeat size is weak in 
spite of the general trend of the more severe the phenotype, the larger the repeat size 
(r = 0.42, p < 0.01, 95% confidence limits = 0.23 to 0.58) and overlapping between 
the various clinical groups does exist (Figure 3.5).
Figure 3.6 shows the relationship of repeat size to apparent age at onset. A 
significant correlation was observed when repeat size was plotted on a logarithmic 
scale (r = -0.62, p < 0.001, 95% confidence limits = -0.48 to -0.75).
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Table 3.1 Range o f  C T G  repeat sizes in kilobase (kb) am ong different clinical categories o f  
myotonic dystrophy (D M ) patients divided by the sex o f  the affected individual.
Male Female
Minimal Change DM
j a. 15-0 25 kb H B H B
0.25-0 ,35  kb 1 i
Classical D M
0.25-2 ,0  kb 14 18
2 0-3 5 kb 4 7
3 .5-6 .0  kb 5 5
C hildhood onse t D M
LI kb 2 IS l l l l l l l l l l l i l
3 .0  kb 2 i
Yaa&sg. asym ptom atic  D M  ;
0 ,5 -1 .4  kb 3 2
1.5-2 0 kb 1 1
Congenital DM
1,7-2,9 kb 1 2
2 .9 -6 .0  kb ■ l I l l M l l i H l B m u  i
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10  -
8 -
Number of patients
I I
□ Minimal Change
■ Adult Onset
■  Childhood onset
■ Congenital
1
. 15-  .25 -  .35 -  0 .5 - 1.0 -  1.5 -  2 .0 -  2 .5 - 3 .0 - 4 .0 -
.25 .35 0.5  1.0 1.5 2.0 2.5  3.0 4.0  6.0
CTG repeat size (kb)
Figure 3.5
Size distribution of the CTG repeat expansion in different DM phenotypes. An 
overlap between different clinical groups is clearly present.
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Figure 3.6
Age at onset for DM patients, plotted against CTG repeat length (logarithmic scale)
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3.1.5 Intereenerational instability of the CTG repeats
To study the intergenerational instability of the CTG repeats 31 parent-child 
pairs, 10 maternal-child and 21 paternal-child pairs, were analyzed. In most cases 
there was an increase of the repeat size during parental transmission with only two 
exceptions (Figure 3.7 and Figure 3.8)
There were two cases where the repeat size has decreased during paternal 
transmission. The first one (Figure 3.9) showed a decrease from the paternal 5.7 kb 
(1900 repeats) to 1.7 kb (-565 repeats). The second one (Figure 3.10) showed a 
decrease from the father (DNA tested in another laboratory, and shown to have a 
moderate expansion, but was not available for this study) to his daughter (0.27 kb; 90 
repeats). The CTG repeat inreased again during the transmission to the grand son 
(350 CTG repeats) and the grand daughter (450 CTG repeats).
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Figure 3.7
CTG repeat size for 31 parent-child pairs. Points above the diagonal indicate repeat 
size greater in child than in parent.
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Change in repeat size (in bp) on transmission from mothers to 1 0  offspring 
(top) or on transmission from fathers to 2 1  offspring (bottom) plotted against 
repeat size of parent.
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(a)
Moderate 
(1900 repeats)
n  in
Asymptom atic 
(~ 580 repeats)
l!l:2
( b )
2
F ig ure  3.9
Reduction of the C T G  repeat length during paternal transmission (a)  Family 
pedigree, (b) Southern analysis o f  the father, II: l (lane 1, —3.4/5.7 kb) and the 
daughter. III 4 (lane 2, -3 .4 /5  14 kb) using Bgfl enzyme and p5B 1.4
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F ig u r e  3 .10
Reduction o f  the C T G  repeat length during paternal transmission followed by increase 
o f  the C T G  repeat upon transmission from the daughter to  the grand offspring, (a) 
Family pedigree, (b)  Southern analysis o f  III: 1 (lane 1, -3 .4 /3 .7  kb), IV 1 (lane 2, 
- 3  4 /4 .4  kb) and IV:2 (lane 3, - 3  4/4.7 kb) using Bgl\ enzyme and p5B l 4 probe (c) 
PCR amplification o f  this family. Lane 1 shows III 1 alleles o f  15 and 90 repeats, lanes 
2 and 3 show  IV. 1 and IV 2 normal alleles (15 and 13 repeats) only, their expanded 
alleles are to big too be amplified by PCR L =  1 kb ladder.
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One family showed a stable transmission of the CTG repeat in two generations 
(Figure 3.11a&b). The grand mother had cataracts at the age of 60 years, died at the 
age of 80 years from head injury, (DNA not available). Her daugther inherited an 
allele with 63 repeats (~0.2 kb) and had cataracts only at the age of 55 years. The 
latter had passed her 63 repeat (-0.2 kb) allele unchanged to her son and a slightly 
increased allele (73 repeats; -0.22 kb) to her daughter.
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F ig u r e  3.1 l b
' P-labelled PCR product from the previous family (Figure 3 .11a) showing the 
expanded  alleles (arrows). Lane 1 (V:6), lane 2 (V:5) and lane 4 (IV:3) Lane 5 shows 
labelled 1 kb ladder.
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3.1.6 Severe infantile myotonic dystrophy of paternal origin
A case of severely affected mentally retarded child with onset in the first year 
of life was found to be due to paternal transmission of an expanded CTG allele (500 
repeats) to his daughter who carried a 700 CTG allele (Figure 3.12).
118
(a)
Age 85 years
Cataract 
(-1 0 0  Repeats)
!1!:2
(-5 0 0  Repeats)
IV l
Severe Infantile 
(-7 0 0  Repeats)
(b)
2 3
F ig u re  3.12
Paternal transmission o f  severe infantile onset DM. (a) Family pedigree (b)  Southern  
analysis o f  II I (lane 1, -3 .4 /3 .7  kb), III: I (lane 2, -3 .4 /4  9 kb) and I V : 1 (lane 3, 
- 3  4/5.5 kb) using Bgll enzyme and the p5B1.4 probe
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3.2 Screening of ALS patients for mutations in the SOD-1 gene
3.2.1 PCR amplification of the SOD-1 gene in ALS patients
DNA samples from 2 familial and 67 sporadic ALS cases were subjected to 
polymerase chain reaction (PCR) amplification of the all five exons of the SOD-1 gene 
(Figure 3.13a). For exon 3 a primer set was designed using the computer program 
Oligo™ (Medprobe) and the PCR reaction was optimised by trying different 
concentrations of DNA, primers and dNTPs and by applying different annealing 
temperatures. Published primer sets (Rosen et al., 1993; Deng et al., 1993) were used 
for PCR amplification from the remaining exons (1, 2, 4, and 5) after optimisation of 
the published conditions. Non-radiolabelled PCR products from the five exons were 
checked on 1% agarose gel in IX TBE buffer (Figure 3.13b).
3.2.2 Screening for the Ilell3Thr mutation in ALS patients
Ilell3Thr mutation creates a new restriction site for the enzyme Bsrl so that 
the PCR product from the normal SOD-1 exon 4 allele will be digested into two 
fragments of 124 and 90 bp while the mutant one will be digested into three fragments 
of 113, 90 and 11 bp respectively (Rosen et al., 1993). This enzyme was used to 
digest the PCR amplification products of the SOD-1 exon 4 from all the studied ALS
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Figure 3 . 13b
PCR  amplification o f  exons 1 to 5 in the SO D -l gene, (a) Amplification products  
from: exon 1 (lanes 1&2, 158 bp), exon 3 (lanes 3&4, 130 bp), exon 4 set a (lanes 
5&6, 214 bp) and exon 5 (lane 7, 216 bp), (b) Amplification products  from: exon 2 
set a (lanes 1-3, 132 bp) and exon 2 set b (lanes 4-6, 207 bp). M l =  100 bp ladder. 
M 2=  1 kb ladder
patients. The digestion products were resolved by denaturing 8 % polyacrylamide gel 
electrophoresis in IX TBE buffer alongside a ladder marker for 4 hours at 280 
constant volts then silver stained. Only normal digestion products were present in the 
screened patients (Figure 3.14).
3.2.3 Screening for the Ala4Val mutation in ALS patients
Ala4Val mutation abolishes a HaeIII restriction site thus producing an 
additional larger restriction fragment of 49 bp in the heterozygous mutants. PCR 
amplifications of SOD-1 exon 1 from all studied-ALS patients have been subjected to 
Haelll restriction endonuclease digestion. The digested products were resolved by 
running them on 8 % denaturing polyacrylamide gel alongside a ladder marker for 2.5 
hours at 280 constant volts then silver stained. This mutation could not be detected 
either in the two familial or the 67 sporadic screened ALS patients (Figure 3.14).
3.2.4 Screening for the CAG repeat expansion in exon 1 of the androgen 
receptor gene
CAG repeat expansion in the exon one of the androgen receptor gene has been 
reported in patients with spinal and bulbar muscular atrophy (SBMA, Kennedy 
disease) (La Spada et al, 1991). A primer set flanking the CAG repeat site in exon 1 
of the androgen receptor gene (Allen et al., 1992) was used and the PCR conditions 
were optimised to amplify DNAs from sporadic ALS patients. The products of PCR 
amplification were resolved by running on 1.5% agarose gels in IX TBE buffer. 
Amplification from the normal chromosomes gave PCR products o f -280 to 310 bp. 
Abnormal chromosomes, with CAG repeat expansion, produce PCR products o f -350 
to 390 bp with no overlap between normal individuals and affected patients. No 
expansion of the CAG repeat could be detected in the tested (67) DNA samples 
(Figure 3 .15).
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(a) (b)
F ig u re  3.14
Screening for the lie 1 13Thr and the Ala4Val mutations, (a) Screening for the exon 1 
Ala4Val mutation  using restriction enzyme (HaeIII) digestion o f  the PCR products  
N o  abnormal (49 bp) product has been seen LI = 75 bp band o f  1 kb D N A  marker
(b )  Screening for the exon 4 lie 113Thr mutation using restriction enzyme (Bsrl) 
digestion o f  the PCR  products  reveals a normal digestion pattern (no abnormal 113 bp 
p roduc t could be seen). L2 = 100 bp band o f  the DNA  marker. A rrow s point to the 
digestion products. N um bers beside the arrow s indicate the size o f  the products  in 
base pair (bp)
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3 9 4  bP^ 
2 9 8  bP ►
Figure 3.15
Screening for the C A G  repeat expansion in exon 1 o f  the androgen  receptor gene in 
sporadic ALS patients. N o C A G  repeat amplification could be detected in the 
screened patients (lanes 2 to  8) Lanes 9 and 10 show the C A G  repeat expansion 
( -3 9 0  bp) in an affected K ennedy’s disease male patient and in a female carrier 
(a rrow ) Lane 1 shows 1 kb D N A  ladder
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3.2.5 PCR-SSCP screening for mutations in the SOD-1 gene in ALS patients
In this technique radiolabelled PCR-amplified products were obtained from the 
five exons of the SOD-1 gene. The SOD-1 gene was screened in two familial and 67 
sporadic ALS patients. With each radiolabelled-PCR set of reactions (20 reactions) 
two non-radiolabelled PCR reactions were done and tested on 1% agarose gel to be 
taken as a guide for the condition of the radiolabelled reactions. Aliquots of 1 pi PCR 
product were mixed with 9 pi SSCP loading mix, denatured by heating for 3 minutes 
at 95° C, quenched on ice for at least 5 minutes and then 3 pi of aliquots were loaded 
into: (1) 0.5 X MDE gel in 0.6 X TBE buffer. The gels were run at 5 watts for 16 
hours at room temperature. (2) 8% non-denaturing polyacrylamide gel with the 
following conditions: (a) 5% glycerol, running at 5 watts for 16 hours at room 
temperature, (b) 10% glycerol, running at 8 watts for 12 hours at room temperature 
and (c) without glycerol, running at 12 watts for 12 hours at 4°C.
A patient from one of the two studied FALS families (Figure 3.16a and table 
3.2) showed an altered migration of the SOD-1 exon 4 PCR product on SSCP 
analysis. The same altered pattern was detected in all affected family members as 
compared with controls (Figure 3.16b).
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11:1 ll:4 ll:6
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IV:1
Figure 3.16a
Diagrammatic representation of the FALS family where an altered SSCP pattern of 
the SOD-1 exon 4 has been observed in the affected family members. Arrow points to 
the proband. DNAs were tested from all the affected members. Individual 11:4 showed 
some manifestations of ALS but refused to be further investigated.
Table 3.2_____________________________________________________________
The age at onset, age at death and duration of the disease process in FALS 
family members who showed the Gly93Ser mutation in exon 4 of their SOD-1 genes.
Patient's
Number
Age at onset Age at death Duration of the disease
1.2 36 years 48 years 12 years
II. 1 40 years 43 years 3 years
II.2 36 years 39 years 3 years
II. 6 28 years 33 years 5 years
III.l 26 years 1 year
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(a)
F ig u r e  3 . 16b
(a) The result o f  SSCP analysis o f  SOD-1 exon 4 in one FALS family (Figure 3 . 16a) 
using M D E  gel. Lane 1 show s results obtained from individual 1:2, lane 2 from 
individual II: 1 and lane 5 from individual 11:2 Lanes 3, 4 and 6 are from individuals 
II:3, 11:5 and a normal control respectively, (b)  The same analysis using 8% non­
denaturing polyacrylamide gel run at 12 w atts  for 12 hours at 4°C. The arrow 
indicates the presence o f  a band shift in the affected family m embers P = patient; N = 
normal.
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3.2.6 Sequencing of the SOD-1 exon 4 from FALS patients showing the 
G277^C mutation which caused the missense Glv93Arg change.
To detect the cause of the band shift in SSCP analysis of this family, direct 
sequencing of both DNA strands of the asymmetric PCR products from the affected 
family members and a normal control were performed. A point mutation (G277 to C) 
was detected in all affected family members but not in a normal control. This caused a 
missense mutation Gly93Arg (Figure 3.17).
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F ig u r e  3.17
(a) Asymmetric PCR amplification p roduc ts  from exon 4 o f  the SOD-1 gene from a 
FALS patient and a normal control Reactions which give good  single strand yield 
(a rrow ) have been used for subsequent sequencing procedure  SS = single strand; DS 
=  double strand, L =  D N A  ladder (b)  Sequence analysis o f  the SOD-1 exon 4 in a 
FA LS patient w ho show ed a band shift with SSCP analysis. The arrow indicates the 
presence o f  the G 277 to  C change in the patient P =  patient, N  =  normal control.
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3.2.7 The G277 to C change in SOD-1 exon 4 creates a new restriction site for
the enzyme Sau5A\
To find if the G277 to C mutation caused changes in the restriction map of 
SOD-1 exon 4, the GCG package from the Unix computer was used. It showed that 
this mutation has creates a new restriction site for the enzyme <Sazf3AI. PCR 
amplification products from the normal chromosome were cut into two fragments of 
135 bp and 79 bp while that from the mutated chromosome were cut into three 
fragments of 135 bp, 44 bp and 35 bp (Figure 3.18).
To screen for the presence of the G277 to C mutation in other ALS patients 
PCR amplification products of SOD-1 exon 4 from 67 sporadic and one familial ALS 
have been subjected to restriction enzyme (Sau3M) digestion. The digestion products 
were resolved in 12% acrylamide gels using IX TBE buffer. The gels were stained 
using ethidium bromide, visualised and photographed under UV light. No such change 
could be detected in any of the screened patients (Figure 3.18)
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F ig u r e  3 .18
(a )  San 3 AI digestion o f  the SO I)-/ exon 4 PCR amplification products  from a G 277 
to C m utant patient and a normal control Arrows point to the presence o f  tw o  extra 
digestion product from the patient. P =  patient; N = normal control (b) Screening for 
the G 277  to C m utation in o ther ALS patients using the Sau3Al restriction enzyme 
digestion. No abnormal products  could be detected
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3.2.8 SSCP analysis showing band shifts due to electrophoresis and/or PCR
errors
When abnormal SSCP band shifts were observed in a patient the analysis was 
repeated for confirmation. In some instances the abnormality would disappear upon 
the second gel run (Figure 3.19).
In one sample the abnormality was expected to be due to PCR error (band 
shift disappeared upon second gel run of newly made PCRs from the whole pannel of 
patients (20 patients) tested before but not from the old one), sequencing of the 
abnormal PCR product detected a PCR incorporation error (Figure 3.20). Subsequent 
sequencing of a newly amplified PCR product failed to detect this abnormality.
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F ig u r e  3 .20
Sequence analysis o f  the PCR product which gave abnormal SSCP band shifts. 
Sequence analysis o f  exon 1 o f  the SO D-/ gene shows a G 34 to A mutation in the 
patient but not in the normal control. This mutation, if real would lead to a missense 
G ly12Ser change
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3.3 Screening for germline mutations in the TSC2 gene
32 patients with tuberous sclerosis (TSC), including both sporadic and 
inherited cases were analysed for germline mutations within ~ 40% of the TSC 2 
coding sequence and 325 bp of the upstream promoter area. All patients were 
diagnosed as TSC according to the revised Gomez criteria (Gomez, 1991).
3.3.1 Screening for structural rearrangements bv Southern blot analysis
To screen for major structural rearrangements (deletions and/or insertions) all 
patients’ DNAs were digested twice by Hindlll and EcoRl restriction endonucleases 
and transferred to Hybond N nylon membranes. The EcoRl membrane was probed 
using the cDNA probe E l.6 and the Hindlll membrane was probed using the cDNA 
E2.5 probe kindly supplied by Dr. M. Nellist, Institute of Medical Genetics, University 
Hospital of Wales, Cardiff. No major structural rearrangements were detected.
3.3.2 Amplification of the TSC2 cDNA bv RT-PCR
Total cellular RNA from whole blood lymphocytes of TSC patients (22 
patients) was used to synthesise cDNA using oligo dT or oligonucleotide primers with 
nucleotide sequences complementary to various regions of the TSC2 mRNA. Four sets 
of PCR primers were designed and PCR conditions were optimised to amplify four 
segments of the TSC2 coding sequence. The first segment spans positions 1041 to 1857 
of the cDNA and contains a possible membrane-spanning regions. The second to the
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fourth segments span positions 4215 to 5471 of the cDNA and contain the GAP3- 
related domain and the polyadenylation signals (Figure 3.21 & 3.22a).
3.3.3 Amplification of exon 1 and exons 38-41 of the TSC2 gene from genomic 
DNA
One PCR primer set was designed and PCR conditions were optimised to 
amplify exon 1, part of intron 1 and 325 bp of the promoter area of the TSC2 gene 
from all patients’ DNAs (32 samples). For a subset of patients (10 patients) only 
DNAs were available and another PCR primer set was designed and optimised to 
amplify TSC2 exons 38-41 (numbering according to Maheshwar, et al. 1996) as one 
amplification segment of 1120 bp (Figure 3.22b).
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(837 b p )
6 0 0  b P M
S eg m e n t  II 
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S e g m e n t  III 
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S e g m e n t  IV 
(505 bp )
F ig u r e  3 .22a
R T -P C R  amplification products  (a rrow s) from the TSC2 cDNA. Four sets o f  PCR 
primers w ere used to amplify 2.072 kb o f  the cD N A  as been shown in the previous figure 
(F igure 3.21). The PCR products  w ere run on 1% agarose gels, stained with ethidium 
brom ide and visualised under the UV  light. L= 100 bp D N A  ladder
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E X O N S  38 to 41 (1120 bp)EXON 1 (663 bp)
Figure 3.22b
PCR amplification o f  exons 1 and 38 to 41 o f  the TSC2 gene L =  100 bp D NA  ladder
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3.3.4 Mutation screening using chemical cleavage of mismatch (CCM) analysis
After initial amplification by PCR, the products were electrophoresed on 1% 
agarose gels to check for any abnormal size alterations. If no alteration was seen, the 
amplification products were analysed by CCM to detect and locate the presence of 
point mutations and small sequence alterations within the amplified parts of the TSC2 
gene. CCM analysis was used to screen all cDNA fragments (I to IV), exon 1 (with 
325 bp of the promoter area and part of intron 1) and exons 38-41 (with their introns) 
from patients with tuberous sclerosis (TSC). Figure 3.23 shows examples of positive 
screening results.
3.3.5 Sequencing of the samples that showed positive screening results
Any mismatch detected by CCM analysis was then confirmed by sequencing of 
the corresponding exon or cDNA segment. Three different sequencing techniques were 
used. Asymmetric PCR amplification of the segment or exon of interest and direct 
sequencing by the Sanger dideoxy chain termination method using USB sequenase 
version 2 sequencing kit was performed to characterise most of the detected mutations. 
For few samples direct sequencing of the PCR, using PRISM™ ready reaction 
Dyedeoxy™ terminator cycle sequencing kit and ABI prism 373 automated sequencer 
and/or double stranded sequencing of cloned PCR segments were performed. Each 
change found on sequencing was confirmed by sequencing the complementary strand. 
Any change found on sequencing the cDNA was confirmed, if possible, by sequencing 
the corresponding exon at the DNA level. For cloned PCR, sequencing of 10 colonies
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F ig u r e  3 .23
An example o f  chemical cleavage o f  mismatch analysis. Osmium tetroxide and 
hydroxylamine are the chemicals used to  modify either T o r C mismatches 
respectively. “L ” stands for labelled 1 kb ladder, (a)  C leavage products  o f  - 3 3 0  bp 
(a rrow s) from PCR products  o f  TSC2 cD N A  segment IV upon both hydroxylamine 
and osm ium  tetroxide modifications, (b)  Cleavage product o f - 3 2 0  bp (arrow ) from a 
PCR product o f  TSC2 cD N A  segment III (c) C leavage product o f -2 4 0  bp (arrow ) 
from a PCR product o f  TSC2 exons 38-41
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was done and the change was confirmed in four of them. If sequence alteration was 
detected in familial case, analysis of other family members for this change was also 
done. Every sequence change seen was analysed, using the GCG package 'MAP' 
program, to see if it created or abolished a restriction enzyme site. If alteration of a 
restriction site was found it has been used as a further confirmation of the sequence 
change.
Using this technique 5 point mutations and one 2 base pair deletion were 
characterised. Of these, three point mutations caused missense amino acid changes 
and the other three mutations were proposed to be polymorphisms.
3.3.6 S1715T missense mutation in exon 40 of the TSC2 gene
One sporadic, mentally handicapped, TSC patient showed a cleavage product 
of his RNA segment IV upon osmium tetroxide modification. To characterise the 
cause of this cleavage, asymmetric PCR of the patient's cDNA (segment IV) and 
DNA (exons 38-41) were performed followed by direct sequencing using the USB 
sequenase version 2 sequencing kit. The cleavage was due to a T5161-»A base 
change converting serine to threonine (S1715T) (Figure 3.24). This mutation creates 
new restriction sites for the enzymes PflML and Dralll. The screening of 100 normal 
chromosomes with these restriction enzymes revealed no further examples of this 
mutation.
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(a) Chemical cleavage analysis o f  cD N A  segment IV revealed a cleavage product 
(a rrow ) upon osmium tetroxide modification (b )  sequencing analysis o f  an asymmetric 
PCR product from segment IV revealed a T 5161~»A  (arrow ) change which produces 
a S1715T missense mutation.
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3.3.7 R1720W missense mutation in exon 40
A second missense change was detected, in a sporadic TSC patient, a few 
amino acids downstream of the previous one. Cleavage products were detected upon 
hydroxylamine modification of cDNA segment IV. To characterise the cause of this 
cleavage three sequencing techniques were used. First by direct sequencing of the 
PCR product using the PRISM™ ready reaction Dyedeoxy™ terminator cycle 
sequencing kit and testing the sequencing products on an ABI prism 373 automated 
sequencer. Secondly, the PCR product from patient's cDNA segment IV was cloned 
in a plasmid vector followed by double stranded sequencing by the Sanger dideoxy 
chain termination method using the USB sequenase version 2 sequencing kit. Thirdly, 
asymmetric PCR amplification of cDNA segment IV and exons 38-41, followed by 
direct sequencing using the USB sequenase version 2 sequencing kit. All three 
techniques revealed the same result. Cleavage was due to a C5176—>T base change 
producing a C mismatch of the wild-type DNA producing a cleavage product upon 
hydroxylamine modification (Figure 3.25). This change causes a missense R1720W 
mutation and creates a new restriction site for the enzyme £coRII. Using this enzyme 
to screen for the presence of that mutation in 100 normal chromosomes revealed no 
further examples of this change.
145
H Y D R O X Y L A M I N E
F ig u r e  3.25
(a) Chemical cleavage analysis o f  cD N A  segment IV revealed a cleavage product 
(a rrow ) upon hydroxylamine modification (b) Sequencing analysis o f  an asymmetric 
PC R  product from  segment IV revealing a C 5 1 7 6 ^ T  change (arrow) and producing 
the missense m utation R 1720W  (c) Double stranded sequencing o f  the cloned PCR 
segm ent IV show s T 5176  instead o f  C at that position (d) A utom ated  D N A  
sequencing o f  the PCR product from segment IV o f  the patient and normal control 
At position 'N' o f  the pa tien t’s sample, a C (blue) to T (red) change is observed
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3.3.8 Missense mutation M1602V in exon 37 of the TSC2 gene
Screening of segment III by CCM revealed a cleavage product in a 25 years 
old sporadic, mildly affected TSC patient. Cloning of the patient's segment III PCR 
product followed by sequencing of the plasmid with the insert showed an A4822-»G 
change and produced a missense M1602V mutation (Figure 3.26). This is the only 
mutation detected in the GAP3-related domain of the TSC2 gene and it creates a new 
restriction site for the enzyme £coRII. The screening of 100 normal chromosomes 
with the enzyme revealed no further examples of this mutation.
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Figure 3.26
(a) Chemical cleavage analysis o f  cD N A  segment III revealed cleavage product 
(a rrow ) upon hydroxylamine modification (b) Sequencing analysis o f  the cloned PCR 
product from segment III revealed a G instead o f  A4822 (arrow ) which produces an 
M 1 6 0 2 V  missense mutation (c) Sequencing analysis o f  the same segm ent from normal 
control.
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3.3.9 Two base pair deletion in one of the polvadenvlation signals
One patient from a TSC family showed a cleavage product on modification 
with osmium tetroxide in RNA segment IV. Direct sequencing of the asymmetric PCR 
from that segment revealed a complex sequencing pattern. Analysis of this pattern 
revealed that it was due to a two base pair deletion (AA numbers 5433 & 5434) of the 
second polyadenylation signal of the TSC2 gene (Figure 3.27). This change was also 
confirmed by sequencing PCR product from exons 38-41 of that patient. This family 
has been proved to be linked to TSC locus on chromosome 9 (data not shown) and 
sequencing of other affected family members did not reveal such change confirming 
that it is a polymorphic one. This change does not change any restriction sites, so 
screening of normal chromosome was done by direct sequencing of asymmetric PCR 
which detected this change in one normal sample.
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(a )  Asymmetric PCR o f  R N A  segment IV from a TSC patient w ho showed a CCM  
cleavage product ss= single strand; ds= double strand (b) Chemical cleavage analysis 
o f  the patient's cD N A  segment IV on modification with osmium tetroxide Cleavage 
produc t is indicated by an arrow, (c) Direct sequencing o f  the asymmetric PCR 
revealed a com plex sequencing pattern due to an AA deletion (indicated by arrow ) o f  
one o f  the TSC 2 polyadenylation signals.
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3.3.10 Silent mutations in exons 37 and 41
Two silent mutations affecting two different serine residues (SI630 and 
SI776) were detected upon screening of segments III and IV of the TSC2 cDNA by 
CCM analysis. The first one (S1630 in exon 37) was detected in one patient and is 
due to a C4908-VT change (Figure 3.28). The second one (SI776 in exon 41) was 
detected in four (-12%) out of the screened 32 patients and is due to a G5346->C 
change (Figure 3.29).
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(a)
H Y D R O X Y L A M I N E
(b)
T C G A
F ig u re  3.28
(a) Chemical cleavage analysis o f  cD N A  segment III revealed a cleavage product 
(a rrow ) upon hydroxylamine modification (b)  Sequencing analysis o f  an asymmetric 
PC'R product from segment III revealed a C 4 9 0 8 -> T  (arrow ) mutation which is silent 
(S I 630).
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(a) (b)
H Y D R O X Y L A M I N E
Figure 3.29
(a) Chemical cleavage analysis o f  cD N A  segment IV revealed a cleavage product 
(a r ro w ) upon hydroxylamine modification and was detected in four different patients.
(b) Sequencing analysis o f  asymmetric PCR products  from tw o different patients 
revealing a G 5 3 4 6 —»C m utation (arrow s) which is silent ( S I 776)
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(4) DISCUSSION
Easy identification of specific sequences and sequence changes plays a central role 
in the diagnosis of human inherited diseases. In the present study three autosomal 
dominant neurodegenerative diseases (myotonic dystrophy, amyotrophic lateral sclerosis 
and tuberous sclerosis), with different underlying molecular pathologies, were studied. To 
each one of them a different mutation detection strategy was optimised and applied to 
screen for the underlying molecular pathology.
4.1 (CTG)n repeat instability in patients with myotonic dystrophy
Myotonic dystrophy (DM) is the most common form of adult muscular dystrophy. 
The disease is transmitted in an autosomal dominant manner with the phenomenon of 
anticipation. The DM locus was mapped to the chromosome 19ql3.3 and an expanded 
(CTG)n trinucleotide repeat in the 3' untranslated region of a protein kinase (DMPK) 
gene family member has been identified as the mutation that causes myotonic dystrophy.
In the present study, a screening strategy for 49 DM families, based on PCR 
testing followed by Southern blot for the suspected cases was adopted.
For the DM families who sought genetic counselling, DNAs of the family were 
screened by PCR amplification of the 3' untranslated region of the DMPK gene that had 
the polymorphic CTG repeats. At the beginning of that study radiolabelled PCR using the 
primer set 409/410 (Mahadevan et al., 1992) was optimised and used as a screening test. 
PCR products were resolved by running on 8% denaturing polyacrylamide gels and 
autoradiographed by exposure to Kodak AR film for 5 to 16 hours. Normal 
chromosomes (carrying 5 to 31 repeats) gave PCR products in the range of 64 bp to 152 
bp and were detected. Chromosomes carrying minimally expanded CTG repeats (-56 to 
83 repeats) were easily distinguished from those carrying the upper normal CTG repeats.
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These expanded CTG alleles always appeared on the gel as mosaic pattern of DNA 
fragments. Similar results were obtained by different groups of investigators and the 
mosaic pattern of the expanded CTG repeat was attributed to be due to the presence of 
somatic instability of the expanded repeat (Lavedan et al., 1993a; Brunner et al., 1993). 
In spite of the reliability and accuracy of that test, it required handling of hazardous 
materials (radioisotopes and polyacrylamide) and it was time consuming (~ 24 hours to 
get the result). To overcome these drawbacks, non-radiolabelled PCR using the primer 
set 409/406 (Mahadevan et al., 1992) was optimised and applied to screen 22 DM 
families. First, the test was applied to some previously radiolabelled-screened samples and 
it gave the same conclusions, reached previously, regarding an individual CTG repeat 
expansion status. Using non-radiolabelled PCR followed by agarose gel electrophoresis, 
the discrimination between the upper normal CTG repeat size and the smallest detected 
CTG repeat expansion was not confusing. The technique was easy to perform, cheap, less 
time consuming (results obtained within few hours) and did not deal with any hazardous 
materials. The only difference was that, by using non-radiolabelled PCR less accurate 
sizing (± few repeats) of the normal or expanded CTG repeats was achieved. But as 
stated by Harper et al. (1992), "We currently have no knowledge of the risk of genetic 
instability in the offspring of minimal mutation carriers, nor do we know the likelihood of 
such individuals later developing cataract or other clinical features". Such reduced 
accuracy should not affect the result of the patient's counselling so that it seemed 
reasonable to adopt the non-radiolabelled PCR screening as a first step in the screening 
strategy of DM families. Comparable results were obtained by different group of 
investigators using the same or different primer sets and using either radiolabelled or non 
radiolabelled technique (Brook et al., 1992; Fu et al., 1992; Mahadevan et al., 1992; 
Barcelo et al., 1993; Abeliovich et al., 1993; Ashizawa et al., 1994b; Goldman et al., 
1995; Krahe et al., 1995a).
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Limitation of PCR amplification of the expanded CTG repeats was detected. It 
preferentially amplifies alleles that carry smaller CTG repeat expansions but reasonable 
amplification could not be achieved of alleles with more than 90 repeats. Similar 
limitation has been reported by other investigators who could not efficiently amplify 
alleles with large CTG repeat expansions (between 80 and 150 repeats) (Brook et al., 
1992; Barcelo et al., 1993). For individuals who showed only one band within the normal 
range upon PCR amplification of their DNAs, it was not possible to tell if they were 
normal homozygous for that allele size or affected heterozygous with the second 
expanded allele too large to amplify. To solve this ambiguity, the second step of the 
screening strategy was to perform Southern blot analysis to detect the presence or 
absence of the expanded allele. To avoid ambiguity, it is preferable that the resolution of 
the system cannot distinguish between normal alleles of the CTG polymorphism but can 
distinguish these from minimal expansions (50 CTG repeats and above).
In the present study BglI digested genomic DNA from all DM family members 
were analysed by Southern blot using p5B1.4 32P-labelled genomic probe. Unambiguous 
discrimination between normal homozygous and DM affected heterozygous was 
achieved. Normal individuals showed only one band while affected members showed 
second band of varying degrees of expansion (-56 to several thousand repeats).
It has been demonstrated that Southern analysis using EcoRl, Hindlll and Ncol- 
digested DNA does not detect small DM-specific expansions (Brook et al., 1992; 
Aslanidis et al., 1992 and Fu et al., 1992). Using enzymes generating smaller target 
fragments containing the CTG polymorphism should increase the resolution of the 
technique. Shelbourne et al. (1992) compared the resolution efficacy of three enzyme 
systems. They used EcoRl, BamHl and Bgli to digest DNAs from normal individuals and 
DM patients with varying repeat sizes. Minimal expansions of the CTG repeats were 
detectable in Bgli and BamHl digests but not in EcoRI digests. They described two 
drawbacks of using BamHl digests. First, its ability to clearly distinguish between two
156
normal CTG alleles when one of them is in the upper normal range. This may lead to 
confusion especially in the diagnosis of isolated cases. Second, many of the large 
expansions were detected as smears with both enzymes, but in BamHl digests, these 
smears were barely distinguishable from background hybridisation. The large fragments 
generated in BglI digests were unambiguously detected.
Goldman et al. (1994) reported a Bgli polymorphism, in normal Southern African 
Negroids, which could lead to erroneous diagnosis of DM in people from this population. 
To exclude the possibility of the presence of such a polymorphism in the DM families in 
the present study, Southern analysis using EcoRl digested genomic DNA from patients 
who showed an expanded allele, upon Bgli digestion, was performed. No single case was 
found to have such a polymorphism. It is possible therefore that this polymorphism is 
specific to Negroes (Goldman et al., 1994).
After applying this screening strategy to all studied DM families collected data 
were analysed. All DM affected members showed a varying degree of CTG repeat 
expansion. CTG repeat sizes in DM patients revealed that minimally affected patients 
have repeat sizes of < 0.4 kb (-130 CTG repeats). Congenital cases had on average the 
largest repeat sizes (3.3 ± 1.4 kb) while the adult onset cases (classical DM) showed on 
average intermediate expansions with a wide range of CTG repeat sizes (1.99 ± 1.37 kb) 
which overlapped with the repeat sizes of all other clinical phenotypes. Moreover, there 
was a significant correlation between the size of the CTG repeat expansion and the age at 
onset of the disease. The larger the repeat the earlier the age at onset (r = -0.62; 
p<0.001). These data are in accordance with the previously published data. Nearly all 
cases of DM (98%; Mahadevan et al., 1992) displayed expansion of the CTG repeat 
region. Moreover, in DM patients the size of CTG expansion in blood lymphocytes 
correlates to a reasonable degree with the age at onset and severity of the disease but it is 
by no means absolute and cannot be reliably used as a single diagnostic or prognostic
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criterion to predict clinical status of the patient (Harley et al., 1993; Nokelainen et al., 
1993 and Lavedan et al., 1993a).
Somatic mosaicism due to mitotic instability was observed in the majority of DM 
patients (Mahadevan et al., 1992; Lavedan et al., 1993a; Wong et al., 1995). Smears of 
hybridisation in Southern blot analysis and the presence of multiple PCR alleles(observed 
in the present study and previous studies) are reflections of this mosaicism. Tissue- 
specific differences in the efficiency or availability of DNA repair systems may account 
for the heterogeneity of CTG expansions (Wohrle et al., 1995). Somatic heterogeneity 
could explain the overlapping in fragment sizes of the different clinical groups, especially 
in adults with classical DM. Lavedan et al. (1993a) raised the possibility that somatic 
mosaicism may explain the absence of a strict correlation between the size of the 
mutation observed in patient lymphocytes and the severity of the disease and it is that 
different degrees of expansion may cause varying phenotypic effects in other more 
relevant tissues (Harley et al., 1993). On the other hand, Zatz et al. (1995) showed that 
no significant correlation was found between the size of the CTG expansion in muscle 
and age at onset of the disease. Moreover, large expansions were observed in muscle 
from all adult symptomatic patients independently of the presence of muscle weakness. 
More studies will be needed to solve this dilemma.
In the present study an apparently unexplained excess of male transmitters was 
found in the ancestors' generation. This has been reported before by many authors 
(Harper, 1989b; Harley et al., 1993; Lavedan et al., 1993a; Passos-Bueno et al., 1995). 
Although ascertainment bias can not be rejected, this male excess could be because 
women with neonatal cases will not appear as grandmothers of affected patients.
A reduction in repeat size upon paternal transmission was detected in two 
child/paternal pairs in the present study. In one of them, the father had an adult onset 
classical DM (age at onset 35 years) and an expanded CTG allele of 5.7 kb (-1900 
repeats). His daughter had inherited a reduced allele of 1.7 kb (-565 repeats) and was
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asymptomatic at the age of 25 years. In the second case, the father, also, had a classical 
adult onset DM (age at onset 42 years). His DNA was tested in Cardiff, before the 
discovery of the CTG repeat instability as the molecular pathology underlying DM, and 
was shown to have a moderately expanded allele. At that time his daughter's DNA did 
not show this expansion and she was told that she did not inherit the affected father's 
allele. In the present study, PCR amplification of the daughter's DNA revealed an 
expansion of ~ 90 CTG repeats which was confirmed by Southern analysis using 
BgtUySBlA  system. She, also, requested testing of her 9 years old asymptomatic son and 
7 years old asymptomatic daughter. Both of them showed expanded alleles of 350 and 
450 repeats respectively. It seemed that the paternal regressed allele had re-acquired its 
ability to expand when transmitted through his daughter's line to his grandchildren. Since 
the two affected fathers had late onset and their daughters are still young, it is not 
possible to assess if their clinical picture will be milder than that observed in their DM 
fathers or not.
Both meiotic expansion and contraction events may occur in the DM  allele but 
expansion is favoured (Jansen et al., 1994). A reduction in CTG repeat number to 
within the normal range was reported before by many investigators (Wieringa et al., 
1994). It was mostly seen upon paternal transmission especially in fathers with a repeat of 
1 kb or greater (Ashizawa et al., 1994b), as was seen in the aforementioned cases. The 
tendency towards contraction of alleles on transmission through the male germline may 
be caused by selection of spermatozoa bearing smaller repeats (Jansen et al., 1994).
Ashizawa et al. (1994b) reported that clinical anticipation still occurred in about 
50% of cases that showed intergenerational CTG repeat contraction. On the other hand, 
Harley et al. (1993) and O'Hoy et al. (1993) reported few cases where the reduction of 
repeat size was accompanied by a later age at onset or less severe phenotype.
In the present study six child/parent DM pairs showed either no change (3 cases) 
or minimal increase (< 9 CTG repeats) upon transmission of the CTG repeat from the
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parent to his/her offspring. In four of these pairs (2 child/maternal and 2 child/paternal) 
the parent repeat sizes were between 52 and 83 repeats. In the other two pairs (parent 
were fathers) the parental repeat sizes were 1.1 (-365 repeats) and 1.25 (-417 repeats) 
and showed no change upon transmission. Relatively stable behaviour of the repeat was 
observed with transmission of alleles less than 80 CTGs (Barcelo et al., 1993) and this 
could partially explain the persistence of this autosomal dominant disease in the 
population despite the presence of anticipation and low reproductive fitness.
A case of uncertain diagnosis of congenital myotonic dystrophy (CDM) was seen 
to be paternally transmitted. She was a 12 years old girl with mental and physical 
retardation, hypotonia, sluggish reflexes and weak musculature. She was an outcome of a 
normal pregnancy with no complications. At birth, she presented with cleft palate, a heart 
murmur and mild talipes deformity of the right foot but there has been no respiratory 
problems or severe hypotonia. She has been slow to reach milestones. She could roll over 
and sit if supported by the age of 10 months and she did not walk until she was almost 
two and half years old. The absence of facial weakness, neonatal hypotonia and neonatal 
respiratory distress in that case weaken the diagnosis of CDM. On the other hand the 
presence of neonatal right talipes and delayed milestones in the first year of life are 
concomitant with the diagnosis of CDM. These data put that case on the border line 
between congenital and early onset DM.
Her mother is normal but her father, who seemed to be an active man and not 
aware of having any health problems, was found to have a mild DM. The grandfather was 
a 65 years old male who had cataract but no muscle weakness or myotonia either 
clinically or by EMG. DNA analysis from this family revealed that the grandfather had a 
small repeat expansion (-100 repeats), the father had an expansion of 1.5 kb (-500 
repeats) and the affected daughter had a 2.1 kb expansion (-700 repeats). These were 
detected by Southern blot analysis using the Bglllp5B\A  system.
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Congenital myotonic dystrophy (CDM) is the most severe form of the phenotype 
which results in significant foetal loss and death in the perinatal period (Harper, 1989b). 
Transmission of that form of the disease has been nearly exclusively maternal with few 
exceptions (Wieringa, 1994). CDM patients usually have large CTG triplet expansions 
although some congenital cases with alleles in the 500 to 999 repeats range were reported 
(Tsilfidis et al., 1992; Harley et al., 1993 and Redman et al., 1993). The finding that 
CDM can be paternally transmitted, even if the incidence of such cases is very low, casts 
doubt upon certain mechanisms previously postulated to explain the maternal 
transmission of the disorder e.g. imprinting and the presence of an intrauterine factor. The 
possibility that CDM may operate with a pathologic mechanism(s) different than that 
adult onset DM can not be excluded and more studies are needed to solve this dilemma.
4.2 Mutation detection in the SOD-1 gene in patients with amyotrophic 
lateral sclerosis (ALS)
Screening for mutations in the SOD-1 gene in 2 familial and 67 sporadic ALS 
cases was performed. Single strand conformation polymorphism (SSCP) analysis was 
optimised to screen the 5 exons of the gene in all cohort of the studied patients. Different 
types of gel matrices and different running conditions were used for the analysis. 0.5X 
MDE™ gel with 5% glycerol running at room temperature and 8% polyacrylamide gels 
with or without 5-10% glycerol running at different watts and temperatures (at room 
temperature and at 4°C) were used along the study. A band shift was detected upon 
analysis of exon 4 from one familial patient. It was detected upon MDE™ analysis and on 
polyacrylamide gel without glycerol running at 12 watts and 4°C. Sequencing of the 
asymmetric PCR of that exon from the corresponding patient revealed a G277-^C 
mutation which caused a missense Gly93Arg change and created a new restriction site for 
the enzyme Sau3Al. This SSCP pattern and its causative mutation were confirmed to be
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present in all other affected family members while it could not be detected upon SSCP 
analysis and restriction enzyme screening of the remaining familial and 67 sporadic ALS 
cases.
Of the various methods applied for the detection of unknown mutations, SSCP is 
by far one of the easiest and cheapest procedures presently available. This technique was 
efficiently used by many investigators to screen for SOD-1 mutations in ALS patients 
(Rosen et al., 1993, Deng et al., 1993, Jones et al., 1995, Deng et al., 1995) where ~ 20% 
of the screened familial cases showed point mutations, nearly all of them caused missense 
amino acid changes. In general, SSCP analysis detects 70 to 95% of mutations in PCR 
product of 200 bp or less (Grompe, 1993). The SOD-1 gene is a single copy gene which 
is known to have five small exons encoding for 153 amino acids. This makes it ideal to 
use single stranded conformational polymorphism (SSCP) analysis as a screening method 
for point mutations or minor sequence alterations in that gene. There are many 
parameters other than the size of the PCR product that can affect the efficacy of the 
technique. Physical factors such as temperature, type of gel matrix, and ionic strength is 
very important such that sequence changes that have little or no effect on conformation in 
one set of conditions can have dramatically different effects under other conditions. A 
new gel matrix (MDE™, AT Biochem.) was used by most of the investigators who 
screened the SOD-1 gene for mutations in ALS patients. This matrix offered a good 
detection rate and did not require many gel condition variations. Overloading of the gel 
sometimes results in abnormal migration of the bands and reduced resolution. For this 
reason, radioisotopic or fluorescent labelling of the PCR products to a high specific 
activity is highly recommended so as samples can then be diluted so that DNA 
concentrations are sufficiently low in the loading solution, yet detectable (Hayashi and 
Yandell, 1993). In the present study a mutation was detected in exon 4 of the SOD-1 
gene using the MDE™ gel and polyacrylamide gel running at 4°C but not at room 
temperature. This emphasises the importance of using different gel conditions if
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polyacrylamide gel is going to be used for SSCP analysis in the SOD-1 gene as had been 
stated by different investigators for other genes (Grompe, 1993).
In the present study, a missense Gly93Arg change was detected in the SOD-1 
gene in one of the two familial patients with ALS. Mutations in Gly93 were previously 
detected in familial ALS patients where Gly93Ala and Gly93Cys were described in one 
report (Deng et al., 1993). This amino acid was shown to be highly conserved among 18 
different species (Pramatarova et al., 1995). Moreover, mapping of the Gly93 to the 
crystallographic structure of the SOD-1 enzyme revealed that it is one of the critical 
glycine residues that allow main chain conformation and packing interactions, closing one 
end of the P barrel structure of the enzyme (Deng et al., 1995). Mutations affecting this 
amino acid should have a deleterious effect on the conformation and stability of the 
enzyme dimer. These together with the detection of the Gly93 Arg mutation in all affected 
family members and not in the other screened patients make it to the most probable cause 
of the disease in that family.
All family members carrying the previously determined missense mutation 
(Gly93Arg) showed an earlier age at onset of the disease (26-40 years) compared to an 
average of about 50 years seen for other mutations. On the other hand, while the disease 
was rapidly progressive in three of them (3 to 5 years till death), one member showed a 
slower disease course (10 years). In screening erythrocytes for SOD-1 enzyme activity in 
27-UK families with FALS (the aforementioned family was one of them), Orrell et al. 
(1995a) found that the previously discovered Gly93Arg mutation showed evidence of a 
dominant negative effect, where the tested proband had only 30% of wild-type enzyme 
levels.
Previous studies showed a variable degrees of reduction in SOD-1 enzyme levels 
associated with different SOD-1 mutations. Moreover, it was apparent that there was no 
relation between the disease phenotypes and the level of the SOD-1 enzyme and 
considerable phenotypic variation occurs within a family among affected members bearing
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the same mutation (Ogasawara et al., 1993; Esteban et al., 1994; Borchelt et al., 1994; 
Gurney et al., 1994; Enayat et al., 1995; de Belleroche et al., 1995). The mechanism(s) by 
which SOD-1 mutations could cause FALS disease is not well understood. The most 
acceptable explanation among investigators working in the SOD-1 /FALS relationship is 
that FALS is caused by a toxic property present in the Cu/Zn SOD-1 enzyme which is 
produced by the mutations (Gurney et al., 1994; Rowland, 1995; de Belleroche et al., 
1995; Brown, Jr., 1995). In the present case, the very low enzyme level together with the 
earlier age at onset of the disease arose by probably two, at present indistinguishable, 
mechanistic possibilities for Gly93Arg: reduced enzyme activity is contributing to the 
disease or Gly93Arg is more toxic than the other mutants and the reduced activity is 
incidental. But, if disease severity was a simple function of SOD-1 toxicity, more toxic 
mutants would be expected to have early onset and short duration. The finding that onset 
and duration appear to act independently suggests that another property of the mutant 
proteins, in addition to toxicity, is involved in the disease mechanism.
Artefacts detected during SSCP analysis
During this study, in some instances, variant bands, which were interpreted as 
mobility shifts, were detected upon SSCP analysis of the PCR products from different 
exons of the SOD-1 gene. In all of them, except one, reloading of the same PCR product 
on a newly made gel was associated by the disappearance of such bands. There is no clear 
explanation for this observation, but errors in sample loading (over loading), gel 
polymerisation, improperly flushed gel wells, uneven gel running or a combination of 
these may play a role in producing such observations. Differentiation among polymorphic 
molecules by SSCP is not entirely predictable and the method can result in false 
negatives, ambiguous results and experimental artefacts (Sheffield et al., 1993).
In one case, the abnormal band shift pattern persisted upon re-running of the same 
PCR product while it disappeared upon electrophoresis of a newly amplified product
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from the same exon from the same patient. To assess for the cause of this condition, the 
radiolabelled PCR which showed this band upon SSCP analysis was recovered out of low 
melting point agarose gel and stored until its radioactivity decayed to a safe level. After 
that l|al aliquots were used in asymmetric PCR amplification reactions to create single 
stranded DNA for sequencing. Sequencing of this product revealed the mis-incorporation 
of a single base, most probably due to a PCR error. The DNA polymerase currently used 
in most PCR assays is isolated from Thermus aquaticus. It lacks 3' to 5' proof-reading 
activity and has an error rate of approximately 1/10 000 bases (Shibata, 1992). In the 
previous case, such a PCR error must be produced early in the PCR amplification to 
make sufficient PCR products detectable by SSCP analysis and DNA sequencing.
SOD-1 mutations in sporadic ALS patients
Because both sporadic and familial ALS have a very similar phenotype with minor 
differences, it was thought that the molecular pathology operating in both of them might 
be similar. In that respect it was decided to screen the present cohort of 67 sporadic ALS 
patients for both unknown and previously known common mutations in the SOD-1 gene. 
For the unknown mutations, SSCP analysis was used as described before. For two known 
mutations, Ala4Val and Ilell3Thr, screening of the PCR products from the 
corresponding exons using restriction enzyme digestion was performed. No abnormal 
SSCP pattern suggestive of the presence of unknown sequence alterations or abnormal 
restriction digestion products were detected in the cohort of the studied patients.
Ala4Val was known to be the most common familial ALS mutation detected in 
SOD-1 exon one (Siddique et al., 1993). This mutation abolishes a,Haelll restriction site 
producing an additional restriction fragment upon the digestion of the PCR product of 
that exon. Using HaeIII to screen for that mutation should be very sensitive with no 
possibility of false negative results. The Ilell3Thr mutation in SOD-1 exon 4 is the 
second most frequent mutation identified in FALS patients (Deng et al., 1995).
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Moreover, it was identified in 3 apparently sporadic ALS patients (Jones et al., 1995). 
This mutation creates a new restriction site for the enzyme Bsrl so that the PCR product 
from the normal SOD-1 exon 4 allele will be digested into two fragments while the 
mutant one will be digested into four fragments. The presence of a Bsrl recognition site 
in the normal exon 4 PCR product served as an internal control for the efficacy of the 
digestion make it unlikely that the digestion products due to such a mutation could be 
missed.
SSCP analysis is a sensitive technique and it was already used to detect mutations 
in ~ 20% of the familial ALS cases studied by different investigators. Moreover, it 
detected a mutation in one of two studied familial cases in the present study.
No data has been published regarding the detection of SOD-1 mutations in 
sporadic ALS although several hundred cases have been screened in North America (de 
Belleroche et al., 1995). The only exception is the published data by Jones et al. (1993; 
1994 and 1995). They detected the Ilel 13Thr mutation in three apparently sporadic ALS 
patients and the Glu21Lys in one other patient. Ilel 13Thr was described before to be the 
second most common mutation in FALS and is known to have a low penetrance 
estimated to be less than 50% by the age of 60 years (Suthers et al., 1994). Because of 
this, Ilell3Thr probably masquerades as a new mutation in apparently sporadic ALS, 
especially when the family history is incomplete (Deng et al., 1995). The inability to 
detect mutations in any of the screened 67 sporadic ALS patients, in spite of using 
reasonable screening techniques, and in other sporadic ALS patients from different 
centres raises the possibility that the molecular pathology is different for the two forms of 
the disease i.e. sporadic and familial ALS. Linkage studies of FALS families revealed 
locus heterogeneity with at least one other FALS gene present in the human genome. It 
may be also the case for sporadic ALS or it may be of non-genetic aetiology. 
Investigators are searching for other candidate genes for ALS and in that respect
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Figlewicz et al. (1994) described mutations in the C-terminal region of the human gene 
for the neurofilament heavy subunit in five patients with sporadic ALS.
4.3 Screening for mutations in the TSC2 gene in patients with tuberous 
sclerosis (TSC)
In the present study, 32 patients with either apparently sporadic TSC or from 
families non-informative for linkage analysis (except one that was later confirmed to be 
chromosome 9 linked) were screened for the presence of germline mutations in the TSC2 
gene using two-step strategy. To screen for deletions and/or other structural 
rearrangements, all patients included in this study were examined by Southern blot 
hybridisation with two TSC2 cDNA probes. Second, to screen for point mutations and/or 
minor sequence alterations, part of the TSC2 gene, expected to be functionally important 
(The European Chromosome 16 Tuberous Sclerosis Consortium, 1993), was examined 
by chemical cleavage of the mismatch (CCM) analysis. Four cDNA segments (spanning 
positions 1041 to 1857 & 4215 to 5471) and one DNA segment (325 bp of the promoter 
area, exon 1 and part of intron one) were amplified by PCR from 22 patients. In another 
10 patients, only DNA was available and from them two DNA segments (exons 38-41 as 
one segment and 325 bp of the promoter area, exon 1 and part of intron 1 as another 
segment) were PCR amplified. All PCR amplification products were analysed by CCM 
analysis.
Using this strategy, no deletions or other structural rearrangements were detected 
on Southern analysis while CCM analysis revealed nine mismatch bands due to 
differences between the target and the normal reference probes. Sequencing of the 
appropriate PCR products from the observed CCM mismatch bands showed three 
missense mutations (in three sporadic TSC patients), two silent mutations (in five 
sporadic TSC patients) and two base pair deletion in one of the polyadenylation signals 
(in one TSC patient).
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Some 5% of germ-line mutations in the TSC2 gene appear to be deletions 
detectable by pulsed field gel electrophoresis (PFGE) or conventional Southern analysis 
(The European Chromosome 16 Tuberous Sclerosis Consortium, 1993). In the present 
study, only 32 patients were screened for the presence of such mutations so it was 
expected to find 1-2 patients with such deletions. This is a quite small number and may 
not be present among the studied group because of chance. Moreover, big deletions that 
could be easily detected upon PFGE will not be detected using conventional Southern 
analysis due to deletion of the whole probe area from the affected chromosome.
At commencing of the present study (1994), only cDNA sequence of the TSC2 
gene was published and there was no available information regarding the number of the 
exons and the exon/intron boundaries. Moreover, there were no reports of point 
mutations in that gene and areas that are hot spots for such mutations. An approach, 
using RT-PCR amplification of -40% of the expressed coding sequence of the gene 
combined with chemical cleavage of mismatch (CCM) analysis, was adopted as a 
mutation screening strategy. Approximately 1.3 kb from the 3' end and 0.8 kb from the 5' 
end of the TSC2 gene were RT-PCR amplified in four segments. The 5' end segment was 
expected to have a possible membrane-spanning regions and the 3' end segments contain 
the GAP3-related domain and the polyadenylation signals. These RT-PCR amplified 
segments were expected to represent critical areas of the gene toward which mutation 
analysis could be directed.
The principle of mismatch cleavage is based upon the cleavage of heteroduplexes 
between strands of nucleic acid mismatched at one or more nucleotides. Chemical 
cleavage of mismatch (CCM) analysis was known to be very sensitive mutation screening 
technique, detecting > 95% of mismatches when only wild-type DNA is labelled and 
100%, when both wild-type and mutant DNA are labelled. It was shown to be an 
excellent method for the detection and location of mutations as it can easily screen up to 
1.7 kb segments of DNA at a time (Grompe, 1993). Using this strategy to screen for
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mutations in the TSC2 gene in 22 TSC patients, 3 missense mutations and three 
polymorphisms were detected. TSC shows locus heterogeneity with two disease- 
determining genes on chromosome 9q34 (TSCI) and on chromosome 16pl3.3 (TSC2). 
Estimates from linkage studies in families suggest that about 50% of the TSC cases are 
related to each gene (Kwiatkowski et al., 1993). If this distribution is the case in the 
studied patients as well, then it was expected to detect 11 mutations if the whole TSC2 
gene was screened. As only 40% of the gene was screened and as there was no apparent 
clustering of mutations within the TSC2 gene according to recently published data 
(Wilson et al., 1996), so it was expected to find ~4 mutations, if the detection rate is 
100%. The RT-PCR/CCM approach adopted in the present study seemed to be effective 
(detected 3 of the assumed 4 mutations). A small percentage of mutations is expected to 
be missed when this approach is used. This may be due to one of the following causes: I) 
Some mutations might affect RNA expression or stability, RT-PCR approach would only 
amplify the normal mRNA and not detect the mutant form. 2) Some of the mutations lies 
outside of the coding sequence that has been amplified by the RT-PCR.
Additional mutations in the TSC2 gene might be detected by screening each exon 
from genomic DNA, but unfortunately, the complex genomic structure of the human 
TSC2 gene with many small exons will make any exon screening approach to mutation 
identification labour-intensive.
When some information of the exon/intron boundaries of the TSC2 gene was 
kindly supplied by Dr. A. Green, Addenbrooke's NHS Trust, Cambridge, screening for 
mutations in the promoter area of the gene was adopted. 663 bp segment was PCR 
amplified from the DNA of 32 patients (including the 22 patients previously screened by 
RT-PCR). This segment included the TSC2 exon 1, part of intron 1 and 325 bp of the 
promoter area. CCM analysis was used to screen for mutations in this segment as before 
but no sequence changes could be detected. In general, mutations in the promoter area
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are not common and it may be necessary to screen more patients to detect such 
mutations.
In 10 patients, only DNA was available as a study material. A primer set was 
designed and the PCR conditions were optimised to amplify the TSC2 exons 38-41 
(numbering according to Maheshwar, et al. 1996) as one segment of 1120 bp. The 
amplified PCR products were screened by CCM analysis and two silent nucleotide 
changes were detected, resulting in no change to the predicted amino acid. No 
conclusions could be derived from these results as the number of the screened patients 
were small and only -12% of the their TSC2 gene was screened.
Missense mutations in the TSC2 gene
In the present study, three missense mutations were detected. First (Ml602V), in 
the GAP3-related domain and second and third (S1715T and R1720W), in the N-terminal 
of the tuberin, the TSC2 gene product. These mutations are novel and the Ml 602V is the 
first mutation to be detected in the GAP3-related domain of the protein. Comparison of 
the predicted human and pufferfish (Fugu rubripes) peptide sequences identified four 
regions of high conservation. These include the GAP3-related domain (human residues 
1593-1631) and an area of -200 amino acid residues which surrounds this, two small 
regions between residues 750 and 1100, and the N-terminal portion of the molecule 
(Maheshwar et al., 1996). This placed these missense mutations in an important part of 
the gene. Moreover, as these changes were not found upon restriction enzyme screening 
of normal controls (100 chromosomes), these mutations likely contribute to the TSC 
phenotype in these patients.
In contrast to what might be expected, Ml602V mutation in the GAP3-related 
domain was not associated with severe phenotype. GAPs act by stimulating the intrinsic 
GTPase activity of the Ras-related encogens, keeping them in the inactive, GDP-bound 
state (Lowy and Willumsen, 1993). The GAP3-related homology of the tuberin suggested
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that tuberin may itself have GAP activity, consistent with its proposed function as a 
tumour or a stem cell growth suppressor (Green et al., 1994a; Carbonara et al., 1994) 
and mutations in that part should be associated with the severe phenotype. This patient 
had the skin manifestations of TSC (fibrous forehead plaque, adenoma sebaceum, peri­
ungual fibromata) and seizures which is now under control and patient's recent EEG was 
normal. This mutation changed methionine to valine and both are neutral and 
hydrophobic amino acids. Such change may not have severe effects on the protein 
stability and function. If this is case it was expected that the second missense mutation 
R1720W, which changed the basic arginine to the neutral and hydrophobic tryptophan, 
will be associated with a more severe phenotype. This is still also not the case. The 
patient that carried R1720W was presented with mild phenotype with skin manifestations 
and seizures as it is the case in most TSC patients. Finally, the missense mutation 
S1715T, which is very close to the previous R1720W, was associated with the most 
severe phenotype. The patient who is 18 years old is mentally handicapped and he is a 
resident of a hospital for the mentally handicapped. The S1715T would normally be 
considered to be a conservative change, both serine and threonine are neutral and polar 
amino acids. However, there are known examples of conservative missense mutations 
that can result in a disease phenotype if they occupy sites in the protein that are key 
determinants of stability or function (Deng et al., 1993).
Until more is known about the function of tuberin and until additional mutations 
have been characterised pin-pointing critical areas, it is difficult to speculate about the 
exact effects these mutations have on tuberin's function. Moreover, until mutations are 
defined in a large set of patients, correlation between genotype and phenotype will be 
difficult to perform.
To date, the mutations that have been identified in the TSC2 gene include the five 
large-scale deletions and five intragenic deletions defined in the original report describing 
the cloning of the TSC2 gene (The European Chromosome 16 Tuberous Sclerosis
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Consortium, 1993) and a further six patients that were described in a subsequent report 
with deletions including both the TSC2 and the PKD1 genes (Brook-Carter et al., 1994). 
In addition, 13 other mutations have been described (Table 4.1). A high percentage of 
apparently expressed missense mutations (50%) is apparent rather than the expected 
nonsense mutations with prematurely truncated protein products (Figure 4.1). The 
proportion of missense mutations is comparable to that seen in the p53 tumour 
suppressor gene where missense mutations have been reported at a relatively high 
frequency (Chiba et al., 1990), but it is quite different from the mutations found in the 
other phakomatoses where truncation mutations are far more prevalent (Legius et al., 
1993; Trofatter et al., 1993; Latif et al., 1993). In p53 the wide spectrum of the missense 
mutations have been shown to disrupt both DNA binding and the stability of the protein 
which may also be the case for tuberin (Wilson et al., 1996).
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Table 4.1 TSC2 mutations detected in different studies in both familial and 
sporadic TSC patients
Serial Sequence Change Codon Change Type of 
Mutation
Reference
1 5110 delA M1698 fs ->stop at codon 
1801
Frame Shift (fs) Kumar etal., 1995a
2 4590/4591 delC V1524/L1525 fs-»stop at 
codon 1553
Frame Shift Kumar etal., 1995b
3 156+1G->A Splice Junction Splice mutation Kumar et al., 1995b
4 C3616-»T R1199W Missense Wilson etal., 1996
5 G1365-+C M449I Missense Wilson etal., 1996
6 C5075-»T P1686L Missense Wilson etal., 1996
7 C5084->A A1689E Missense Wilson et al., 1996
8 C1849-»T R611W Missense Wilson etal., 1996
9 C1531-*T R505Stop nonsense Wilson etal., 1996
10 1112/1113
del(TC)
1365 fs->stop at codon 
385
Frame Shift Wilson et al., 1996
11 4474/4476
del(TTC)
F1486 In Frame 
Deletion
Wilson etal., 1996
12 4519/4547 29 bp 
tandem duplication
L1510 fs-»stop at codon 
1541
Frame Shift Wilson et al., 1996
13 A52-»T K12Stop nonsense Vrtel et al., 1996
14 T5161—>A S1715T Missense Present Study
15 C5176—>T R1720W Missense Present Study
16 A4822—>G Ml602V Missense Present Study
Numbering of the bases and codons is given relative to the published cDNA sequence (The European 
Chromosome 16 Tuberous Sclerosis Consortium, 1993). fs= frame shift.
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Nonsense
13%
Splice Junction 
6%
In-frame deletion 
6%
Frame Shift 
25%
Missense
50%
Fieure 4.1
Percentage distribution of point mutations and minor sequence alterations within the 
TSC2 gene.
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Polymorphisms in the TSC2 gene
Two silent mutations, C4098—»T and G5346—»C caused silent Seri630 and 
Seri 776 changes respectively, were detected in five out of the screened 33 patients. One 
of these mutations, G5346—>C change, was detected in four patients. This change seems 
to be frequent as it has been also reported in one TSC patient (Wilson et al., 1996). 
Unfortunately, this mutation does not change a commercially available restriction site so 
it was not able to screen the normal chromosomes for its presence. Designing a primer set 
to introduce a restriction site, use of ASO or ARMS analysis could be useful to screen 
normal population for that polymorphism which may be used later (if proved useful) for 
linkage studies in the TSC2 gene.
The third polymorphism was due to an AA deletion at positions 5433 and 5434 in one of 
the two partially overlapping polyadenylation signals of the gene. It was detected in one 
of the familial cases, which proved, later on, to be linked to markers on the chromosome 
9q34 (TSC-J locus). Sequencing of the relevant part of the TSC2 gene in other affected 
family members failed to detect this mutation. Moreover, sequencing of 20 normal 
chromosomes detected this mutation in one of them. Kumar et al. (1995b) reported a 
polymorphic 4 base pair deletion, 5425del4, in the two partially overlapping 
polyadenylation signals in one TSC family and in six of 72 African-American control 
chromosomes examined. The role of polyadenylation signals at the 3' untranslated region 
of the genes is well documented. Deletion and/or substitution of any nucleotide in the 
conserved AATAAA polyadenylation signal can result in abnormal processing of mRNA 
(Lewin, 1990). The TSC2 gene has two partially overlapping polyadenylation signals that 
may cause differential polyadenylation (The European Chromosome 16 Tuberous 
Sclerosis Consortium, 1993). As the AA deletion still leaves one completely functional 
polyadenylation signal and as it could not be detected in other affected family members 
but detected in one normal chromosome, it is reasonable to consider it as a polymorphic 
change.
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4.4 Conclusions and future work
Mutation detection strategy is influenced by the expected nature of the mutation, 
size and structure of the gene in question, availability of mRNA and the degree of 
required sensitivity. Taking this into consideration, three different mutations strategies, 
each for a different gene, were optimised and proved to be useful screening techniques 
for the detection of mutations within the DMPK, the SOD-1, and the TSC2 genes.
When the mutation in a gene like DMPK is due to the new molecular mechanism 
of trinucleotide repeat length expansion, PCR amplification to detect this change in length 
aided by Southern blot analysis, when the PCR fails to amplify large repeat expansions 
will, theoretically, be the ideal mutation detection method. Nearly all trinucleotide repeat 
expansions that are known to be associated with disease conditions are GC rich and using 
high annealing temperature and hot start for PCR will improve the PCR results. When 
accurate number of CTG repeats is important to know (e.g. in the upper normal range of 
the repeat size), radiolabelled PCR resolved by denaturing polyacrylamide gel 
electrophoresis is mandatory. On the other hand, non-radiolabelled PCR proved to be a 
useful first step screening technique. Southern blot analysis is needed to confirm PCR 
results and to detect alleles that carry more than 80-150 repeats. Choosing proper 
enzyme/probe system for Southern analysis is very important to provide an unambiguous 
detection of both normal (homozygous or heterozygous) and affected individuals.
The mechanism by which the expanded trinucleotide repeat in the 3' untranslated 
region of the DMPK gene leads to the clinical features is unclear. The DM region of 
chromosome 19 is gene rich, and it is possible that the repeat expansion may lead to 
dysfunction of a number of transcription units in the vicinity, perhaps as a consequence of 
chromatin disruption. Further work will be needed to study different genes in the vicinity 
of the CTG trinucleotide repeat to clarify the role of this repeat expansion in the disease
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process. Moreover, intensive study of DM patients who did not show CTG repeat 
expansions (-2% of DM patients) might be of importance in that respect.
The SOD-1 gene is a small well-characterised gene with few exons. It is known 
that nearly all expected mutations within the gene in FALS patients will be point 
mutations causing missense amino acid changes, so that using DNA as a template for 
PCR/SSCP analysis seems to be a reasonable mutation detection strategy. In the present 
study SSCP analyses of the SOD-1 gene were performed to screen for mutations in both 
familial and sporadic ALS patients. Different gel matrices and different running conditions 
were tried and it was shown that using MDE™ gel with 5% glycerol running at room 
temperature was the most suitable choice to screen this gene for mutations. One missense 
mutation was detected in one familial ALS patient (out of two screened familial cases) 
but no mutations were detected in any of 67 screened sporadic ALS patients. In this 
study, false positive results upon SSCP analysis were obtained and careful result 
interpretation and repeating of the experiments which show positive band shifts are 
mandatory to exclude possible errors.
Only 5% of ALS cases are familial, and of these, fewer than 20% map to the 
SOD-1 gene, so there is locus heterogeneity (Rowland, 1995). Failure to detect mutations 
in the sporadic ALS cases (67 patients) in the present study may be simply because the 
SOD-1 gene is not the gene responsible for that disease phenotype. As this gene is very 
small, direct sequencing of the gene (100% detection rate) in sporadic ALS may prove or 
disprove such a possibility. Linkage study analysis of more FALS families is 
recommended to detect other genes responsible for the disease process. This will help in 
more understanding of ALS molecular pathology and will improve genetic counseling of 
ALS patients.
RT-PCR and CCM analysis for the detection of sequence variations in PCR 
fragments is an ideal mutation detection method for genes with big transcripts and 
multiple small exons, especially if the gene mRNA can be easily obtained from peripheral
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blood lymphocytes and when the genomic organisation of the gene is not yet known. 
Using this strategy to screen the TSC2 gene allowed the amplification and screening of a 
large area of the coding sequence of the gene (-40%) using only 4 sets of PCR primers. 
Moreover, by using mRNA as a template it was possible to begin screening for mutations 
in the TSC2 gene before the genomic organisation was known (exon/intron boundaries 
were recently published, Maheshwar et al., 1996). CCM analysis allowed accurate 
localisation of the mutation thus enabling sequencing of a limited area instead of the 
whole product. Moreover, the nature of altered bases was predicted depending on the 
modifying chemical. Osmium tetroxide modifies T mismatches and hydroxylamine 
modifies C mismatches. This further confirms the nature of the mutation in sequencing. In 
the present study, 3 missense and two silent mutations and one two base pair 
polymorphic deletion were characterised and the adopted mutation detection strategy 
proved to be useful.
Since 60% of the gene is still to be screened, little is known about the function of 
tuberin and only few mutations were characterised so far, a clustering of mutations in the 
yet unanalysed part of the TSC2 gene cannot be ruled out. Moreover, it will be difficult to 
speculate about the exact effects these mutations have on disease phenotype and on 
tuberin's function. Using CCM analysis to screen the whole TSC2 cDNA in more patients 
is highly recommended to clarify some of these unknown queries. To decrease the 
hazards of radioactivity and to improve mutation detection rate from 95% to 100%, 
optimising a silver staining technique of CCM analysis is also recommended.
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APPENDIX!
Solution used for DNA extraction from peripheral blood
(1) Lysis Buffer
(2) Nuclei Lysis Buffer
(3) Phenol/Chloroform
(4) T.E. Buffer
(5) ProtinaseK (lOmg/ml)
0.32M Sucrose 
lOmM Tris-HCl, PH 7.5 
5mM MgCl2 
1% Triton X-100
0.4M NaCl
lOmM Tris-HCl, PH 8.2 
2mM EDTA
Water Saturated Phenol one volume 
lMTris, PH 7.5 
0.1% 8-hydroxyquinoline 
Chloroform one volume
lOmM Tris-HCl, PH 7.5 
ImMEDTA
Boehringer Mannheim
Solutions used for RNA extraction
(1) Histopaque '1077f
(2) Solution D
(3) 2MNa acetate, PH 4.0
(4) Water-saturated phenol
(5) Chloroform.isoamyl alcohol (49:1)
(6) Phosphate buffered saline, PH 7.2 
(PBS, GibcoBRL)
(7) diethylpyrocarbonate (DEPC), 0.1%
Sigma
4M guanidinum thiocyanate (Fluka) 
25mM Sodium citrate, PH 7.0 
0.5% Sarcosyl (Sigma)
0.14MNaCl 
3mM KC1
0. ImM sodium hydrogen phosphate 
ImM potassium dihydrogen phosphate
Solutions for RNA sample electrophoresis
(1) 10XMOPS 200mM MOPS
50mM Na acetate, PH 7.0 
lOmMEDTA
(2) 37% formaldehyde solution
(3) Formamide
(4) Loading mix
(5) E. Coli ribosomal RNA 
Reagents used for reverse transcription
(1) SXfirst strand buffer (Gibco BRL)
(2) D TT (0.1M dithiothreitol
(3)M-ML V reverse transcriptase
(4) oligo (dt)12.i8
(5) dNTPs (dTTP, dATP, dCTP, dGTP) 
Reagents used for PCR
(1) 1 OX GeneAmp PCR buffer 
(Perkin-Elmer/Cetus)
(2) AmpliTaq DNA polymerase
(3) dNTPs (dTTP, dATP, dCTP, dGTP)
2g Ficoll
lml 2.5% bromophenol blue 
lml 2.5 xylene cyanol 
0.2ml 0.5MEDTA 
8ml water
Boehringer Mannheim
250 mM Tris-HCl, PH 8.3 
375 mM KC1 
15 mM MgCl2
Gibco BRL
200 units/pl (Gibco BRL)
Pharmacia Biotech.
lOOmM each, Boehringer Mannheim.
500mM KC1 
lOOmM Tris-Cl, PH 8.3 
15mMMgCl2 
1000 (ig/ml gelatin
5 units/pl, (Perkin-Elmer/Cetus)
lOOmM each, Boehringer Mannheim.
b
Reagents used in plasmid work
(1) Luria broth (LB), 1 litre
(PH 7.5, adjusted by 5MNaOH)
(2) LB-agar
(3) SOC Media, 1.020 litre
(PH 7.0, adjusted by SMNaOH)
Reagents used for Southern blotting
(1) T.A.E. buffer SOX
(2) Depurination solution
(3) Denaturation solution
(4) Neutralization solution
(5) 20X SSC (standard saline citrate)
(6) 100XDenhardt's solution
(7) Prehybridization solution
(8) 6X agarose gel loading buffer
lOg bactotrypton 
5g bacto yeast extract 
5g NaCl
Like LB + 5g bacto agar/litre
20g bactotrypton 
5g bacto yeast extract 
0.5g NaCl
10 ml of 250mM HC1
20 ml of 1M filter sterile glucose
242g Tris base 
57.1 ml glacial acetic acid 
100 ml 0.5M EDTA, PH 8.0 
Up to 1 litre by dH20
0.25M HC1
0.5M NaOH 
1.5M NaCl
3M NaCl
0.5M Tris-HCl, PH 7.4 
3M NaCl
300 mM Na citrate, PH 7.4
2% (w/v) BSA (bovine serum albumin) 
2% (w/v) Ficoll
2% (w/v) polyvinylpyrrolidone (PVP)
5XSSC 
1% SDS (v/v)
5X Denhardt's solution
0.25 bromophenol blue 
40% (w/v) sucrose 
IX TBE buffer
c
Reagents used for chemical cleavage of mismatches
(1)ToiE
(2) 10X hybrid buffer
(3) Stop/precipitation mix
(4) 10X One-Phor-All buffer plus 
(Pharmacia Biotech.)
(5) T4 Polynucleotide kinase
lOmM Tris-HCl, PH 7.4 
0. ImM EDTA
3M NaCl
1M Tris-HCl, PH 8.0
63mM Na acetate 
20|iM EDTA 
80% ethanol
lOOmM Tris-acetate 
lOOmM Magnesium acetate 
500mM potassium acetate
~ 10 units/pl (Pharmacia Biotech.)
Solutions used for sequencing (all supplied with Seauenase version 2.0 kit, USB)
(1) 5X sequenase buffer 200mM Tris-HCl, PH 7.5 
lOOmM MgCl2 
250mM NaCl
(2)5X labeling mix (dGTP) 7.5pM dGTP 
7.5pMdCTP 
7.5pM dTTP
(3) Termination mix (ddG,T,C or ATP) 8pM ddG,T,C or ATP 
80(j,M dNTPs 
50mM NaCl
(4) Stop solution
(5) 20XT.T.E buffer
95% formamide 
20mM EDTA 
0.05% bromophenol blue 
0.05% xylene cyanol
216 g Tris base 
72 g taurine 
4 g EDTA
distilled water up to 1 litre
d
(6) Glycerol enzyme dilution buffer 20mM Tris-HCl, PH 7.5
2mM DTT 
0.ImM EDTA 
50% glycerol
(7)Sequenase version 2.0 T7 DNA 13 units/p.1 
polymerase
Solution used for fluorescent automated sequencine
(1) Terminator premix 
(Prism™ Ready Reaction 
DyeDeoxy™ Terminator Cycle 
Sequencing Kit, Perkin Elmer)
(2) Phenol:water: chloroform 
(68:18:14)
(3)gel loading mix
(4) 10XT.B.E. buffer
1.58pM A-DyeDeoxy 
94.47|iM T-DyeDeoxy 
0.42|jM G-DyeDeoxy 
47.37|oM C-DyeDeoxy 
78.95^M dITP
15.79pM of each dATP,dCTP & dTTP 
168.42mM Tris-HCl, PH 9.0 
4.21mM (NH4)2S04 
42.10mM MgCl2
0.42 units/fil AmpliTaq DNA polymerase
86 ml of water saturated phenol 
14 ml chloroform
5 parts deionized water 
1 part of 50mM EDTA, PH 8.0 
30 mg/ml blue dextran (Sigma)
108 g Tris base 
55 g boric acid 
9.3 g EDTA
Distilled water up to 1 litre
Reagents used for ligation of PCR products (all supplied by Promega)
(1) 10X ligase buffer 300mM Tris-HCl, PH 7.0
lOOmM MgCl2 
lOOmM DTT 
lOmM ATP
(2) T4 DNA ligase 1 Weiss unit/fil
e
(3) p G E h f'-T  vector 50 ng/pl
(4) p G E I^ f-T  vector control DNA 4 ng/fil
(5) IPTG stock solution (0.1M) 24 mg/ml
(6) X-Gal (100 mg) was dissolved in 2 50 mg/ml 
ml o f  N ,N ' dimethylformamide
